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Abstract
Studying proteins is hard. Even in well studied model systems, some proteins are
recalcitrant to production in useful amounts in soluble form. These proteins can
be difficult to over-express and/or are not soluble and often the lack of protein
solubility is blamed on poor/improper protein folding. However, in general, small
proteins are easier to express in soluble form than large proteins.
Protein evolution has produced many modular multi-domain proteins that are
made from several smaller folded domains in series, as it is more efficient to
fuse established functional domains together than to construct a large protein
de novo. It has been known for a long time that distinct domains of large
proteins can be more easily over-expressed than the full-length protein, and many
full-length proteins have been studied by over-expressing their domains separately.
This Thesis presents a new pragmatic methodology for truncating and identifying
soluble fragments of proteins. This new technique was used to identify previously
unattainable soluble domain constructs of proteins of interest to our research
group. The new technique for protein domain truncation uses exonuclease III
to delete a protein gene in a specially constructed plasmid. Gene deletion can
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be performed to result in truncation from either the amino- (N-) or carboxy-
(C-) termini of a protein and makes a library of truncated protein genes. The
truncated protein genes in these plasmids are fused to a downstream gene for
either enhanced green fluorescent protein (EGFP) or dihydrofolate reductase
(DHFR). The fused EGFP or DHFR gives cells expressing the fusion protein a
distinct phenotype depending on whether the truncated protein-fusion is soluble
or not. This technique allows pragmatic protein domain identification as soluble
truncated proteins can be assumed to not include incomplete protein domains,
and are thus truncated at a domain boundary.
Truncation of Acinetobacter baylyi DNA primase (DnaG) successfully produced
genes for soluble expression of both the zinc binding domain (ZBD) and an RNA
polymerase-helicase binding domain fusion (RPD-HBD) that were not able to
be produced using existing methods. Several constructs for both the ZBD and
RPD-HBD were confirmed to be soluble after purification and ZBD constructs
were further investigated by circular dichroism and nuclear magnetic resonance
(NMR) to show that they were folded. Examination of some ZBD proteins by
mass spectrometry indicated that they bind zinc, which only occurs in the ZBDs
of other species when they are correctly folded.
At the commencement of this Thesis no isolated domains of Staphylococcus aureus
EzrA (extra Z-rings) or its homologues were known. A comprehensive library of
genes encoding N- or C- terminally truncated EzrA were produced and used to
identify soluble proteins at each of EzrA’s 5 domain boundaries. One-dimensional
and total correlation spectroscopy NMR experiments showed that most of the
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truncated EzrA fragments were at least partially folded, and in the case of
proteins for domains 1–2 (EzrA24–214), 4–6 (EzrA302–564) and 6 (EzrA484–564) were
well folded without flexible ends. Although not all of the soluble fragments of
EzrA were investigated, those that were allowed identification of protein domain
boundaries for domains 2–6.
The technique we have developed and utilised for pragmatic protein domain
identification allows a large number of shortened protein genes to be produced and
easily screened to identify soluble protein constructs. Characterisation of purified
truncated soluble proteins using techniques such as NMR allow identification of
domains in previously uncharacterised proteins or that have been resistant to
investigation by other methods.
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Chapter 1
General introduction
1.1 Problem: producing soluble proteins
Production of soluble, correctly folded protein is usually the first step for in vitro
investigation of biochemical and three-dimensional properties of a protein. Many
straightforward methodologies for cheaply producing large quantities of a protein
of interest have been developed using Escherichia coli and other bacteria as a
host. Protein over-expression in bacterial hosts provides an advantage as protein
translation in bacteria can be an order of magnitude faster than in eukaryotes
and several protein over-expression techniques have been developed for directing
massive production of a target protein. However, many proteins are not initially
soluble or correctly folded when over-expressed.
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1.2 Protein structure and folding
Proteins are regularly composed of distinctly folded domains, commonly ranging
in size from 100 to 150 amino acids in length (11 to 17 kDa) (Berman et al., 1994;
Xu and Nussinov, 1998) which can clearly be seen by the clustering of proteins
in multiples of this range in gel electrophoresis in species such as Escherichia
coli (∼ 14 kDa; Savageau, 1986). Protein folding is a complex process with
conflicting energetic factors that scale differently; entropic loss from restricting
conformational space of the folded polymer must be compensated by enthalpic
intra-molecular interactions and exclusion of water from hydrophobic regions (Xu
and Nussinov, 1998).
Entropic energy loss from protein folding scales with protein length in a quadratic
function, whereas enthalpic intra-molecular interactions scale linearly (Xu and
Nussinov, 1998). These two conflicting sequence length dependencies result in a
“sweet spot” of protein domain length. Proteins that are very short do not exclude
water or have sufficient enthalpy from inter-residue contacts to balance the
entropy loss from folding, while for very large domains, the cost of configurational
entropy increases beyond the capacity of intra-molecular interactions (Xu and
Nussinov, 1998).
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1.2.1 Protein folding
Protein folding is a intricate process, where an initially unfolded, high entropy
polypeptide can attain a productively folded, low entropy state on a time-scale
of milliseconds to seconds (Dinner et al., 2000). Protein folding is believed to
progress in a somewhat directed manner, whereby partially folded intermediates
form transiently, and these transient intermediates then combine to form a
thermodynamically favourable native state (Dobson et al., 1998). In the polar
intra-cellular environment, association between hydrophobic residues is strong,
leading to folded protein conformations with dense hydrophobic cores and
hydrophilic surfaces.
A semi-directed pathway for protein folding is required to compensate for the
Levinthal paradox, where, if protein folding occurred solely by randomly sampling
all the possible conformations, each protein molecule would require astronomical
time scales to fold to its native shape (1011 years for a 100 amino acid protein;
Levinthal, 1969; Dinner et al., 2000). Semi-directed protein folding can be
explored through the concept of an energy landscape which shows the relationship
between steps of folding and overall free energy (Figure 1.1; Dill and Chan, 1997;
Dinner et al., 2000; Dobson, 2003). The many energetic factors contributing to
protein folding occur both within local protein regions and across the larger
distances through a protein, with each interaction contributing either positively
or negatively to the free energy of the protein.
Initially the high entropy unfolded protein is in high conformational flux. As new,












Figure 1.1: Protein folding energy landscape. Denatured, high free energy protein with many
conformations progresses to a native state protein with low free energy and few conformations. Points
I–IV show the progression of a 27-mer protein from unfolded through to a folded protein and the
number of available conformations (Dinner et al., 2000). Local free energy minima are indicated with
*. With increasing depth of free energy minima, re-entry to the protein folding pathway becomes less
favourable and may prevent the protein from folding to more compact and low energy conformations.
Figure adapted from Dinner et al. (2000).
small, transiently folded regions form, favourable intra-molecular interactions
reduce the available conformations of the protein chain. These sterically restrained
conformations have a lower overall free energy and lead to an incremental process,
whereby as native-fold contacts are formed, they progressively lower the overall
numbers of possible conformations and protein free energy until a transition state
occurs, from which the protein collapses quickly into the native fold (Dinner et al.,
2000; Dobson, 2003). However, protein folding does not always lead to stable,
natively folded conformations. Stalled, partially folded intermediates may become
trapped in regions of local free energy minima, restricting further productive
folding.
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For example, two different theoretical protein folding trajectories are shown in
Figure 1.1. Trajectories A and B progress from an unfolded, high free energy state
and progress through many intermediates, to a lower free energy conformation.
During the folding pathways, a localised region of low free energy is experienced
(at *), and the accessible conformations are restricted; the intermediate cannot
continue to productively fold. In order for folding along trajectory A or B
to progress further, an increase in free energy is required to access more
conformations. Trajectory A has a small local free energy minimum and the
protein here can more easily re-enter the folding pathway and progress to the
native fold than the one following trajectory B, which has a very low local energy
minimum. If the energy required to re-enter the folding pathway is too great the
intermediate state may become trapped and folding will stall (Bollen et al., 2004;
Wu et al., 2007).
When a protein is in a partially folded state, hydrophobic residues destined for
the hydrophobic core are solvent exposed. If a partially folded protein does not
progress to its low free energy native conformation, aggregation can decrease
the local free energy through hydrophobic, inter-molecular and solvent excluding
interactions with other protein molecules. The resulting dense aggregates of
non-natively folded polypeptides are stabilised by hydrophobic interactions and
a severe reduction in surface area. Consequently, once a protein aggregate has
formed, unfavourable, large energy inputs are required to release the proteins
to allow productive protein folding to recommence. As protein size increases,
proportionately more partially folded states are encountered, and the risk of
Jeffrey R. Barrett 5
protein aggregation increases (Jahn and Radford, 2005; Brockwell and Radford,
2007).
1.2.2 Protein size and folding rates
Protein folding generally proceeds more slowly as protein size increases (Figure
1.2; Fersht and Daggett, 2002; Ivankov and Finkelstein, 2004; Ouyang and
Liang, 2009) and this is due to several factors. Increased protein size leads
to a larger entropy loss upon folding, resulting in less favourable native folds
and more complex protein folding trajectories. These proteins can spend longer
times in intermediate folded states which increases the likelihood of aggregation.
Larger proteins also pose a larger aggregation potential as increased domain size
necessitates a larger number of hydrophobic core residues (Kiraga et al., 2007).
Protein domains in larger proteins fold with a large degree of autonomy from
each other, which is useful for attaining faster protein folding rates (Figure 1.2),
but the close proximity of domains does not allow folding to occur as quickly as
for protein domains in isolation.
1.2.3 Protein synthesis and folding chaperones
The densely packed environment within cells promotes macromolecular association
and encourages protein aggregation (van den Berg et al., 1999; Jahn and Radford,
2008). Cellular processes have developed to mitigate aggregation of unfolded
proteins by chaperoning aggregation prone nascent proteins and aiding in
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Figure 1.2: Protein folding rate is related to protein size. Data for proteins for which both
in-water folding rates and protein structures are known, compiled from Ivankov and Finkelstein (2004)
and Ouyang and Liang (2009). Single domain, •; multi-domain, •. Primary Y-axis shows in-water
folding rates, k f (s−1); secondary Y-axis half-folding time; t1/2 (s).
productive protein folding (Hartl, 1996; Hartl et al., 2011). Protein folding
chaperones in general act to sequester hydrophobic regions present in nascent
protein chains. By inhibiting inter-molecular interactions between immaturely
folded proteins, aggregation through these regions is reduced. Folding chaperones
function by one of two modes: I) chambered chaperones provide an environment
promoting protein folding; and II) passive chaperones hold hydrophobic regions
of nascent chains while folding occurs.
Protein synthesis in E. coli occurs in polysomal ribosome clusters, where
many unfolded polypeptides exit ribosomes in close proximity and where the
hydrophobic sections of the new polypeptides pose an aggregation risk to
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each other. For this reason two proteins with chaperone capacity are found to
localise near the ribosome exit to help mitigate aggregation of newly synthesised
polypeptides. Both DnaK, which associates with nascent chains (Gaitanaris et al.,
1994), and the peptidyl-prolyl cis-trans isomerase trigger factor, which localises
to the mouth of the ribosome exit tunnel (Stoller et al., 1995; Hesterkamp et al.,
1996), act to chaperone new proteins in the cell.
After sequestering hydrophobic protein folding intermediates, DnaK passively
supports protein folding through cyclically releasing and binding partially folded
proteins in an ATP hydrolysis dependent manner (Deuerling et al., 1999; Teter
et al., 1999). The half-time for DnaK cycling is on the order 2 minutes (Liberek
et al., 1995), which provides sufficient time for polar regions to productively
interact while aggregation prone hydrophobic regions are protected. The cyclic
nature of DnaK action allows intra-molecular hydrophobic interactions to occur
when appropriate. E. coli DnaK can identify partially folded proteins by the
presence of its binding motif that occurs on average once every 36 amino acids
in the E. coli proteome (Rüdiger et al., 1997). These recognition sequences
distinguish partially folded states from natively folded proteins as mature protein
states do not contain the DnaK binding sequence on their surfaces and therefore
can not interact with DnaK.
In addition to passive protein chaperones, E. coli produces the GroE chaperone
protein complex, which takes an active role in protein folding by forming a large,
empty, hydrophilic chamber where a protein may fold without inter-molecular
interactions (Xu et al., 1997; Hartl et al., 2011). The GroE complex is comprised of
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two GroEL heptamers in alternate, ATP-dependent interconverting conformations
which vary significantly in cavity size and hydrophobicity (Figure 1.3). The
trans-cavity, which initially interacts with nascent protein chains, has a small
(85,000 Å3) hydrophobic cavity while the cis-conformation has a large (175,000
Å3) hydrophilic cavity (Fenton et al., 1994; Hlodan et al., 1995; Itzhaki et al., 1995;
Xu et al., 1997). The hydrophobic nature of the GroEL trans-cavity promotes its
association with hydrophobic, partially folded proteins, while the smaller cavity
acts as a gatekeeper to restrict the size of the encapsulated proteins to below
70 kDa; the trans-GroEL cavity accommodates maximally a globular folded 60
kDa protein (Xu et al., 1997; Fenton and Horwich, 2003). After the trans-GroEL
cavity binds an unfolded polypeptide, a heptamer of GroES seals the GroEL
cavity, triggering a shift to the large, hydrophilic cis-cavity conformation which
provides a suitable protected, polar and dilute environment for protein folding
(Saibil et al., 1993; Xu et al., 1997; Horwich et al., 2009). Dissociation of the
GroES cap allows the folded protein to exit GroEL.
The half-time between the GroEL cis-conformational change and protein release
is 10 s (Fenton et al., 1996; Rye et al., 1997; Taguchi et al., 2001; Hartl et al.,
2011), allowing even very long folding trajectories to proceed. In fact the extended
folding time allows thermodynamic sampling of multiple protein conformations
(Clarke, 1996; Ellis and Hartl, 1996). GroEL also appears to act as a passive
protein folding chaperone, as experiments supplementing E. coli with a GroEL
mutant incapable of forming the cis-form, can still promote correct folding of
proteins, even in cases where the proteins are too large to be encapsulated by
trans-GroEL (82 kDa; Chaudhuri et al., 2001).















Figure 1.3: Crystal structure of the GroE complex. The GroE complex is composed of three
heptameric structures, GroES7 (red); cis-GroEL7 (yellow) and trans-GroEL7 (blue). I) Nascent folded
client proteins first interact with hydrophobic trans-GroEL7 and cis-GroES7 dissociates from the GroE
complex. II) A large conformational change interconverts the trans- and cis- GroEL7 cavities. GroES7
then re-binds over the new hydrophilic cis-GroEL7 cavity, trapping the client protein in the hydrophilic
environment (PDB: 1AON; Xu et al., 1997).
1.2.3.1 Chaperone capacity in growing Escherichia coli
Under normal growth conditions, E. coli clearly has sufficient chaperone capacity
to fulfil cellular needs. However, protein over-expression in the laboratory can very
quickly overwhelm the cellular chaperone apparatus and the regulatory networks
that maintain balanced protein folding. Laboratory strains of E. coli, when grown
at 37◦C in minimal medium, contain on average 3.52 × 106 proteins (2.34 × 10−13
g protein/cell; average protein mass of 40 kDa; Bremer and Dennis, 1996). With
a doubling time of 40 min, average protein synthesis is around 1,500 proteins per
second. Some, but my no means all of these proteins require chaperone assistance
to fold correctly.
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Under standard conditions, there are around 12,000 DnaK molecules within an
E. coli cell (Oh and Liao, 2000; Tomoyasu et al., 2002; Lu et al., 2006). With an
ATP hydrolysis cycle half-life of 2 min (Liberek et al., 1995), there is insufficient
DnaK capacity inside of the cell to accommodate the ∼ 180,000 proteins produced
during this time. DnaK is implicated in productive folding of 20% of nascent
proteins by mass. This is biased towards larger proteins (Teter et al., 1999), likely
due to an increased number of DnaK binding sites. In fact, large proteins appear
to rely more on DnaK to fold productively; the majority of proteins greater than
60 kDa are detectable in aggregates following DnaK depletion (Deuerling et al.,
1999, 2003).
Under similar conditions, E. coli has a GroEL 14-mer concentration of about
1,580 per cell (Lorimer, 1996; Vanbogelen et al., 2005). Accounting for the 10 s
half-time in which GroEL encapsulates a nascent protein within the cis-cavity,
and assuming only a single binding cycle with GroEL, it is apparent that E. coli
has an order or magnitude fewer available GroEL complexes than newly produced
proteins. However, not all nascent proteins synthesised in E. coli interact with
the GroE complex to fold. Few proteins less than 20 kDa interact with GroEL
during folding as these proteins most often fold quickly and efficiently. It is the
larger, multi-domain proteins that require the help of GroEL (Houry et al., 1999).
It has been show that about 300 (12%) of the E. coli cytosolic proteins interact
with GroEL during normal culture conditions, accounting for up to 30% of the
chaperone capacity. These clients are mostly between 20 and 60 kDa in size
(Houry et al., 1999; Kerner et al., 2005; Fujiwara et al., 2010).
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Since the DnaK and GroE complex chaperone capacities of E. coli are capable
of folding around 100, and 150 new protein molecules per second respectively,
these cells therefore have the capacity to fold, at most, just 10% of total
cell protein synthesis (assuming one molecule of chaperone is required per
protein). Over-expression of a large multi-domain protein can therefore quickly
become problematic and overload cellular chaperone capacity. In addition to
over-expression of chaperone-requiring proteins overwhelming normal chaperone
capacity, over-expression of poorly soluble protein often sequesters cellular
chaperones to inclusion bodies as aggregation occurs while the chaperone is bound
to its client (Allen et al., 1992; Carrio et al., 1998).
E. coli has developed feedback mechanisms to cope with environmental conditions
which burden protein folding. However, these regulatory mechanisms are not
optimised for artificial over-expression of a poorly soluble protein. The chaperones
DnaJ and DnaK participate in a sequestration feedback loop where free chaperone
sequesters the sigma factor responsible for chaperone gene transcription (El-Samad
et al., 2005). Unfortunately, chaperone up-regulation during high level protein
over-expression loads produces or leads to maximally about a two fold increase
in levels of both GroEL (Cheng and Lee, 2010) and DnaK (Oh and Liao, 2000;
Tomoyasu et al., 2002; Lu et al., 2006). This is insufficient to cope with problematic
proteins during their over-expression. Co-over-expression of cellular chaperones
can improve yields of soluble proteins during over-expression but can be of limited
use (Goloubinoff et al., 1989; Cole, 1996; Thomas et al., 1997; Machida et al., 1998).
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1.2.4 Passenger solubilisation
In some cases amino-terminal (N-) fusions of proteins such as thioredoxin (LaVallie
et al., 1993), glutathione S-transferase (Smith and Johnson, 1988; Nygren et al.,
1994), maltose-binding protein (MBP; di Guan et al., 1988; Bach et al., 2001;
Salema and Fernández, 2013), E. coli N-utilizing substance A (NusA; Davis et al.,
1999), periplasmic protein disulfide isomerase (DsbA; Zhang et al., 1998), protein
A (Nilsson et al., 1987; Samuelsson et al., 1994), and ubiquitin (Power et al., 1990)
can be used to improve the solubility of a passenger fusion protein. However,
these solubility-promoting fusion partner proteins are not equal in their ability to
improve soluble passenger protein yield (Kapust and Waugh, 1999), and success
can vary depending on the identity of the passenger protein (Hammarström et al.,
2002; Raran-Kurussi and Waugh, 2012). In some cases, they do not promote
folding to native, active conformations (Louis et al., 1991; Saavedra-Alanis et al.,
1994; Sachdev and Chirgwin, 1998; Raran-Kurussi and Waugh, 2012).
The role of passenger solubilising fusion proteins is not always clear, and may
not be universal, but in the exceptionally useful case of MBP, it appears to have
a chaperone-like effect, where MBP interacts with unfolded intermediates and
prevents inter-molecular aggregation during high level over-expression (Richarme
and Caldas, 1997; Kapust and Waugh, 1999; Bach et al., 2001; Fox et al., 2001;
Raran-Kurussi and Waugh, 2012); essentially producing a chaperone molecule for
each protein molecule sythesised.
N-terminal solubility promoting fusions are more successful than carboxyl-terminal
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(C-) fusions, likely due to these domains being synthesised first and folding while
the passenger protein is being synthesised. This proposition is supported by
observations that C-terminal, in contrast to N-terminal, MBP and thioredoxin
fusions do not usually support over-expression of soluble protein, but still may
aid in protein re-folding (Sachdev and Chirgwin, 1998; Dyson et al., 2004).
1.2.5 Protein domain evolution
Protein domains are distinct independently folded protein units, and can manifest
as distinct proteins, contain flexible extensions, or be joined into multi-domain
assemblies. Distinct protein domains often represent modules of function, mutation
and/or fusion of which can lead to new protein chemistry and functions (Apic
et al., 2001; Gough, 2005; Vogel et al., 2005). Fusion of two protein domains
allows new cooperative functions, for example enabling sequential reactions to be
promoted (Ostermeier and Benkovic, 2000). De novo evolution of a functional
polypeptide is many orders of magnitude slower than the rate at which an existing
protein domain can differentiate to a new function or specificity, or be joined with
other protein domains to create new combinations of specificity and function. In
addition, distinct protein domains fold more quickly than multi-domain proteins.
As such, protein domain recombination is a process through which many protein
functions have developed over time (Apic et al., 2001; Qian et al., 2001; Gerstein
and Levitt, 1998).
Recombination of genes encoding protein domains can produce a range of domain
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configurations; however, most frequently the result is addition of DNA encoding a
new domain at the end of an existing gene (Björklund et al., 2005; Weiner et al.,
2006). Exploring the possible fusion events for protein domains shown in Figure
1.4, at step I) A and B are two separate genes. Then at step II) a recombination
event produces soluble fusion protein A–B (various other possible configurations
are indicated by *, **, ***). Insertion of a new domain into the start or end of a
protein — where flexible non-structured regions are common and disruption of
native contacts are less detrimental to protein folding — is the most likely event
to produce a soluble fusion protein. The result of this type of gene fusion also
commonly makes fused domains joined by flexible linkers. Other domain fusion
orientations are possible if insertion occurs at a non integral position, such as an
external loop (*; Pascarella and Argos, 1992). A recombination event forming a
fusion product of a partial protein domain A, can result in production of a fusion
protein where a single domain is able to stably fold (B at **), or otherwise a
protein incapable of productively folding, resulting in aggregation (***).
1.3 Small proteins are often better suited for
three-dimensional structure determination
Determination of three-dimensional shape can help illuminate the properties
of a protein of interest. However, many properties of a protein may make it
unsuitable for structural determination. TargetTrack (formerly TargetDB; Chen
et al., 2004), a database tracking structural genomics sample progress, clearly
















Figure 1.4: Protein domain fusion is a process whereby genes encoding two independent
protein domains recombine. I) Protein domains A and B are independent. II) Insertion of a protein
domain produces domains fused end to end, often linked by a flexible polypeptide linker; * domain
fusion can result in domain B inserting into a loop in domain A, producing a soluble multi-domain
protein where both domain A and B can productively fold; ** insertion of protein domain B disrupts
folding of domain A, producing a flexible extension to protein B; *** protein domains A and B fuse in
a position which perturbs productive folding of the multi-domain protein producing a non-functional,
aggregating product. III) and IV) Following domain fusion, flexible regions linking domains A and
B can atrophy over time, reducing spacing between them. V) Domains A and B evolve a folding
pathway which integrates A and B into a distinct folded unit.
shows the high attrition of target proteins through the pipeline to protein
structure determination. Following cloning of target protein genes, both the lack
of protein expression and solubility greatly reduce the number of useful targets
(Figure 1.5). Longer proteins display poorer expressability, and separately, poorer
protein solubility when over-expressed (Canaves et al., 2004; Pédelacq et al.,
2005; Slabinski et al., 2007). However, even when longer proteins are expressed
in soluble form, other properties of larger size, such as increased flexibility
and consequently poorer crystallisability, confer poor suitability for structural
determination (Christendat et al., 2000; Goh et al., 2004). Currently, structural
genomics initiatives try to avoid large proteins due to poor suitability and success
rates (Oldfield et al., 2005; Chandonia et al., 2006; Slabinski et al., 2007).
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Figure 1.5: Bottlenecks in structural biology pipelines. TargetTrack (Chen et al., 2004) lists
success statistics for protein structural determination experiments from structural genomics groups.
A large number or protein targets are not able to proceed past expression and soluble expression
stages. Accessed 14 May 2013; http://www.sbkb.org/tt/.
1.3.1 Nuclear magnetic resonance and protein size
Solution nuclear magnetic resonance (NMR) spectroscopy allows investigation of
protein structure in the solution state, and can provide information on protein
folding, structure, protein interfaces, binding processes and protein dynamics.
Protein NMR has numerous inherent restrictions which bias applicability to small
proteins, placing an upper limit on structural determination at 25 kDa for routine
NMR (Güntert, 1998; Kwan et al., 2011). Protein NMR experiments require high
quality, well resolved NMR spectra, which become increasingly difficult to obtain
as protein size increases.
Protein size is inversely correlated with molecular tumbling, where slow molecular
tumbling reduces the lifetime of NMR excited states and broadens NMR spectra,
giving rise to the size restrictions of NMR (Keeler, 2011; Kwan et al., 2011).
Molecular tumbling is further restricted at lowered temperatures where the
increased viscosity of water slows the rate of protein tumbling and reduces NMR
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signals. These issues restrict useful temperatures at which NMR measurements
can be made and this further challenges structure determination of larger proteins
that typically have reduced temperature stability. Analysis of proteins up to 50
kDa is plausible for many cases; however, proteins larger than 20–30 kDa require
special high field instruments and sample deuteration (Gardner et al., 1998; Kwan
et al., 2011). Although some complex state-of-the-art techniques increase the size
threshold for protein NMR in solution into the 100s of kDa, they do not efficiently
enable structure determination (reviewed in Kwan et al., 2011).
Macromolecular NMR is also limited to well-behaved proteins. NMR produces
low signal intensities, requiring high protein concentrations, and long timescales
over which to take significant measurements. The requirement for high protein
concentration restricts study of proteins of poor solubility, a problem that is
exacerbated by the need for low ionic strength buffers for useful signal intensity
(Kwan et al., 2011).
Simplification of the protein molecule into smaller, soluble fragments reduces
the complexity of both the NMR experiment and sample preparation. A protein
of a single, soluble domain (10–20 kDa) is easier to produce, more likely to be
soluble, produces a superior spectrum and is easier to analyse following NMR
measurement. A more soluble protein will also often have reduced requirement for
a high ionic strength buffer, and better temperature stability compared to a low
solubility sample.
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1.3.2 X-ray crystallography and protein size
Many characteristics of larger proteins can impede structure determination
by X-ray crystallography, separate from protein expressability and solubility.
Numerous studies have highlighted protein properties which negatively affect
protein crystallisation, including average hydropathy, isoelectric point, presence
and length of low-complexity disordered regions, proportion of coil and/or
coiled-coil secondary structures, presence of signal peptides and presence of
transmembrane helices (Canaves et al., 2004; Goh et al., 2004; Chandonia et al.,
2006; Slabinski et al., 2007). These protein features that appear to impede their
successful crystallisation are less associated with properties of individual folded
domain units, but instead increase with numbers of domains, and the addition of
associated flexible inter-domain regions.
Structures in the protein data bank (PDB) show an apparent size bias towards
smaller proteins. Comparing the two proteomes most represented (E. coli and
human) to molecule size in PDB entries reveals that proteins ∼ 50 kDa and above
are under-represented and this bias may be related to the advantages of smaller
proteins for these techniques (Figure 1.6).
1.4 Protein domain identification
The techniques used to produce proteins for biochemical study can produce
poor yields for larger proteins due to poor expressability or solubility. In many
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Figure 1.6: Size distribution of published protein structures. Comparison of size for A Escherichia
coli and B human protein structures in the protein data bank (PDB), by technique and the
respective proteome as of March 2013. Complete reference proteomes were extracted from UniProtKB
(http://www.uniprot.org) and protein size estimated by converting length in amino acids to molecular
weight (1 residue = 110 Da). The PDB structures were extracted based on molecular weight of chain
A from all unique structures for each species (proteins with 100% similarity were removed). E. coli
proteome, •; human proteome, •; NMR structures, •; X-ray structures, •.
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cases, over-expression of a larger, or otherwise problematic protein can overload
the innate capacity of expressing cells to fold proteins. A large proportion of
known proteomes are composed of large multi-domain proteins, 40% in both
prokaryotic domains and 65% in eukaryotes (Ekman et al., 2005). As distinct
protein domains often fold more efficiently than larger multi-domain proteins,
a greater yield of soluble protein can be achieved by targeting distinct protein
domains. The common “domains in series” configuration of multi-domain proteins
usually allows for straightforward segregation of large multi-domain proteins into
distinct domains in determined structures, but it is often more difficult to predict
domain boundaries from primary sequence alone.
In general, truncation of a multi-domain protein to complete folding domains
produces protein fragments that are able to independently fold. However,
truncation of a protein within a distinct folding region more often produces an
aggregating protein species which can not fold appropriately (Figure 1.7). Many
proteins can be fragmented effectively into distinct soluble domains, although
some proteins prove problematic to fragment successfully. Indeed predicting
protein domains can be difficult (Sippl, 2009), as can finding an appropriate
position within a protein to form truncations.
1.4.1 Computational methods for protein domain identification
Computational methods are available for identification of the modular pieces
of a protein, which is often straightforward for proteins with close homologues
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Protein/gene fragmentation
Whole protein domains are soluble
Figure 1.7: Domain fragmentation. Cartoon representation of a multi-domain protein and truncated
protein domains. Long multi-domain proteins are composed of distinct folded domains. Truncation of
individual domains allows biochemical study of each piece in isolation and can be more successful.
Truncation of multi-domain proteins to distinct folded domains often results in a soluble protein.
However, truncation of a protein to a position within a folded unit commonly produces proteins
which do not fold. Coloured boxes represent well folded domains and grey boxes represent incomplete
protein domains which can not productively fold.
of known structure or domain boundaries, especially when domains are linked
by long flexible regions. Where close homologues are known, protein sequence
alignments can provide suggestions on where a folding unit ends and can be
useful in determining a suitable protein truncation. However, the ends of protein
domains often play a smaller role in folding pathways and structure stabilisation,
and are more likely to be obscured over evolutionary time.
1.4.1.1 Hidden Markov models and Pfam for protein domain identification
Statistical methods for predicting protein domains assume that the function,
structure and folding properties of a protein are conserved within a family, and
that this information must be represented somehow in the primary amino acid
Jeffrey R. Barrett 22
sequence. Thus, when folded protein features are conserved, the responsible
components of the amino acid sequence must also be conserved (Krogh et al.,
1994). In the vast majority of instances, the structure and folding properties
of proteins within a domain family are unknown, so statistical methods for
identifying conserved folded features from the primary sequence are required.
Hidden Markov model (HMM) profiles provide the probabilities of the identity of
each sequence position in a family of proteins and can even cope with insertions
and deletions. These HMM profiles can, with high success, identify related protein
sequences (Krogh et al., 1994), and with further examination of a HMM profile
can inform on the common structure present in the family.
The HMM methodology is utilised for the Pfam database, a tool for analysis
and collection of protein family relationships (Bateman et al., 2000, 2002).
For proteins represented by a Pfam entry (which covers about 80% of the
UniProt Knowledgebase; Punta et al., 2012), domain annotation can often be
straightforward. However, computational methodologies may not be appropriate
in all cases and are not useful for proteins with no homologues of known structure.
Knowing the likely protein domain boundary does not always help in identifying
an engineered protein that can be expressed in a soluble form.
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1.4.2 Experimental methods for protein domain identification
Varied methodologies are available for experimentally identifying protein domains
and these work either by truncating the protein itself or by expressing genes
coding for shortened mutants of the protein of interest. Limited proteolysis
approaches the identification of protein domains by relying on protease sensitivity
of the flexible inter-domain linkers commonly present between protein domains,
and has been in use for a long time (Schechter and Berger, 1967; Fontana et al.,
2004). Treatment of purified multi-domain proteins with limited amounts of
purified protease can result in cleavage of the full-length multi-domain protein
preferentially at flexible inter-domain linkers. These flexible linkers are able
to adapt into the protease active site, where bulky domains are inaccessible
(Herschlag, 1988). It can then be inferred from the positions of proteolysis which
regions of a protein are distinct folding units.
For limited proteolysis, useful protease active sites are selective and require peptide
binding in an unfolded state, which can often require a flexible extension 8–10
amino acids long that is not obstructed by the folded domains present (Herschlag,
1988). However, limited proteolysis does not select proteins for the complete
information to correctly fold or for regions important for maintaining protein
solubility, and in some cases, domain fragments liberated by limited proteolysis
are not expressable as soluble protein and/or are not soluble, presumably because
protease cleavage can often occur at surface loops within folded domains.
Linkers for closely fused domains are poorly accommodated within protease active
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sites and these are harder to identify (Tougu et al., 1994), and potentially flexible
linkers, which are identified in a binary manner with limited proteolysis, may be
in some form, functional. Also, to perform limited proteolysis, one must be able
to produce folded full-length protein. Methodologies which do not require the
ability to first produce soluble full-length proteins can potentially provide protein
domain information where techniques such as limited proteolysis can not.
1.5 Protein domain libraries
Gene fragmentation approaches the domain identification problem from a
perspective of protein folding; a truncated gene is expressed and assessed for
the ability to fold into soluble protein. Gene fragment libraries, where many
length variants are produced, contain protein coding genes shortened by some
semi-random process (Ostermeier et al., 1999; Ostermeier, 2003), which must then
be screened for production of soluble protein.
Methodologies for gene fragmentation can be classified into two modes: I)
uni-directional and II) bi-directional fragmentation. Uni-directional gene
truncation methodologies commonly utilise directional nuclease enzymes such as
exonuclease III (ExoIII) to processively remove one-or-other gene end (Ostermeier
et al., 1999), while bi-directional fragmentation methodologies fragment the gene
at each end simultaneously by digestion with DNAse I, utilising endonuclease
V hydrolysis at randomly incorporated dUMP sites (Miyazaki, 2002), or simply
by cloning sheared DNA. Bi-directional gene truncation has the advantage over
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uni-directional truncation that all possible variants of a gene may be produced;
however, a complete bi-directional library for a gene N nucleotides long is
comprised of ≈ N22 mutants while complete uni-directional libraries contain only
N mutants. Thus, uni-directionally deleted gene libraries are more straightforward
to sample to completion and should be sufficient as most protein domains occur
in series.
Production of uni-directionally deleted protein-fragment libraries can be targeted
for discovery of useful suspected domain boundaries, but may also be performed
over the entire gene to illuminate soluble-protein break points that are not
otherwise obvious. The methodology also has the advantage over limited
proteolysis, in that a number of slightly distinct deletions may be identified, for
example including and excluding flexible linkers or disordered regions that may
play functional roles.
1.6 Selecting for protein solubility
There are two categories of methodologies to screen for over-produced protein
solubility: I) direct examination from a soluble cell lysate, or II) implicit
examination using a proxy — where a measurable signal can be generated in vivo
that indicates soluble/insoluble protein has been over-expressed — to deduce
expression of soluble protein. Direct measurement of protein solubility from
cell lysates is straightforward; however, this methodology is poorly suited for
examining many proteins in a timely fashion.
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Proxy measurements for protein solubility allow uncomplicated examination
of protein solubility during over-expression by examining colony phenotype or
growth characteristics of the cell lines involved, and can be carried out at scale.
To this end, protein solubility reporting techniques regularly utilise a C-terminal
fusion protein, which allows for selection based on truncated gene reading
frame, and protein solubility (Waldo, 2003; Dyson et al., 2008). However, proxy
measurements for protein solubility require greater care to ensure the protein is
folded and useful; small peptides, proteolytic fragments, unintended translation
initiation and “passenger solubilised” proteins can produce a soluble proxy
protein in the absence of a useful protein of interest (Kawasaki and Inagaki, 2001;
Nakayama and Ohara, 2003). Other methodologies for discovering well folded
proteins include selection regimes utilising phage display (Sieber et al., 1998;
Jung et al., 1999; Christ and Winter, 2006) or use of cellular stress/mis-folding
responsive promoters, which drive a reporter gene (Cha et al., 1999; Cortazzo
et al., 2002; Lesley et al., 2002).
1.6.1 Dihydrofolate reductase and solubility reporting
Dihydrofolate reductase (DHFR) is essential in E. coli as the principal source
of tetrahydrofolate (THF) by NADPH reduction of dihydrofolate (DHF). THF
is itself essential due to its involvement as a coenzyme for synthesis of purines,
thymidylate and several amino acids (Fierke et al., 1987). DHFR can be inhibited
with the antibiotic trimethoprim (TMP) which binds in the DHF binding site
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of DHFR in place of DHF (Figure 1.8; Sawaya and Kraut, 1997; Barrow et al.,
2004).
A: Escherichia coli dihydrofolate reductase
occupied by dihydrofolate in its binding pocket
B: E. coli DHFR: dihydrofolate binding
site occupied by dihydrofolate
C: E. coli DHFR: dihydrofolate binding
site occupied by trimethoprim
Figure 1.8: Trimethoprim blocks the dihydrofolate binding site in dihydrofolate reductase. A:
Front view of Escherichia coli DHFR in complex with dihydrofolate (PDB: 1RF7; Sawaya and Kraut,
1997). B: Close up of E. coli DHFR binding site with resident DHF. C: Trimethoprim was modelled
into 1RF7 using the structure of Bacillus anthracis DHFR with bound TMP (PDB: 3JW3; Barrow
et al., 2004) and is shown as a close up of E. coli DHFR binding site.
Complementation of E. coli growth with TMP resistant murine DHFR in the
presence of TMP forms the basis of several bacterial selection systems (Mössner
et al., 2001; Koch et al., 2006; Dyson et al., 2008). However, over-expression of
soluble, endogenous E. coli DHFR can also overcome the TMP sensitivity of E.
coli (Liu et al., 2006). As such, both murine and E. coli DHFR have been used
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as solubility reporting fusion partners (Liu et al., 2006; Dyson et al., 2008) where
only cells expressing soluble DHFR-fusions can be grown in the presence of TMP.
However, this methodology has one caveat: fusion proteins that are capable of
correctly folding, yet are aggregation prone, are capable of “mopping up” TMP
prior to aggregation, thus it may serve more as a reporter of protein folding than
of overall protein folding and aggregation resistance.
Liu and colleagues (2006) showed that strains expressing various proteins fused
to the N-terminus of DHFR are resistant to TMP in proportion to the solubility
of the N-terminal protein. In these experiments two of the proteins were insoluble
when expressed alone and were not solubilised when expressed as a DHFR fusion.
After showing that TMP resistance was correlated with the solubility of the
N-terminal fusion protein, the authors then searched for solubilising mutations
of a newly discovered acetyltransferase (ACE) by performing DNA shuffling
(Stemmer, 1994). The resulting mutated ACE genes were then expressed as a
library of N-terminal fusion proteins to DHFR in E. coli, and from these they
were able to identify soluble ACE mutants by their resistance to TMP.
In another study, Dyson and colleagues (2008) were able to isolate soluble
protein fragments using murine DHFR as a C-terminal solubility reporting fusion
protein. Genes for a transcription factor and cell adhesion protein were randomly
fragmented with a nuclease, cloned upstream of DHFR and then expressed as
libraries in E. coli. From these experiments they were able to identify numerous
soluble fragments of both proteins by selecting for strains that could grow in the
presence of TMP.
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1.6.2 Green fluorescent protein and solubility reporting
Green fluorescent protein (GFP) is a well documented protein solubility reporter
(Waldo et al., 1999; Pédelacq et al., 2002; Nakayama and Ohara, 2003; Yumerefendi
et al., 2010). Maturation of GFP — from folding to assembly of its chromophore
— is a slow, multi-step and ordered process that has mostly been studied in
vitro (Figure 1.9; Reid and Flynn, 1997; Sniegowski et al., 2005b; Pouwels et al.,
2008); however, the time-scale for fluorescence development in vivo is similar
(Reid and Flynn, 1997). The GFP maturation process proceeds through protein
folding and then intra-molecular cyclisation at residues Ser65–Tyr66–Gly67, after
which reaction of the modified SYG residues with molecular oxygen generates the
green fluorescent chromophore (Figure 1.9A Reid and Flynn, 1997; Pouwels et al.,
2008). For maturation of the chromophore, each step must occur in sequence.
Correct protein folding places the SYG residues in a conformation required for
rearrangement and does not occur in incorrectly folded GFP and non-cyclised
SYG does not oxidise (Reid and Flynn, 1997; Pouwels et al., 2008). During the
final step of chromophore maturation, the chromophore is protected inside the
GFP structure and does not have ready access to oxygen, which must instead
diffuse through restricted pores within GFP (see Figure 1.9B–D; Heim et al.,
1994; Reid and Flynn, 1997; Rosenow et al., 2005; Sniegowski et al., 2005a).
The unfavourable oxidation step proceeds with a half-time on the order of one hour.
The slow maturation rate of GFP makes it exceptionally useful as a protein-fusion
Jeffrey R. Barrett 30








B: Ribbon diagram of GFP C: Surface diagram of GFP;
front
D: Surface diagram of GFP;
top
Figure 1.9: Chromophore maturation in green fluorescent protein. Development of green
chromophore fluorescence in green fluorescent protein takes a long time after expression of the
protein. GFPs have internal cavities through which molecular oxygen can access the immature
chromophore. The crystal structure for GFP (PDB: 1EMA; Ormo et al., 1996) was analysed using
Caver 3 (Chovancova et al., 2012), identifying internal channels with internal bottleneck dimensions
greater than 0.9 Å. A: Ball-and-stick representation of the GFP chromophore maturation pathway
(reaction half-times from Reid and Flynn (1997)). B: Ribbon diagram of GFP (front view) showing
the internal chromophore as a ball-and-stick model. C: (front) and D: (top) Surface diagram of GFP
(green) with internal cavities (white).
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solubility reporter. Once GFP has folded correctly, molecular oxygen must diffuse
to the solvent restricted protein core to oxidise the chromophore intermediate
to give rise to fluorescence and this does not occur when GFP is expressed in
inclusion bodies (Reid and Flynn, 1997). A GFP-fusion must fold correctly and
be maintained in solution for a long time prior to attainment of green fluorescence.
Numerous studies have used C-terminal GFP-fusions to measure the solubility
and stability of fused proteins (e.g., Pédelacq et al., 2002; Nakayama and Ohara,
2003; Pédelacq et al., 2005; Yumerefendi et al., 2010). For example, Waldo
and colleagues (1999) compared 20 Pyrobaculum aerophilum proteins that were
expressed with and without C-terminal GFP fusions in E. coli. These authors
found a very strong correlation between the measured fluorescence of cells that
expressed fusion-GFP and the amount of soluble protein without GFP. Waldo
et al. (1999) then randomly mutated genes for an insoluble ferritin protein and
cloned them to make C-terminal GFP fusions. When they expressed a library
of mutated ferritin-GFP genes in E. coli they were able to identify soluble
and functional ferritin. These results show that GFP is useful for correlating
fluorescence and the expression of productively folded and soluble proteins fused
with GFP.
1.7 Aims of this Thesis
In contrast to full-length proteins, smaller, distinct protein domains are generally
over-expressed more efficiently, fold faster and more efficiently, require less folding
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chaperone activity, are less likely to aggregate, and are more suited to structural
determination and other studies. Yet, protein domains are individual modules of
function and can yield much information about the biochemistry of a full-length
protein. However, identification of useful truncated protein domains can be
difficult. This work aimed to develop a pragmatic methodology to identify soluble
protein fragments (Chapter 3). We propose a plasmid system for gene truncation
and protein solubility selection using GFP or DHFR as solubility reporting fusion
proteins. Neither GFP nor DHFR appear to passenger solubilise protein fusions
(Dyson et al., 2004) and have previously been used for similar purposes (Waldo
et al., 1999; Pédelacq et al., 2005; Liu et al., 2006; Dyson et al., 2008).
Although bi-directional gene fragmentation can potentially produce isolated
examples of every domain present within a protein — and individual protein
folding units may be better behaved than a series of domains — this new
technique deletes genes uni-directionally. This methodology provides for more
straightforward sample manipulation and mutant analysis is more straightforward
as the possible variation is much smaller (N vs. ≈ N22 for bi-directional truncation).
Where the goal is identification of protein domain end points, deletion of a gene
uni-directionally and then selecting for soluble truncated proteins should be
sufficient, as only truncation end points outside of domains should make soluble
proteins. If indeed truncated proteins with more that one domain are less soluble
than if they had been first produced as single domain constructs, in many cases
they should still be partially soluble. Information about the solubility of mutants
truncated at different positions in the protein sequence can be used to infer the
proteins domain boundaries and facilitate the design of single domain proteins.
Jeffrey R. Barrett 33
This Thesis further aimed to use this pragmatic domain identification technique
to identify soluble domains of Acinetobacter baylyi DNA primase and the
Staphylococcus aureus cell division protein EzrA. In the case of A. baylyi DNA
primase, the protein has been resistant to identification of soluble constructs for
the N-terminal domain by traditional means. Meanwhile no domains are known
for S. aureus EzrA or its homologues.
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Chapter 2
General materials and methods
2.1 Chemicals, reagents, enzymes and instruments
All chemicals and reagents were of high quality and were purchased from
commercial suppliers. Restriction enzymes, mung bean nuclease and T4
deoxyribonucleic acid (DNA) ligase for molecular genetics were obtained from
New England Biolabs. DNA polymerase I Klenow fragment, exonuclease III,
S1 nuclease and T4 DNA ligase for construction of DNA truncation libraries
were from Promega. KOD DNA polymerase was from Novagen. ACCUZYME,
AccuSure, VELOCITY and BIOTAQ Red thermostable DNA polymerases were
supplied by Bioline (Australia), as were HyperLadder I DNA molecular size
marker and HyperPAGE protein molecular weight marker.
MilliQ water (18 MΩ.cm resistivity ultrapure water) was sourced from a MilliQ
system (Merck Millipore) and used in all experiments.
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2.2 Bacterial strains and transformation
The E. coli strains used in this study and their genotypes are listed in Table 2.1.
Table 2.1: Bacterial strains used in this work.
Strain Genotype
AN14591 E. coli K12 F−supE44 thi-I leuB6 thr-I ilvC hsdR recA
srlA::Tn10
BL21(λDE3)recA2 E. coli B F− ompT gal dcm Ion hsdSB(rB−mB−) gal
λ(DE3 [lacI lacUV5-T7 geneI indI sam7 nin5 ]) recA
srlA::Tn10
BL21(λDE3)recA/pLysS3 E. coli B F− ompT gal dcm Ion hsdSB(rB−mB−) gal
λ(DE3 [lacI lacUV5-T7 geneI indI sam7 nin5 ]) recA
srlA::Tn10 pLysS(CmR)
1 Elvin et al. (1986)
2 Studier and Moffatt (1986); Williams et al. (2002)
3 Studier and Moffatt (1986); Studier (1991); Williams et al. (2002)
2.2.1 Routine growth of Escherichia coli
Strains of E. coli were routinely grown in LB medium (Millers modification;
10 g.L−1 tryptone, 5 g.L−1 yeast extract and 10 g.L−1 NaCl; Miller, 1972)
supplemented as required with agar (15 g.L−1) and antibiotics (see Table 2.2).
Cultures were grown at 37◦C (unless otherwise stated) with shaking or in a plate
incubator as required.
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Table 2.2: Antibiotics used in this work.
Antibiotic Concentration used Stock solution
ampicillin 100 µg.mL−1 100 mg.mL−1
chloramphenicol 34 µg.mL−1 34 mg.mL−1
kanamycin 50 µg.mL−1 50 mg.mL−1
The standard measure of culture growth was optical density at 600 nm (A600)
measured using a BioPhotometer (Eppendorf). Culture density was measured in
a 1 cm path-length cuvette after dilution in fresh growth medium to cell densities
that gave readings below A600 of 1.
2.2.2 Clonal isolation of transformants
E. coli strains were clonally isolated by inoculation onto LB-agar using a sterile
pipette tip. Successive streaks with a sterile inoculating loop provided single,
isolated colonies after overnight incubation.
2.2.3 Transformation of Escherichia coli
Electrocompetent E. coli were prepared by inoculating LB with an overnight
culture and grown to an A600 of 0.6 AU. Bacterial cells were then collected by
centrifugation at 8,000 × g for 10 min. Cells were washed four times with 1/10
culture volume of water by resuspension and centrifugation at 8,000 × g for 10
min. Cells were resuspended in 1/50 culture volume of 10% glycerol, frozen in
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liquid nitrogen and stored at −80◦C.
Transformation of electrocompetent E. coli cells was carried out using a
MicroPulser system (Bio-Rad; Ausubel et al., 1987; Miller and Nickoloff, 1995)
as per manufacturer’s instructions with a chilled 0.1 cm cuvette (single 1.8 kV
pulse; Bio-Rad) with either 1 µL of supercoiled plasmid DNA or 4 µL of ligation
mixture. Immediately following transformation, E. coli cells were recovered with
1 mL LB and incubated at 37◦C for 1 h. Recovered transformed E. coli cells
were spread on an appropriate LB agar plate and incubated overnight at the
appropriate temperature.
Transformation efficiency of ligations was increased when required by heat
inactivating T4 DNA ligase by incubation at 65◦C for 10 min and/or desalting
the ligation mixture using a Nanosep size exclusion spin column (MWCO 300
kDa, Pall).
2.2.4 Long term storage of bacterial strains
For storage, E. coli strains were prepared by adjusting 1 mL of an overnight
culture to contain 7% dimethyl sulfoxide (DMSO) and stored at −80◦C.
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2.3 Molecular genetics
2.3.1 Preparation of plasmid DNA
2.3.1.1 Plasmid purification by mini-prep
Small scale preparation (< 20 µg DNA) of cloned plasmids from E. coli was
performed using QIAprep Spin Miniprep kit (QIAGEN) using the methods
supplied, except that cells for plasmid DNA preparation were collected from
overnight cultures on LB agar plates containing the appropriate antibiotics
(Section 2.2.1) and plasmids were eluted and stored in 10 mM Tris-HCl, 1 mM
EDTA, pH 8.0 (TE).
2.3.1.2 Plasmid purification by maxi-prep
Large scale purification (< 500 µg DNA) of plasmids from E. coli was performed
using QIAGEN MAXI kits using the protocol supplied for low copy number
plasmids. Plasmids were eluted and stored in TE.
2.3.2 Restriction digestion of DNA
Restriction endonuclease digests were carried out in buffers supplied and at
temperatures recommended by the manufacturer (New England Biolabs; Appendix
D). When two or more restriction enzymes with different buffer requirements
were used, digestion conditions were as suggested by the manufacturer for double
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or sequential digestion. As a general rule, reactions were designed to digest twice
the amount of DNA present; the number of units of (each) enzyme was twice the
DNA content of the mixture in µg and the reaction was for 1 h.
2.3.3 Preparation of oligonucleotides
Synthetic oligonucleotides used throughout this study were supplied as lyophilised
powders at PCR/sequencing grade from GeneWorks. Prior to use oligonucleotides
were resuspended and stored in TE at 100 mM (−20◦C) or 5 mM (4◦C).
Oligonucleotide sequences can be found in Appendix C.
2.3.4 Amplification of DNA by polymerase chain reaction
Several thermostable DNA polymerases were used in this work; some of them
were used under unique DNA extension conditions. Typical polymerase chain
reaction (PCR) cycle parameters were 60 s incubation at 96◦C followed by 30
cycles of 96◦C for 15 s; 55◦C for 15 s; and see Table 2.3 for DNA extension
conditions. Reactions were completed with a final cycle at 72◦C for 5 min.
A typical PCR mixture contained the appropriate enzyme buffer (Appendix D)
with 500 µM each deoxynucleoside 5'-triphosphate (dNTP) and 2 mM MgCl2
and 50 mUnits of DNA polymerase per 10 µL total volume. PCR products were
analysed by agarose gel electrophoresis (Section 2.3.6).
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Table 2.3: Extension parameters for thermostable DNA polymerases
DNA polymerase Extension temperature Incorporation rate
BIOTAQ Red 72◦C 30 s.kb−1
ACCUSURE (activated at 95◦C for 10 min) 72◦C 30 s.kb−1
ACCUZYME 72◦C 120 s.kb−1
VELOCITY 72◦C 30 s.kb−1
KOD 72◦C 30 s.kb−1
2.3.4.1 Colony PCR
Colony PCR was conducted on clonally isolated E. coli by inoculating a single
colony to a 10 µL BIOTAQ Red PCR mixture and an LB agar plate in series.
Reaction conditions were as in Section 2.3.4 with an initial denaturation step for
three min at 96◦C for cell lysis. Cells on the plate were grown overnight and PCR
positive mutants were selected from the matching smear.
2.3.5 Colony PCR and storage of truncation libraries
To allow storage of colonies from truncation libraries, the colony PCR methodology
(Section 2.3.4.1) was modified to allow for freezer strains to be made at the same
time as colony PCR. Prior to inoculation of BIOTAQ PCR mixtures, storage
strains of isolated colonies were produced by inoculation of 200 µL LB medium
containing 7% DMSO in wells of a 96-well plate. 1 µL aliquots of the colony storage
solution were used to inoculate a colony PCR as per Section 2.3.4.1. Truncation
library colonies in 96-well plates were stored at −80◦C.
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2.3.6 Electrophoresis of DNA
Agarose gels for electrophoresis of DNA were cast in a Mini-Sub Cell GT
apparatus (Bio-Rad) containing agarose concentrations of 0.5–2% (w/v) in TBE
(89 mM Tris-borate, 2 mM EDTA; Sambrook et al., 1989) containing 0.5 µg/mL
ethidium bromide. DNA samples were mixed with 1/6 volume of TriColor DNA
loading dye (Bioline) and loaded into agarose wells. Samples were electrophoresed
at 50 V, or transferred to the gel matrix at 20 V then separated at 50 V using
a PowerPac Basic Power Supply (Bio-Rad). DNA in agarose gels was visualised
using a long-wave UV handheld lamp or visualised and imaged using a short-wave
UV transilluminator (Molecular Imager Gel Doc XR+ System; Bio-Rad).
2.3.7 Isolation of DNA reaction products by agarose gel
electrophoresis
Isolation of DNA fragments separated by agarose gel electrophoresis (Section
2.3.6) was done using QIAquick Gel Extraction kits (QIAGEN). DNA bands were
visualised under long-wave UV and gel slices extracted using a scalpel. DNA
extraction from agarose gel slices followed manufacturer’s instructions; DNA was
eluted and stored in TE.
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2.3.8 Isolation of DNA reaction products by silica column
Purification of PCR products and some DNA restriction fragments was carried
out using QIAquick DNA purification kits. For purification of products larger
than 100 bp, the manufacturer’s protocol for purification of PCR products was
followed. For purification of 70–100 bp products, a modified gel purification
protocol was performed following manufacturer’s instructions (substituting the
total reaction volume for the value of gel volume). DNA was eluted and stored in
TE.
2.3.9 Isolation of DNA reaction products by ethanol precipitation
DNA precipitation was performed by addition of 0.1 volume of 3 M sodium
acetate (pH 5.3), 0.1 volume of 125 mM EDTA and 2.5 volumes of absolute
ethanol. After 15 min at 0◦C, the sample was centrifuged for 15 min at 21,000
× g. The supernatant was replaced with 70% ethanol (−20◦C), re-centrifuged
and then removed. Once the pellets had air dried, the purified DNA was gently
resuspended in TE to a suitable volume.
2.3.10 Ligation of DNA
Routine DNA ligations were done using T4 DNA ligase (New England Biolabs)
overnight at 4◦C.
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2.3.10.1 Ligation of cohesive DNA termini
Typical subcloning or cloning of PCR products aimed to include 40 ng of plasmid
DNA, 200 ng of insert DNA and 200 cohesive end units of T4 DNA ligase per 20
µL reaction in New England Biolabs T4 DNA ligase buffer (Appendix D).
2.3.10.2 Ligation of oligonucleotide linkers to plasmid DNA
Routine ligation of oligonucleotide linkers into plasmid DNA aimed to include 40
ng of plasmid DNA, 25 µM of each unphosphorylated, unhybridised oligonucleotide
and 200 cohesive end units of T4 DNA ligase per 20 µL reaction in New England
Biolabs T4 DNA ligase buffer.
2.3.11 Dye terminator sequencing of DNA
Plasmid DNA sequences were determined using DNA products made using
ABI BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems). Cycle
parameters were: 60 s incubation at 96◦C, followed by 10 cycles of 96◦C for 10 s,
50◦C for 5 s, 60◦C for 75 s, then 5 cycles of 96◦C for 10 s, 50◦C for 5 s, 60◦C for 90
s, then 5 cycles of 96◦C for 10 s, 50◦C for 5 s, 60◦C for 120 s (Platt et al., 2007).
Product DNA was recovered by ethanol precipitation (Section 2.3.9). Purified
sequencing reaction products were separated and visualised on an ABI 3130xl
Genetic Analyzer (Applied Biosystems). Sequencing of the protein coding regions
and multiple cloning sites (MCSs) within T7 expression plasmids used primers
PET3, PET4, 235 and 549; PET3 primes the sense strand from the T7 promoter,
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PET4 primes the anti-sense strand from the T7 terminator and primers 235 or
549 prime the anti-sense strand from the start of the egfp gene (Table 2.4).
Table 2.4: Sequencing primers.
Primer Sequence 5'-3' Position DNA Strand
PET3 1 CGACTCACTATAGGGAGACCACAAC T7 promoter sense
PET4 1 CCTTTCGGGCTTTGTTAGCAG T7 terminator anti-sense
235 CTCGCCCTTGCTCACC start of egfp anti-sense
549 CAGGATGGGCACCACC start of egfp anti-sense
1 (Neylon et al., 2000)
2.4 Estimation of DNA concentrations
2.4.1 Estimation of DNA concentration by agarose gel electrophoresis
Estimation of DNA concentration by agarose gel electrophoresis was conducted
with multiple dilutions of a single sample by comparison with known amounts
of DNA molecular size standard, following staining with ethidium bromide and
visualisation with UV irradiation.
2.4.2 Spectrophotometric determination of DNA concentration
Spectrophotometric estimation of DNA concentration was performed by
measuring absorbance at 260 nm (A260) using a NanoDrop 2000c instrument
(Thermo Scientific), using two µL samples referenced against equivalent/identical
Jeffrey R. Barrett 45
buffer. In early experiments, spectrophotometric estimation of concentrations of
DNA was made by measuring A260 using a UVette cuvette and BioPhotometer
spectrophotometer (Eppendorf).
2.5 Protein over-expression and purification
Protein coding DNA sequences were placed downstream of the T7 promoter and
the ribosome binding site (RBS) of vector pETMCSI (and derivatives; Neylon
et al. 2000), by placing the initiation codon within the NdeI (5'-CATATG-3') site.
Alternatively N-terminal deletion plasmids use an NcoI (5'-CCATGG-3') site for
initiation following library construction. pETMCSI and related plasmids confer
resistance to ampicillin through the included bla gene.
2.5.1 Protein expression by auto-induction
Over-expression of protein encoded on T7 promoter plasmids was carried out
in the E. coli BL21(λDE3)recA strain by the auto-induction method (Studier,
2005). Culture vessels (2 L baffled Erlenmeyer flasks) contained 350 mL of
ZYP-5052 medium (10 g.L−1 tryptone, 5 g.L−1 yeast extract, 2 mM MgSO4, 50
mM Na2HPO4, 50 mM KH2PO4, 25 mM [NH4]2SO4, 5 g.L−1 glycerol, 0.5 g.L−1
glucose, 2 g.L−1 α-lactose monohydrate) and were incubated at 30◦C with shaking
at 200 rpm for 24–36 h. Following cell growth, all steps in protein isolation were
conducted at 4◦C unless otherwise stated.
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2.5.2 Cell lysis by French press
As required, E. coli cells were harvested by centrifugation (8,000 × g), resuspended
in a lysis buffer containing 50 mM Tris-HCl, 300 mM NaCl (15 mL per g of cells),
and lysed in a French press cell disruptor using a 40 K pressure cell (Thermo
Electron Corporation) set to 16,000 psi. Typical samples were lysed in 30 mL
aliquots with three passes through the chilled cell.
2.5.3 Clarification of bacterial lysates
Following French press lysis, cellular lysate was clarified by centrifugation in a
chilled SS34 rotor in a Sorvall RC6+ centrifuge at 30,000 × g for 30 min. The
supernatant containing soluble proteins was either flash frozen with liquid N2 and
stored at −80◦C or directly processed. When required, proteins in the pellet were
solubilised in 8 M urea.
2.5.4 Protein purification using ÄKTA FPLC systems
Proteins were purified chromatographically using fast protein liquid
chromatography (FPLC) with ÄKTApurifier systems (GE Healthcare Life
Sciences). Resins, protocols and columns used in protein chromatography are
described in the text. Proteins and buffers for chromatography were vacuum
filtered through 0.45 µm filters (Merck Millipore).
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2.5.5 Determination of protein concentration
Protein concentrations were determined by measuring absorbance at 280 nm (A280)
using either 500 µL quartz cuvettes and a BioPhotometer spectrophotometer
(Eppendorf) or two µL samples using a NanoDrop 2000c. Predicted molar
extinction coefficients of proteins were estimated from their amino acid
compositions using ProtParam (Gasteiger et al., 2005).
2.5.6 Protein dialysis
Protein buffer exchange was performed by dialysis in Spectra/Por dialysis
membrane sacs (Spectrum Laboratories), typically with a molecular weight cut
off (MWCO) less than half of the protein’s molecular weight. Dialysis was at
4◦C using at least 10 volumes of buffer relative to sample, with three buffer changes.
2.5.7 Storage of proteins
Partially or fully purified proteins were frozen in liquid N2 and stored at −80◦C.
2.5.8 Concentration of protein samples
Purified proteins were concentrated using Amicon Ultra-4 centrifugal filter
units (Merck Millipore) with a MWCO less than half of the protein’s molecular
weight following manufacturer’s instructions. Filter units were rinsed repeatedly
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with MilliQ water prior to addition of the protein sample. Centrifugation for
protein concentration used a Sorvall Super T21 refrigerated centrifuge fitted with
an ST-H750 rotor (Thermo-Scientific). To prevent over concentration, protein
samples were mixed by inversion between additional centrifugation steps.
2.5.9 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
Electrophoresis of proteins under denaturing conditions used NuPAGE Novex
Bis-Tris pre-cast polyacrylamide gels (Invitrogen) or Mini-PROTEAN TGX
4–20% pre-cast polyacrylamide gels (Bio-Rad), with electrophoresis at 200 V for
an appropriate duration.
Proteins for sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis
(PAGE) were mixed with an appropriate amount of either SDS sample buffer
(1X: 50 mM Tris-HCl pH 6.8, 2% w/v SDS, 0.1% bromophenol blue; Sambrook
et al., 1989) or NuPAGE LDS sample buffer (1X: 61.75 mM Tris-HCl pH 8.5,
0.5% lithium dodecyl sulphate, 2.5% glycerol, 0.13 mM EDTA, 0.06 mM SERVA
Blue G250, 0.44 mM phenol red; Invitrogen) freshly prepared with 50 mM
dithiothreitol (DTT), and then heated at 80◦C for 10 min prior to loading into an
appropriate pre-cast SDS-PAGE gel. Before loading, crude protein samples from
SDS-lysed cells were routinely drawn into a 50 µL syringe (Hamilton) to shear
DNA.
SDS-PAGE gels were washed with water, then fixed and stained for 20 min in
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hot staining solution (40% methanol, 10% acetic acid and 0.2% Coomassie blue)
and destained in hot de-staining solution (10% acetic acid and 10% propan-2-ol).
De-stained SDS-PAGE gels were imaged with a Molecular Imager Gel Doc XR+
System (Bio-Rad).
2.5.9.1 Invitrogen NuPAGE gels
NuPAGE 4–12% Bis-Tris pre-cast gels (Invitrogen) were prepared in a XCell4
SureLock Midi-Cell tank (Invitrogen) with MES running buffer (50 mM MES,
50 mM Tris-base, 0.1% SDS, 1 mM EDTA, pH 7.3) as per manufacturer’s
instructions. Samples were loaded into wells and separated by electrophoresis for
45 min at 200 V with a PowerPac Basic Power Supply (Bio-Rad).
2.5.9.2 Bio-Rad gels
Mini-PROTEAN TGX 4–20% pre-cast polyacrylamide gels (Bio-Rad) were
prepared in a Mini-PROTEAN System tank (Bio-Rad) with Tris/glycine running
buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3). Samples were loaded
into wells and separated by electrophoresis as above (Section 2.5.9.1).
2.5.10 Mass spectrometry of proteins samples
Prior to mass spectrometric analysis, protein samples were dialysed at 4◦C
(three buffer changes) in either native (100 mM ammonium acetate pH 7.2
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and 1 mM β-mercaptoethanol) or denaturing (0.1% formic acid and 0.5 mM
β-mercaptoethanol) buffers.
Mass spectrometry was done at the University of Wollongong Mass Spectrometry
User Resource and Research Facility with either a quadrupole time-of-flight
(Q-ToF) Ultima mass spectrometer (factory modified for high mass/charge
transmission; Waters), or a Synapt Q-Tof/ion mobility mass spectrometer
(Waters), each calibrated using a solution of caesium iodide (10 mg.mL−1 in 70%
isopropanol). Mass spectra were collected in positive ion mode using electrospray
ionisation and analysed using MassLynx 4.1 software (Waters). Numerous
acquisitions were combined and smoothed using a Savitzky-Golay algorithm.
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Chapter 3
Gene deletion and solubility selection
3.1 Introduction
Multiple distinct properties of a protein can lead to a poor soluble protein yield
during over-expression, producing protein aggregates that are not generally useful
for experimental study. Large multi-domain proteins can contain multiple regions
that fold poorly or slowly, causing aggregation of over-expressed protein. In
these situations, the contribution of each troublesome protein region to reducing
soluble protein yield is multiplicative. As a result, expression of protein domains
individually can produce higher soluble protein yields compared to expression of
the same domains as part of a multi-domain protein.
By separating a large multi-domain protein — that does make soluble protein
when over-expressed — into distinct smaller, folded sections, soluble protein yield
is improved and the resulting proteins can be more suitable for experimental
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study. However, designing a truncated version of a protein is not necessarily
straightforward. Multiple methodologies have been developed for discovering
soluble protein truncation variants; however, in the case of some protein variants
a difference of a single amino acid can lead to poor yield of an over-expressed
protein and make identification of useful truncated protein more difficult.
Uni-directionally deleted gene libraries for a gene of interest can be made using
a combination of ExoIII and mung bean nuclease (Henikoff, 1984); and can be
utilised to provide a random pool of genes encoding proteins of varied sizes.
A truncated protein library should contain mostly incomplete domain units —
which have been truncated within a folding unit — but in the mix there may
also be useful mutants which are not truncated within a domain. Protein mutants
which have been conveniently truncated in a unstructured region, in many cases,
are likely to represent the boundaries of protein domains. Screening of truncated
gene libraries for useful domain truncations can then make use of the expected
differences between mutants which contain whole folding units and those that do
not. Intact folded protein domains should often be soluble, whereas incomplete
domains will often aggregate; but in the end, having any soluble, well-behaved
protein to work with is all that is required to enable structural and functional
studies to proceed.
By performing domain deletion experiments so that the resulting truncated
proteins are expressed as fusions to a second protein with an easily observable
phenotype, colonies expressing useful protein mutants can be identified easily
by culture on agar plates. Although this methodology may not be useful for
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all proteins, protein domain identification using this technique promises to be
quick and straightforward for screening lots of unique protein mutants at once.
Truncated protein mutants which are folded, soluble and useful for further study
can then be expressed separately and used for other experiments.
3.1.1 Gene truncation using exonuclease III
ExoIII is a double stranded DNA (dsDNA) specific exonuclease which hydrolyses
DNA in the 3' to 5' direction in a non-processive manner to generate products
with single-stranded (ss) 5' overhangs (Putney et al., 1981; Henikoff, 1984). It can
then be utilised in combination with a ssDNA nuclease to perform uni-directional
DNA truncation (Hoheisel, 1993; Ostermeier, 2003). The ExoIII reaction is well
understood and deletion using ExoIII allows tailoring of deletion distributions to
interesting regions by careful timing of truncation reactions (Ostermeier, 2003).
ExoIII can only digest DNA from 3' ends in dsDNA, and cannot hydrolyse
DNA past a modified α-thio-substituted (αS) nucleotide (Putney et al., 1981;
Henikoff, 1984). To produce uni-directional gene truncations in a plasmid destined
to subsequently be recircularised (as here), dissimilar DNA ends are required
in a dsDNA fragment, one end that is resistant to digestion with ExoIII and
one that is not. Often ExoIII protected ends are produced by using a DNA
polymerase to incorporate αS nucleotides at 5' DNA overhangs of plasmids
that have been linearised by a restriction endonuclease (producing a linearised
plasmid with two ExoIII resistant ends). Subsequent removal of a single ExoIII
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protected DNA end with a second endonuclease produces a template suitable
for uni-directional truncation. Since uni-directional gene truncation with ExoIII
removes only one DNA strand, production of plasmids with truncated genes
requires removal of ssDNA using mung bean (or S1) nuclease. DNA truncation
products made with ExoIII and mung bean nuclease often ligate poorly, so DNA
end repair using the Klenow fragment of DNA polymerase I is required prior to
plasmid ligation. Hoheisel (1993) experimentally identified that the ExoIII reaction
produces products of lengths that follow a Gaussian distribution (Equation 3.1),
where L = mean truncation length, N = number of bases truncated and standard
deviation σ = cL (c = 0.075; however, 9% of truncated gene products are truncated







; z = L−N
σ
(3.1)
As the ExoIII reaction proceeds, the distribution of truncation lengths expands,
so that deleting short sections of a gene produces a pool of different lengths with
a small standard deviation compared to longer deletions. As a result, removal
of small portions of a gene requires many individual time-point samples to
adequately analyse an extended region of interest to compensate for the tight
grouping of truncations, while removing longer sections produces a wide spread of
sizes; for illustration see Figure 3.1.
















Figure 3.1: Distribution of exonuclease III truncation reaction products. The predicted
distribution of products of an ideal ExoIII uni-directional truncation reaction modelled using Equation
3.1 where L = mean truncation length (50, 250, 450 and 650 nucleotides), N = truncated gene
size and c = 0.075 (Hoheisel, 1993; Ostermeier, 2003). As the ExoIII deletion reaction proceeds the
distribution of different sized products expands.
3.2 Aims
This Chapter presents a plasmid based methodology to I) produce a comprehensive
large library of protein mutants of varied lengths and II) use a pragmatic assay
of truncated mutants to select for protein solubility (and those in the correct
reading frame) to infer successful expression of folded protein segments. The
plasmids designed for these experiments also encode appropriately placed protein
purification tags for straightforward purification of interesting mutant proteins
and are modular to allow easy modification to remove the purification and/or
solubility reporting fusion protein depending on experimental need.
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3.3 A technique for gene truncation and solubility selection
The methodology developed in this work is based around a series of plasmids
described in this Chapter. Separate plasmids for N- or C-terminal gene deletion
encode downstream purification and solubility reporting protein fusions and
contain two restriction sites X and Y (or M and N ) at the end of the gene to
be truncated (Figure 3.2A). Restriction endonuclease treatment of a deletion
plasmid at X (or M ) generates a 5' overhang that is end filled with DNA
polymerase I (Klenow fragment) and dNTP-αS to make a linear DNA that
is resistant to ExoIII hydrolysis. Then, digestion with Y (or N ) generates a
new 5' overhang that is susceptible to uni-directional digestion with ExoIII
(Figure 3.2B). Timed exonuclease reactions generate a library of gene deletions
targeted to end in a region of interest. After a truncated gene library has been
made, the plasmids are circularised and the pool can then be transformed into
an E. coli protein over-expression strain and cultured on agar plates where
induction of over-expression produces a different truncated protein in each colony;
over-expressing colonies that develop the phenotype associated with expression
of a folded solubility reporting protein should be expected to contain in-frame,
folded and soluble truncated mutants of the protein of interest. Plasmids with
genes that direct expression of putative soluble protein fragments can then be
easily identified and used for further study.
The technique we developed uses a suite of plasmids derived from the T7
expression plasmid pETMCSI (Neylon et al., 2000) which allow high-level protein
over-expression. Separate vectors were made (see Section 3.4.9) for each of: I) gene
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B: Overview of methodology for generating uni-directional gene truncation library
I) Linearise with Endo X
II) End fill with PolI α-S nucleotides
III) Cleave with Endo Y
V) ssDNA removal with 
mung bean nuclease
VI) Repair and re-circularise
plasmid library
VII) Express truncated





Figure 3.2: Methodology for uni-directional gene truncation. A: Plasmids for domain truncation
contain an N-terminal gene of interest and, when plasmids are appropriately truncated, an in-frame
sequence encoding a C-terminal purification tag and solubility reporting protein. Restriction sites X
and Y (at the start of the gene or M and N at the end) are used to produce a DNA template
for uni-directional gene deletion. B: Methodology for uni-directional gene deletion and solubility
selection: I, Linearisation of deletion plasmids with restriction enzyme X (or M). II, End filling with
DNA polymerase I (Klenow) and αS nucleotides produces linear DNA resistant to ExoIII. III, Cleavage
with Y produces a 5' overhang from which ExoIII can produce uni-directional deletions through the
gene of interest. IV, Timed ExoIII reactions allow the size of truncated genes to be targeted to regions
of interest. V, ssDNA extensions are removed from deleted plasmids with mung bean nuclease. VI,
Truncated plasmids are repaired and ligated using DNA polymerase, dNTP and T4 DNA ligase. VII,
Plasmid pool is transformed into an E. coli strain to express truncated proteins and solubility reporting
fusion proteins, enabling useful truncated proteins to be identified or selected. 58
deletion from the 5' or 3' end; II) protein purification with a His6, Ktag (Bioline
Australia, personal communication) or biotinylation tag (E. coli biotin ligase
recognition sequence); and III) passenger solubility reporting using enhanced
green fluorescent protein (EGFP) or E. coli dihydrofolate reductase DHFR.
3.3.1 Gene fusion for solubility selection
The gene fusion plasmids presented here are designed to encode solubility
indicating proteins (EGFP or DHFR), which have been previously shown to
indicate folding and solubility when expressed as fusions to other proteins (see
Sections 1.6.1 and 1.6.2).
A uni-directional gene truncation library produced with ExoIII results in DNA
products terminating at all three codon positions. As a result, two out of three
resulting genes within a library will contain a non-sense gene of interest. Selection
against out-of-frame truncated mutants is carried out by placing the solubility
reporting gene downstream of the gene of interest so that genes resulting from
truncation with ExoIII — when not in the correct reading frame — will either not
initiate protein translation (out-of-frame N-deleted mutants), or not be expressed
as a fusion with the solubility reporting protein (out-of-frame C-deleted mutants).
In addition, to stop non-truncated plasmids from producing solubility reporter
in in vivo solubility assays, the plasmids have been designed so that I) genes of
interest in N-terminal deletion plasmids are not expressed or II) genes of interest
in C-terminal deletion plasmids are not in-frame with (and have stop codons
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before) the solubility reporters until after truncations have been made with ExoIII.
3.3.2 Layout of plasmids for gene truncation using exonuclease III
All gene deletion plasmids in this work have been designed so that the start codon
of a gene of interest is placed within a unique NdeI restriction site (5'-CATATG-3')
and the end of the gene is immediately followed by a BamHI site (Figure 3.3).
The separate plasmids for generating N- or C-terminal deleted genes are designed
so that digestion with NcoI (5'-CCATGG-3') and subsequent protection using
DNA polymerase I (Klenow) to incorporate dGMPαS (and dAMP, dCMP and
dTMP) produces ExoIII resistant DNA ends.
gene of interest solubilityselection
purification tag
NdeI BamHINcoI (N-del) NcoI (C-del)
Figure 3.3: General layout of gene truncation and solubility reporting plasmids. The start codon
of a gene of interest is placed at a unique NdeI restriction site and the gene directly followed by a
unique BamHI site. N-terminal deletion plasmids have a unique NcoI restriction site that ultimately
contains the start codon of the gene of interest and C-terminal deletion plasmids have an NcoI
restriction site downstream of the end of the gene of interest.
3.3.2.1 Plasmids for N-terminal deletion
In an experiment to generate an N-terminal gene deletion library (Figure 3.4),
the gene of interest is placed in-frame with the solubility reporter. The original
start codon of the gene is deleted by ExoIII, so plasmids for gene deletion are
designed to introduce a new start codon. The use of a unique NcoI site — which
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NcoI NdeI BamHI
  |                                 |                       |
ACCATGGCGACCTCGTGAAGGGTGTGCCTGAGTACATATGNNNNNNNNNNNNNNNNNN-GGATCC
---------+---------+---------+---------+---------+---------+---------+---------+
   M  A  T  S  *
*        M                     G  S
NcoI NdeI                   BamHI  
|                                           |                       |
ACCATG CATGGCGACCTCGTGAAGGGTGTGCCTGAGTACATATGNNNNNNNNNNNNNNNNNN-GGATCC
TGGTAC GTACCGCTGGAGCACTTCCCACACGGACTCATGTATACNNNNNNNNNNNNNNNNNN-GGATCC
M                                           M
NcoI BamHI
|                                                                   |
ACCATG TATGNNNNNNNNNNNNNNNNNN-GGATCC
TGGTAC             ACNNNNNNNNNNNNNNNNNN-GGATCC
M                                           M
NdeI                    BamHI  
                                              |                        |
AC    CATGGCGACCTCGTGAAGGGTGTGCCTGAGTACATATGNNNNNNNNNNNNNNNNNN-GGATCC
TGGTAC     CGCTGGAGCACTTCCCACACGGACTCATGTATACNNNNNNNNNNNNNNNNNN-GGATCC













|                                 |                                      |
ACCATGGCGACCTCGTGAAGGGTGTGCCTGAGTACATATGGTAGAGGCTTTGCTATTCAGCGTTTGATGAATGAGGATCC
---------+---------+---------+---------+---------+---------+---------+---------+
   M  A  T  S  *
*        M





Insert gene of interest
Figure 3.4: Cloning site for N-terminal gene truncation and solubility reporting plasmids.
N-terminal deletion site for a gene of interest; f0–2 show the three reading frames where f0 is the
reading frame of the protein translation start codon and f2 is the reading frame of the solubility reporter
starting with the sequence Gly-Ser (BamHI site). After a gene of interest is placed between the NdeI
and BamHI sites ending in f2 (no additional nucleotides are present between the gene coding sequence
and the BamHI site; represented by NNN. . . ), the gene of interest and that encoding the solubility
reporter are in-frame and uni-directional gene deletion using this series of plasmids is accomplished by
restriction with NcoI and end filling with dGTPαS (red); dATP, dCTP and dTTP (green) using DNA
polymerase I (Klenow). Restriction with NdeI generates the substrate for N-terminal uni-directional
deletion with ExoIII. Following gene truncation, one in three mutants will be in-frame with the start
codon at the remainder of the NcoI restriction site (green and red). When the gene of interest is
placed in-frame with the downstream purification and solubility reporting fusion gene, deleted ge
can be screened in vivo for expression of in-frame and soluble protein.
nes
contains the sequence ATG — to produce the ExoIII resistant αS-protected sites
in N-terminal deletion plasmids is placed in an appropriate position downstream
of the RBS for initiation of protein synthesis. The initiation codon present in the
NcoI site of N-deletion plasmids is out-of-frame with the gene, ensuring that it
can only be over-expressed after truncation by ExoIII. Digestion of the ExoIII
resistant linear plasmids with NdeI makes a DNA substrate for uni-directional
ExoIII truncation.
3.3.2.2 Plasmids for C-terminal deletion
For C-terminal gene deletion (Figure 3.5), the gene of interest is inserted in-frame
with the protein translation initiation codon and the end of the gene is followed
by stop codons in all three reading frames to prevent expression of the solubility
reporter in the event that deletion from the 3' end has not occurred. The unique
NcoI site in the C-terminal deletion plasmids is placed downstream of the gene of
interest and is used to generate the ExoIII resistant site by end filling. After gene
truncation, the protected NcoI site codes for the start of the flexible linker prior
to the protein purification tag. Protection using dGTPαS generates a sequence
encoding a peptide linker starting with His-Gly while use of dCTPαS makes
one that begins with Gly. The ExoIII sensitive end is generated by digesting the
plasmid with BamHI. A gene of interest cloned into frame 1 cannot be expressed
in-frame with the solubility reporter until the plasmid has been digested with
ExoIII.
A further C-terminal deletion plasmid was designed that uses Nt.BbvCI — a
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    RBS         NdeI                    BamHI             NcoI
|---------|      |                        |                |
TAAGAAGGAGATATACATATG-NNNNNNNNNNNNNNNNNNNGGATCCTAAGTAACTAACCATGGCTCCTCTGGG
---------+---------+---------+---------+---------+---------+---------+----
                  M                      G  S  *        N  H  G  S  S  G
                                                   *        






End-fill with  dGTPαS and dATP, dCTP, dTTP
Restriction with BamHI
fusion
                   BamHI                 
                     |                     
NNNNNNNNNNNNNNNNNNNNGGATCCTAAGTAACTAAC                  CATGGCTCCTCTGGG
NNNNNNNNNNNNNNNNNNNNCCTAGGATTCATTGATTGGTAC                  CGAGGAGACCC
                                                        
                    
Gene of interest fusion
                   BamHI                 
                     |                     
NNNNNNNNNNNNNNNNNNNNGGATCCTAAGTAACTAACCATG               CATGGCTCCTCTGGG
NNNNNNNNNNNNNNNNNNNNCCTAGGATTCATTGATTGGTAC               GTACCGAGGAGACCC
                                                         H  G  S  S  GGene of interest fusion
                                
                                      
NNNNNNNNNNNNNNNNNNNNG                                    CATGGCTCCTCTGGG
NNNNNNNNNNNNNNNNNNNNCCTAG                                GTACCGAGGAGACCC
                                                         H  G  S  S  GGene of interest fusion
ExoIII-resistantExoIII-sensitive
Figure 3.5: Cloning site for C-terminal gene truncation and solubility reporting plasmids.
C-terminal deletion DNA sequence for uni-directional gene truncation; f0–2 show the three reading
frames where f0 is the reading frame of the initiation codon. Placing a gene of interest so that it
ends in f1 (by addition of a single nucleotide between the gene coding sequence and BamHI site)
will prevent expression of in-frame solubility reporter unless truncated with ExoIII. After a gene of
interest (represented by NNN. . . ) is placed between the NdeI and BamHI restriction sites, cutting
the plasmid with NcoI, end filling with dGTPαS (red); dATP, dCTP and dTTP (green) and DNA
polymerase I (Klenow) makes a linear plasmid resistant to deletion using ExoIII; then digestion with
BamHI removes one protected end to enable C-terminal uni-directional deletion with ExoIII. Following
gene truncation, one in three mutants will be in-frame with the downstream solubility reporting fusion
gene for in vivo selection for expression and solubility of in-frame proteins.
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modified type I restriction endonuclease that produces a single DNA nick — from
which ExoIII can uni-directionally delete DNA (Figure 3.6). Treatment of these
C-terminal deletion plasmids with Nt.BbvCI makes a DNA nick between the
sequences CC and TCAGC, forming a single 3' end that ExoIII can attack. After
initiation of gene truncation, ExoIII must remove 19 nucleotides before deletions
are generated in the gene of interest. C-terminal gene truncation plasmids for use
with Nt.BbvCI are similar in design to the other C-terminal deletion plasmids,
except that the C-terminal peptide linker starts with Ser-Ala-Gly and a gene of
interest is translated in frame 0 (not 1), and cannot be expressed in-frame with
the solubility reporter until the plasmid has been digested with ExoIII.
    RBS NdeI BamHI BbvCI
|---------|      |                        |                |
TAAGAAGGAGATATACATATG-NNNNNNNNNNNNNNNNNNNGGATCCTAAGTAACTAACCTCAGCGGGCTCCTCTGGG
---------+---------+---------+---------+---------+---------+---------+--------
M                      G  S  *









                     |                |
NNNNNNNNNNNNNNNNNNNNGGATCCTAAGTAACTAACCTCAGCGGGCTCCTCTGGG
NNNNNNNNNNNNNNNNNNNNCCTAGGATTCATTGATTGGAGTCGCCCGAGGAGACCC
           S  A  G  S  S  G fusion
ExoIII-sensitive
Gene of interest
Figure 3.6: Alternate cloning site for C-terminal gene truncation and solubility reporting
plasmids. Uni-directional C-terminal deletion DNA sequence; f0–2 show the three reading frames
where f0 is the reading frame of the gene of interest and f1 the solubility reporter. A gene cloned into
f0 will not be in-frame with the solubility reporter unless truncated with ExoIII. Uni-directional gene
deletion using this series of plasmids is accomplished by treatment with Nt.BbvCI, which generates a
DNA nick — a single strand break — making a single 3' end available for digestion with ExoIII. Where
a gene of interest has been cloned with the start codon at the NdeI site — and after uni-directional
gene truncation — one in three mutants will be in-frame with the downstream purification and
solubility reporting fusion gene. Deleted genes can be screened in vivo for expression of in-frame,
expressed and soluble protein.
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3.3.2.3 Genetic removal of fusion tags from gene truncation plasmids
The series of T7 expression plasmids are capable of inducible high-level protein
over-expression and make production of useful protein truncation mutants
straightforward. However, following identification of putative soluble protein
truncations, further experiments using fusions to the solubility reporting protein
are not necessarily useful. To facilitate easy removal of the solubility reporting
and/or protein purification tags, restriction sites were incorporated such that
simple genetic modifications could be performed to appropriately introduce stop
codons with minimal sample handling or purification.
Separating the truncated gene sequence from the purification fusion tag is an
EcoRI site. The restriction site was carefully placed such that digestion with
EcoRI and then filling the ssDNA overhangs converts the original GAATTC
sequence to GAATTAATTC making an in-frame stop codon and resulting in a
C-terminal protein sequence which no longer has the purification tag or solubility
reporting fusions (Figure 3.7). Following fusion removal from truncated genes,
the unnatural C-terminal sequences are: N-terminally deleted proteins, GSSGN*;
C-terminally deleted proteins, HGSSGN* and C-terminally deleted proteins
(made with Nt.BbvCI), SAGSSGN*.
In addition, the sequences encoding the purification tags are separated from
the downstream solubility reporting fusion gene by an MfeI site (Figure 3.8A).
The restriction sequence was placed so that treatment with MfeI and then
ligation of a 5'-unphosphorylated palindromic DNA oligonucleotide (Figure 3.8C)
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N- or C-terminal protein library (encoding in-frame and soluble truncated proteins fused to












II) Pol I and dNTPs
III) transform
N- or C-terminal library encodes in-frame and soluble truncation
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EcoRI
Pol I and dNTPs
Figure 3.7: Removal of purification and solubility reporter tags from truncated genes of
interest.Methodology for converting gene libraries so that they no longer encode C-terminal fusions to
the truncated gene of interest, yellow; in-frame solubility reporter gene, green; out-of-frame solubility
reporter gene, grey. Both the purification and solubility reporting genes are downstream of the EcoRI
site in these gene truncation plasmids. Plasmids are converted by linearising the library with EcoRI,
end filling with DNA polymerase I (Klenow fragment) and dNTPs, and then transformation into an
E. coli BL21(λDE3)recA expression strain. Plasmids are efficiently recircularised by ligation in vivo.
After treatment with EcoRI and DNA polymerase I (Klenow fragment), recovered plasmids no longer
encode C-terminal fusions to the truncated gene of interest.
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would produce a C-terminal sequence of QL* directly after the purification tag.
Plasmids modified by this process can be screened for successful recombinants
by the loss of solubility reporter phenotype when expressed in BL21(λDE3)recA
cells. Otherwise entire selected or unselected truncated gene libraries can be
digested with MfeI and KpnI and the tag removed by replacing the solubility
reporting gene with a (unphosphorylated) DNA linker (Figure 3.8B). C-terminal
His6 fusion tags after removal of solubility reporting fusions are; N-terminally
deleted, GSSGNSHHHHHHQL*; C-terminally deleted, HGSSGNSHHHHHHQL*
and C-terminally deleted (nicked with Nt.BbvCI) SAGSSGNSHHHHHHQL*.
3.4 Assembly of plasmids for gene truncation and solubility
selection
3.4.1 Strategy for construction of solubility selection plasmids
The strategy for making the different plasmids with protein purification (His6
tag, biotinylation sequence and ktag) and solubility selection (EGFP and DHFR)
protein tags is outlined in Figure 3.9. First a new plasmid with a multiple cloning
site (pJB1705) was made by three successive linker ligation cloning steps (making
pJB1703 and pJB1704 in the process). From pJB1705 a protein purification and
solubility selection plasmid (pJB1706) was assembled that encodes a C-terminal
His6 and EGFP fusion protein. From pJB1706, biotinylation and Ktag EGFP
variants were made by replacing the His6 tag between the EcoRI and MfeI sites
with DNA encoding either the E. coli biotin ligase recognition sequence or the
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A: Removal of just the C-terminal solubility reporting tag from truncated genes of interest
KpnI
N- or C-terminal protein library (encoding in-frame and soluble truncated proteins fused to 















II) ligate DNA linker
III) transform
N- or C-terminal library encodes in-frame and
soluble truncation proteins with a purification
tag but not solubility reporting protein fusion
Gene of interest
     HindIII
       |    
AATTGTAAGCTTAC     420
---------+--------
    CATTCGAATGTTAA 420
  L  * 
                                                                        
f0 Solubility fusion gene
             HindIII
               |    
AATTATAAGACGCGAAGGTTGCGTAC
---------+---------+------
    TATTCTGCGCTTCCAACG
  L  * 
                                                                        
f0 Solubility fusion gene
B: Removal of solubility reporter
C: Reversible removal of solubility reporter
KpnI KpnI KpnI KpnI
Figure 3.8: Removal of solubility reporting gene fusion from truncated genes of interest.
A, Removal of solubility reporter from the reading frame of the gene of interest and protein
purification tag is carried out by treating the plasmids with MfeI, and ligating an oligonucleotide
linker to make a stop codon upstream of the solubility reporter gene. B, Oligonucleotides
5'-AATTATAAGACGCGAAGGTTGCGTAC and 5'-GCAACCTTCGCGTCTTAT can be inserted
between the MfeI and KpnI sites of truncated plasmids. C, the self complementary oligonucleotide 420
can be inserted into the MfeI site of truncated plasmids. Gene of interest, yellow; in-frame solubility
reporting gene, green; out-of-frame gene for solubility reporting protein, grey.
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Ktag peptide sequence. Finally, biotinylation and Ktag versions with a DHFR
solubility selection fusion protein were made by replacing the egfp sequence in
pJB1708 and Ktag-EGFP with folA.
pETMCSI pJB1703 pJB1704Add BamHI site
i) NdeI/EcoRI



































Figure 3.9: Strategy for construction of protein purification and solubility selection plasmids.
Plasmids with varied protein purification (His6 tag, biotinylation sequence and ktag) and solubility
reporting (EGFP and DHFR) protein tags were constructed from pETMCSI. Detailed steps are
explained in the text. Numbers refer to 5'-unphosphorylated oligonucleotide linkers with appropriate
overhanging ends.
3.4.2 Construction of pJB1703
The creation of a new T7 based multiple cloning site for solubility selection
was done in three sections using oligonucleotide linkers (summarised in Figure
3.10). pJB1703 was constructed by digesting pETMCSI (Neylon et al., 2000)
with the restriction enzymes NdeI and EcoRI (Section 2.3.2), from which
linearised plasmid was purified by agarose gel electrophoresis (Section 2.3.7).
Complementary oligonucleotides 137 and 138, with complementary overhangs to
NdeI/EcoRI digested pETMCSI, were mixed with it and ligated (Section 2.3.10.2;
Figure 3.10). Ligated plasmids were transformed into E. coli AN1459 (Section
2.2). Transformant colonies were clonally isolated, grown on an LB agar plate and
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used for plasmid isolation (Section 2.3.1.1). Selected plasmids that tested positive
for the introduction of a BamHI restriction site were sequenced to confirm linker
insertion (Section 2.3.11).
3.4.3 Construction of pJB1704
To make pJB1704, which introduces a six-histidine encoding sequence,
complementary oligonucleotides 139 and 140 were inserted between the EcoRI
and KpnI sites of gel purified pJB1703 (Figure 3.10). Ligated plasmids were
transformed into AN1459 and then transformants were streak-diluted on LB
agar plates to obtain single colonies, smeared on an LB agar plate, grown and
plasmids were isolated. Successful cleavage by MfeI indicated the presence of the
new linker. Plasmids which tested positive for MfeI digestion were sequenced to
confirm the presence of the insert.
3.4.4 Construction of pJB1705
pJB1705 was made by replacing the small MfeI and NcoI restriction fragment
of pJB1704 with complementary oligonucleotides 141 and 142 (Figure 3.10).
Ligated plasmids were transformed into AN1459, and transformants were clonally
isolated. Plasmids from selected transformants which tested positive for KpnI
digestion were sequenced to confirm that the insert was present. Note that the
linker sequence is such that the NcoI site is not regenerated.
Jeffrey R. Barrett 70






































i) NdeI & EcoRI
ii) ligate DNA linker
i) EcoRI & KpnI
ii) ligate DNA linker
i) MfeI & NcoI
ii) ligate DNA linker
BamHI
|
TATGGGATCTAGCGGATCCTCAGGTGGG     137
---------+---------+---------+--
  ACCCTAGATCGCCTAGGAGTCCACCCTTAA 138
                       MfeI 
                         |   
AATTCTCATCACCATCACCATCACCAATTGAGTAC 139
---------+---------+---------+-----
    GAGTAGTGGTAGTGGTAGTGGTTAACT     140
N  S  H  H  H  H  H  H  Q  L  S
KpnI
|












B: Multiple cloning site of pJB1705
   T7 promoter                                                    RBS
|-----------------|                                           |---------|
TAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATA
---------+---------+---------+---------+---------+---------+---------+-------
NdeI BamHI EcoRI MfeI KpnI
  |             |             |                        |                    |
CATATGGGATCTAGCGGATCCTCAGGTGGGAATTCTCATCACCATCACCATCACCAATTGAGGTAGTTCTAAGGTAC
--+---------+---------+---------+---------+---------+---------+---------+----
M  G  S  S  G  S  S  G  G  N  S  H  H  H  H  H  H  Q  L  R  *     *
Figure 3.10: Construction of pJB1705. Successive DNA linkers replaced the multiple cloning site
of pETMCSI. A: pETMCSI was digested with NdeI and EcoRI and ligated with oligonucleotide linkers
137 and 138 to make pJB1703. pJB1704 was made by inserting oligonucleotide linkers 139 and 140
between the EcoRI and KpnI sites of pJB1703. pJB1705 was made by inserting oligonucleotide linkers
141 and 142 between theMfeI and NcoI sites of pJB1704. B: Multiple cloning site of pJB1705 showing
phage T7 promoter (PT7), RBS and the reading frame from the start codon. pJB1705 encodes a His6
purification tag.
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3.4.5 Construction of pJB1706
To make a His6-EGFP fusion plasmid, the egfp gene was amplified from pEGFP-N1
(Clontech) with oligonucleotides 205 and 206 (Appendix C) using Accuzyme DNA
polymerase. Primer 206 introduces an MfeI restriction site at the start of egfp and
205 a KpnI site after it. The PCR product was purified by using a silica column
(Section 2.3.8) and digested with restriction enzymes MfeI and KpnI for insertion
between the MfeI and KpnI sites of the expression plasmid pJB1705 (Section
3.4.4). AN1459 transformants were clonally isolated and plasmids were extracted.
They were digested using EcoRI and KpnI to identify plasmids containing the 759
bp egfp gene fragment. Plasmids were sequenced to confirm the inserted sequence,
and one was retained as pJB1706 (Figure 3.11).
Transformants of BL21(λDE3)recA containing pJB1706 were observed to have a
green fluorescent phenotype on LB agar plates. Although expression of EGFP
was not intentionally induced, the lacUV5 promoter controlling expression of T7
RNA polymerase, which in turn transcribes mRNA from T7 promoters, is not
fully repressed in BL21(λDE3)recA grown in LB medium (Mertens et al., 1995).
3.4.6 Construction of pJB1707
The E. coli folA gene, which codes for DHFR was prepared for cloning into the
solubility selection vector by PCR. The E. coli folA gene contains an EcoRI site
which was silently mutated by strand overlap-extension PCR. Oligonucleotides
152, 153 (Appendix C) and KOD DNA polymerase were used to amplify the










































Figure 3.11: Construction of pJB1706: a C-terminal His6-EGFP fusion plasmid for protein
purification and solubility reporting. The egfp gene was amplified from pEGFP-N1 (Clontech) by
PCR using oligonucleotides 205 and 206, digested with MfeI and KpnI and inserted between the MfeI
and KpnI sites of pJB1705 (Figure 3.10). pJB1706 directs over-expression of EGFP with an additional
N-terminal sequence of MGSSGSSGGNSHHHHHHQL.
5' segment of folA and oligonucleotides 151, 154 (Appendix C) and Accuzyme
DNA polymerase were used to amplify the 3' fragment of the gene (Figure 3.12).
Oligonucleotide primers 151 and 152 are complementary to each other and encode
a silent mutation removing the EcoRI site. The two folA PCR products were
purified using QIAQuick columns, and assembled by PCR with Accuzyme DNA
polymerase using the outer primers 153 and 154.
The purified folA PCR product was digested with MfeI and KpnI for insertion
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iii) purify and mix 
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Figure 3.12: Construction of pJB1707: a His6-DHFR fusion plasmid for protein purification
and solubility reporting. The folA gene was amplified from E. coli genomic DNA by PCR in two
overlapping sections using oligonucleotide pairs 153–152 and 151–154 and then recombined in a
further PCR using 153 and 154. The product was digested with MfeI and KpnI and inserted between
the MfeI and KpnI sites of pJB1705 (Figure 3.10). pJB1707 directs over-expression of DHFR with
an additional N-terminal sequence of MGSSGSSGGNSHHHHHHQL.
between the MfeI and KpnI sites of the expression plasmid pJB1705 (Section
3.10). Transformants of AN1459 were clonally isolated, and extracted plasmids
were digested with EcoRI and KpnI; successful restriction digestion of pJB1707
gave a product of 509 bp. Selected plasmids were sequenced to confirm the insert,
and one was stored as pJB1707.
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3.4.7 Construction of enhanced green fluorescent protein expression
plasmids with biotinylation or Ktag purification tags
Alternate versions of the EGFP expression plasmid pJB1706 were designed
with an E. coli biotinylation (Beckett et al., 1999) or a Ktag (Bioline, Aust.)
purification sequence. The cloning of these purification tags was such that an
initial PCR reaction amplified the protein purification tag sequence from an
existing plasmid, and the primers were designed with a complement to the 5'
end of the egfp PCR product generated previously (Section 3.4.5). A nested PCR
containing the purification tag PCR product and the egfp PCR product created
a purification tag-egfp gene fusion which was then cloned between the MfeI and
KpnI sites of pJB1705 (Figure 3.13).
The biotinylation tag insert for pJB1708 was produced by amplifying the DNA
encoding the small E. coli biotinylation sequence MAGLNDIFEAQKbioIEWHEH
from pKO1285 (a derivative of pKO1274 which has the E. coli tus gene inserted;
Jergic et al., 2007) using oligonucleotides 184 and 209 (Appendix C) and
Accuzyme DNA polymerase. The two amplification products were then combined
by PCR using oligonucleotides 184 and 205.
The gene insert for pJB1710 was constructed by amplifying the small Ktag
region from pQIS214 (gift from Bioline Aust.) using oligonucleotides 207 and
208 (Appendix C) and Accuzyme DNA polymerase, and the two amplification
products were then assembled by PCR using oligonucleotides 208 and 205.
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Figure 3.13: Construction of pJB1708: a bio-EGFP fusion plasmid for protein purification and
solubility reporting. The E. coli biotin ligase recognition sequence MAGLNDIFEAQKbioIEWHEH
was PCR amplified from pKO1285 using primers 184 and 209 and the egfp gene was amplified
from pEGFP-N1 by PCR with 205 and 206. The E. coli biotinylation sequence and egfp gene
were combined by PCR and cloned into the MfeI and KpnI sites of pJB1705 (Figure 3.10). The
same methodology was used to produce a plasmid with a Ktag purification sequence (pJB1710).
pJB1708 and pJB1710 direct over-expression of EGFP with an additional N-terminal sequence of
MGSSGSSGGNSMAGLNDIFEAQKIEWHEHQL or MGSSGSSGGNSEDVDECSENMSAQLCQL
respectively (purification tag sequence in bold).
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pJB1705 that had been digested with with EcoRI and KpnI was ligated with
EcoRI and KpnI digested and gel purified bio-egfp and Ktag-egfp amplification
products. Ligated plasmids were selected in BL21(λDE3)recA. Leaky expression
from the T7 promoter (Mertens et al., 1995) allowed transformants to be
identified by their green fluorescent phenotype. Plasmids were prepared from
green fluorescent cells and sequenced to confirm the small insert in pJB1708
(bio-egfp) and pJB1710 (Ktag-egfp; Figure 3.13).
3.4.8 Construction of dihydrofolate reductase expression plasmids
with biotinylation or Ktag purification tag
Alternate versions of the DHFR expression plasmid (pJB1707) with an E. coli
biotinylation sequence (pJB1709) or a Ktag (pJB1711; Bioline, Aust.) were
made from pJB1708 (bio-EGFP) and pJB1710 (Ktag-EGFP), respectively, by
replacement of the egfp gene (Figure 3.14). pJB1708 and pJB1710 were digested
with MfeI and KpnI, gel purified and ligated with the folA PCR product used
for cloning the His6-DHFR plasmid (pJB1707; Figure 3.12). The sequences of the
folA inserts in pJB1709 and pJB1711 were confirmed by DNA sequencing.
3.4.9 Construction of gene-truncation plasmids
The suite of N-terminal deletion plasmids was produced by separately digesting
pJB1706–1711 (Figure 3.9) with NdeI and EcoRI. The linear plasmids were gel
purified and ligated with oligonucleotides 301 and 302 (Appendix C) to make
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Figure 3.14: Construction of pJB1709: a bio-DHFR fusion plasmid for protein purification
and solubility reporting. A DHFR expression plasmid with an N-terminal E. coli biotinylation
sequence was made by replacing the egfp gene from pJB1708 with the E. coli folA gene. The folA
gene was amplified from genomic DNA by PCR in two overlapping sections using oligonucleotide
pairs 153–152 and 151–154 and then recombined in a further PCR using primers 153 and 154,
digested with MfeI and KpnI and inserted between the MfeI and KpnI sites in pJB1708. An
identical methodology was used to produce a plasmid with a Ktag purification sequence (pJB1711).
pJB1709 and pJB1711 direct over-expression of DHFR with an additional N-terminal sequence of
MGSSGSSGGNSMAGLNDIFEAQKIEWHEHQL or MGSSGSSGGNSEDVDECSENMSAQLCQL,
respectively (purification tag sequence in bold).
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N-deletion plasmids pJB1726–pJB1731 (Figure 3.15A; Table 3.1). Note that the
linker ligation destroys the original NdeI site, replacing it with an NcoI site, and
creating a new NdeI site downstream. A new BamHI site is installed just before



































I) NdeI & EcoRI
II) ligate DNA linker
301 & 302
I) BamHI & EcoRI




















I) BamHI & EcoRI
II) ligate DNA linker
307 & 308
C: C-terminal deletion with BbvCI
Figure 3.15: Gene truncation plasmids. Plasmids for gene truncation were constructed from
purification-solubility fusion expression plasmids pJB1706, pJB1707, pJB1708, pJB1709, pJB1710
and pJB1711 (see Figure 3.9).
C-terminal deletion plasmids were produced by separately digesting pJB1706–1711
with BamHI and EcoRI. Each linear plasmid was gel purified and ligated with
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Table 3.1: Gene deletion and solubility selection plasmids.
Purification tag and solubility selection gene Plasmid














C-terminal deletion plasmid for use with BbvCI (Figure 3.15C)
His6-egfp pJB1732
oligonucleotide linkers 305 and 306 (Appendix C) to make C-deletion plasmids
pJB1720–pJB1725 (Figure 3.15B; Table 3.1). This strategy moves the BamHI site
a further 21 bp downstream of the NdeI site (see Figure 3.5) to ensure efficient
restriction endonuclease cleavage (during insertion of the gene of interest) and
installs an NcoI site preceded by TAA stop codons in all three reading frames (see
Figure 3.5).
A similar strategy was used to make a further C-terminal deletion plasmid which
provides a Nt.BbvCI nicking endonuclease cleavage site. pJB1706 was digested
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with BamHI and EcoRI, gel purified and ligated to oligonucleotide linkers 307
and 308 (Appendix C) to make pJB1732 (Figure 3.15C; Table 3.1; see also Figure
3.6).
3.4.10 Truncation apparatus
An apparatus for making highly sampled ExoIII truncated libraries was
constructed but was not required for the work performed in this Thesis. See
Appendix A.
3.5 Conclusion
Multi-domain proteins are very often arranged with each folded protein domain
in series, and may be linked by non-structured flexible regions. These protein
domains have structures and functions which can be studied in isolation and
provide information on their contribution to the properties of the full-length
protein. This can be particularly useful when the full length protein cannot be
studied. Yet, it can sometimes be problematic to produce soluble protein domains.
We have developed a methodology that makes many truncated versions of a
protein of interest by uni-directional deletion into a gene — in an expression
plasmid — using ExoIII. As complete protein domains are more likely to fold
well and not aggregate — in contrast to incomplete domains — genes that direct
expression of soluble proteins are probably directing production of proteins that
do not contain incomplete segments of a folded domain. Therefore, genes for
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soluble shortened proteins are those that have been truncated to regions between
folding units — a domain boundary. The presence of a C-terminal fusion protein
(EGFP or DHFR) means that once an expression plasmid library for many
truncated versions of a protein is produced, and is transformed into an E. coli
expression strain, protein over-expression in unique colonies can allow screening
for putative soluble proteins by looking for the distinct phenotypes related to
correctly folded and soluble EGFP or DHFR.
The plasmids made for this new technique, after gene truncation with ExoIII, form
expression plasmids that direct expression of truncated proteins with, in order, a
C-terminal purification tag and a solubility reporter protein. This arrangement
of fusion protein genes in these plasmids, while initially allowing selection of
soluble truncated mutants, can be modified in a straightforward manner to direct
expression of truncated proteins alone, or just with a useful protein purification tag.
To generate truncations of a protein of interest, its gene can be placed between
the NdeI (containing the gene start codon) and BamHI (directly following the last
codon) restriction sites of any of the plasmids. In general the same gene sequence
can be inserted into plasmids for either N- or C-terminal deletion. However, for
C-terminal deleted genes, an additional nucleotide following the gene of interest
ensures that the library template must be truncated by ExoIII before the gene
of interest can be in-frame with the solubility reporter to prevent recovery of
non-truncated genes in libraries. The plasmids presented here were used to produce
and select for soluble truncated proteins, as described in the following Chapters of
this Thesis.
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Chapter 4
Domain identification in Acinetobacter
baylyi DNA primase
4.1 DNA primase and DNA replication
Chromosome replication in bacteria requires a large number of proteins to work
in a concerted manner (Benkovic et al., 2001). To provide DNA polymerase III
— the chromosomal DNA replicase — with access to ssDNA, the hexameric
helicase DnaB translocates along DNA in the 5' to 3' direction, unwinding
dsDNA in its path. Once the parental DNA strands have been separated, each
is duplicated by individual DNA polymerase III molecules tethered to the helicase.
DNA synthesis by DNA polymerases occurs only in the 5' to 3' direction,
dictating that replication of antiparallel dsDNA occurs in distinct modes on the
two complementary strands (Figure 4.1; Ogawa and Okazaki, 1980). On the 3'

















Figure 4.1: DNA replication fork. Chromosome replication occurs by two different modes,
depending on the orientation of the template DNA strand and occurs after DNA helicase has separated
the parental DNA strands. Leading-strand replication is straightforward, where DNA polymerase III
can synthesise the leading-strand duplicate in the 5' to 3' direction. As DNA polymerase III can
only synthesise DNA with 5' to 3' polarity, the lagging-strand needs to be duplicated in the opposite
orientation to the lagging-strand. DNA primase synthesises an RNA primer on the lagging strand so
that DNA polymerase III can begin DNA synthesis.
to 5' leading strand template, replication is relatively straightforward and can
progress continuously, but on the complementary 5' to 3' lagging strand template,
DNA polymerisation must still occur with 5' to 3' polarity. The cellular DNA
replication machinery facilitates replication fork movement in one direction by
copying the lagging strand template in many short 5' to 3' segments known as
Okazaki fragments. Subsequent ligation of Okazaki fragments results in faithful
replication of the lagging strand template (Ogawa and Okazaki, 1980; Wu et al.,
1992). Lagging strand DNA synthesis is further complicated because the genomic
DNA polymerase requires the 3'-OH of a pre-existing 5' nucleotide to incorporate
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a new 3' residue; these 5' residues are not present on unwound, lagging strands.
To prime a lagging strand for DNA polymerisation, DNA primase (DnaG) places
a short RNA primer on the nascent lagging strand, and then DNA polymerase
III is able to copy the lagging strand template (Bouché et al., 1978; Wu et al., 1992).
4.1.0.1 DNA primase (DnaG)
The importance of DNA replication makes DnaG an essential protein (Katayama
et al., 1989; Mushegian and Koonin, 1996; Hutchison et al., 1999; Forsyth et al.,
2002; Gerdes et al., 2003; Kobayashi et al., 2003; Gil et al., 2004; Glass et al.,
2006) that performs three distinct functions (Frick and Richardson, 2001).
The three functional domains of DNA primase perform, in order from amino-
to carboxyl-terminus (Figure 4.2), single stranded DNA recognition/binding
(zinc-binding domain, or ZBD; Mendelman et al., 1994; Griep and Lokey, 1996;
Biswas and Weller, 1999), RNA synthesis (RNA polymerase domain, RPD; Frick
and Richardson, 2001), and helicase binding (helicase binding domain, HBD;









Figure 4.2: The domains of DNA primase. DNA primase has three domains. The zinc-binding
domain binds the lagging strand DNA, the RNA polymerase synthesises an RNA primer and the
helicase-binding domain attaches DNA primase to DNA helicase.
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4.1.1 Preliminary work on Acinetobacter baylyi DNA primase
Species in the Acinetobacter genus have emerged as clinically acquired pathogens
over the last 20 years. Many Acinetobacter strains have developed resistance to
some, or all current classes of antibiotic, and members of this genus appear to
be especially adept at acquiring new resistance mechanisms (Bergogne-Berezin
and Towner, 1996; Gales et al., 2006; Perez et al., 2007), resulting in a significant
number of pathogenic outbreaks, predominantly in hospitals (Villegas and
Hartstein, 2003; Dijkshoorn et al., 2007).
The limited availability of effective antibiotics, and increasing observations of
highly antibiotic resistant Acinetobacter spp. is troubling. The emergence of
antibiotic resistant and pathogenic Acinetobacter spp. warrants investigation
of important biochemical pathways in the search for novel antibiotic targets.
Towards the goal of identifying new antibiotic targets against Acinetobacter
spp., the Dixon group has started projects to investigate components of DNA
replication in A. baylyi ADP1 (Robinson et al., 2010). One such project involves
DnaG primase. Members of the Dixon research group have in the past set out
to make single and double domain A. baylyi DnaG mutants with the goal of
identifying new antibiotic targets. These experiments used sequence alignments
to predict domain boundaries, and successfully produced both C-terminal HBD
and ZBD-RPD domain constructs. However, these rational design experiments
did not find suitable breakpoints between the ZBD and RPDs able to produce
soluble RPD-HBD or ZBD protein constructs (Andrew Robinson and Stephanie
Ruiz; unpublished).
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4.1.2 The DNA primase zinc-binding domain
During Okazaki fragment synthesis, the bacterial primase ZBD is believed to be
involved with RNA primer initiation site recognition, lagging strand binding and
in limiting RNA primer length (Kuchta and Stengel, 2010). Multiple primase
molecules are tethered to the helicase during DNA replication, where they can
act on the lagging strand after the double helix has been separated. A model
proposed for phage T7 DNA gp4 helicase-primase suggests that neighbouring
primase domains — each bound to the same helicase — interact in trans, so that
the ZBD of one primase unit binds to the template strand just ahead of the path
of a neighbouring primase, blocking further synthesis of the RNA primer (Qimron
et al., 2006). Mutations in the E. coli ZBD increase the length of RNA primers
(and reduce primase activity; Corn et al., 2005), supporting that the ZBD in E.
coli is responsible for limiting RNA primer size, similar to the suggested manner
for T7 DNA primase (Kuchta and Stengel, 2010).
The structure of the ZBD appears to be highly conserved throughout bacteria;
the two known ZBD structures from the distantly related Aquificae and Firmicute
phyla are highly similar (Cα RMSD: 1.16 Å over 88 residues; Figure 4.3;
Shindyalov and Bourne, 1998; Pan and Wigley, 2000; Jia et al., 2004; Corn et al.,
2005). The ZBD structures are folded (Pan and Wigley, 2000) and resistant to
proteolysis (Tougu et al., 1994; Bird et al., 2000).
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Figure 4.3: Bacterial primase zinc-binding domains. Cartoon diagram of A, ZBD of Aquifex
aeolicus (PDB: 2AU3; residues 3–96; Corn et al., 2005) and B, ZBD of Geobacillus stearothermophilus
primase (PDB: 1D0Q; residues 2–101; Pan and Wigley, 2000). Red, α-helix; yellow, β-sheet; green,
loop. Zinc-binding residues are shown in ball-and-stick representation with the zinc atom in grey. The
ZBDs of A. aeolicus and G. stearothermophilus primases are highly conserved (Cα RMSD: 1.16 Å).
4.1.3 Few soluble constructs for bacterial zinc-binding domains are
known
Although DnaG has three distinct folded units, for most bacterial species only
functional domains for the RPD and HBD have been produced. With the
exception of the ZBD of the thermophile Geobacillus stearothermophilus (Pan
et al., 1999) — from which the ZBD was identified by limited proteolysis and
then cloned for soluble over-expression (Pan et al., 1999; Bird et al., 2000) — no
bacterial ZBD has been isolated as a folded, soluble protein.
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A boundary for the N-terminal ZBD has been known for some time thanks
to proteolysis experiments. Limited trypsin digests of E. coli DnaG initially
produce two fragments, a 16 kDa C-terminal fragment, and a 49 kDa N-terminal
fragment which contains the RPD and the ZBD (Tougu et al., 1994); extended
proteolysis produces distinct ZBD fragments that have been cleaved after residues
Arg110 and Arg113 (Figure 4.4). Although two protein structures for ZBDs
are known and proteolytic fragments have been produced for E. coli and G.
stearothermophilus DnaG, our group has had no success producing soluble A. baylyi










Figure 4.4: Domain location and known soluble constructs of DNA primase. DnaG proteins
from G. stearothermophilus (Gst), E. coli (Eco) and A. baylyi (Aci). Each protein is shown according
to annotations in Pfam (http://pfam.sanger.ac.uk; Bateman et al., 2000, 2002): (•), N-terminal
zinc-binding; (•), RNA polymerase and (•), C-terminal helicase binding domains. Also shown are
soluble DnaG domain mutants with breakpoints near the ZBD (pale-coloured); G. stearothermophilus
2–103, Pan et al. (1999) and E. coli 115–426, Keck et al. (2000). Shown in grey are ZBD fragments
produced by limited proteolysis (Tougu et al., 1994).
The Aquifex aeolicus multi-domain ZBD-RPD structure shows the ZBD sitting
snugly against the surface of the RPD (PDB: 2AU3; Corn et al., 2005). Potentially
the DnaG ZBD is often closely associated with the RPD, and this is supported by
the delayed liberation of the ZBD during limited proteolysis (Bird et al., 2000).
The close association of the ZBD and RPD may explain the difficulty in producing
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appropriate truncations for soluble ZBD other than in G. stearothermophilus, as
the region linking the domains may be short and hard to identify.
4.1.4 The zinc-binding domain of Acinetobacter baylyi DNA primase
is followed by a novel sequence insertion
Interestingly, the A. baylyi DnaG protein contains a large 69 amino acid extension
to the conventional C-terminus of the ZBD and a similar sequence appears in all
sequenced members of the Moraxellaceae family (of which Acinetobacter species
are members; Robinson et al., 2010). The sequence insertion, which ranges from
50–100 amino acids, appears to be restricted to the Moraxellaceae, where the
sequence has very poor conservation (Figure 4.5), and has no homology to any
sequence present in the nucleotide data banks.
4.2 Aims
We were interested in dissecting the ZBD from the RPD of A. baylyi DnaG as
a testing platform for the pragmatic protein domain identification methodology
proposed in Chapter 3. We aimed to perform deletion of the dnaG gene to express
libraries of deletions of the DnaG protein from both the I) C-terminus and II)
N-terminus surrounding the ZBD sequence extension and RPD boundaries; and
III) to examine any putative soluble DnaG truncated proteins for bona fide
protein solubility and foldedness.
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IRFLMDIDNR NFIDVMKELS GNTGVELPKD NTDNKKLSY- ---TRQVT-K PSTPPKTVA- -----E--PT 125
IRFLMDIDGR NFIDVMQELS SKSGVELPKD NFEQKKLSY- ---KRNTQ-K PEPKPVVNT- -----EKSAP 127
IRFLMDIDNR NFIEVMKELS SSTGIELPKD NTENKKLSY- ----TRQVTK PPVTKTNAA- -----E--PV 125
IRFLMDIDNR NFIDVMKELS SSAGVELPKD NTENKKLSY- ----TRQVTK PPVAKA-NTA -----E--PV 125
ISFLRDYENL TFIEAVNELS KQTGIEVPKE EQQNVSYQR- ----AKPKPK SAIKPATSAT HLQKNDSQPV 133
ISFLRDYENL TFIEAVNELS KQTGIEVPKE EQQNVSYQR- APVKPKSKPK SAVKPATSAT HLRKNDSQPV 137
IKFLREYENQ TFMEAVQELS RQTGIEIPKE DNKDLRYKR- ---SAKPTPT APAPSWTGNG KRLN-DTHTA 133
ITFLKEFERM SFIESVKFLS EQTGIELPKD DTDQKKFKY- --KKTVKTQG AKLPTQPSP- -----DPSSR 129
LGFVMDHDQL EFPQAVEELA KRAGMDVPRE ERGGRGHTPR ---------- ---------- ---------- 110
LGFIMDHDNL DFPQAVEELA KAAGMEIPRE ESGR-QHKPR ---------- ---------- ---------- 109
LGFLMDHDHL EFPQAVEELA RRAGLEVPRE ERGG-PHQPR ---------- ---------- ---------- 109
LGFVMDYERL SFPEAVEQLA RITGLEVPRE VQSEAEAKRE ---------- ---------- ---------- 110
TQ---API-- ---------- -------EDQ YNTFEPVY-- ---------F DD-------- ---------- 144
SHHAAIS--- ---------- ----ESSEQI DGLQAPSY-- ---------F DD-------- ---------- 151
IPQQPS---- ---------- -------DES YNTLEPVF-- ---------F DD-------- ---------- 145
TPTPQQPT-- ---------- -------DES YNTLEPVF-- ---------F DD-------- ---------- 147
TNNK-SSMSM PA-------- -------DDT QPPTY----- ---------- DD-------- ---HHSYDNY 161
SNNQ-SSIIM PA-------- -------DDT Q---PPIY-- ---------- DD-------- ---HHSYDNY 165
ATTPHSGQTN GLATNTTSVA DAPPAYFDED SYFNLDSAPP SDWDMGDTPG DNLGYDSGFT DMSSSNFGGQ 203
QNFIHHQS-- ---------- -------DTR PSPATDWVND LSAY------ DTY---SGLA DPSHHTGQVN 171
---------- ---------- ---------- ---------- ---------- ---------- ---------- 110
---------- ---------- ---------- ---------- ---------- ---------- ---------- 109
---------- ---------- ---------- ---------- ---------- ---------- ---------- 109
---------- ---------- ---------- ---------- ---------- ---------- ---------- 110
---------P FAQFEQPFS- FDGPV----- ---------- ---------- -----QEG-- ---NLYDLLE 169
---------P FAQFDQSYMG FEDAP----- ---------- ---------- -----QEG-- ---NLYDLLE 177
---------P FAQFEQPFS- FDEPV----- ---------- ---------- -----QEG-- ---NLYDLLE 170
---------P FAQFEQPFS- FDEPV----- ---------- ---------- -----QEG-- ---NLYDLLE 172
PPLDAYDAVP YAMDGYDAHY QDDDNYPPAW LAGGDMAGLH GSDINHSFDN NNDSNEDG-- ---NLYDLLE 226
PPLDAYDAVP YVMDGYDAHY QDDNGYPPAW LTGDDNTALY ------N-DN -SISDKDG-- ---NLYELLE 222
ATI------- ---------- ---------- ---------- ---------- ----EQDG-- ---NLYELLI 217
ELYGTRAPIL TQSPNAAQGD ---------- ---------- ---------- ---------- ----LYSLLT 197
---------- ---------- ---------- ---------- ---------- --------QP TDSPLYPLLS 122
---------- ---------- ---------- ---------- ---------- --------QP TDSPLYPLLT 121
---------- ---------- ---------- ---------- ---------- --------QS ADSPLYPLLA 121
---------- ---------- ---------- ---------- ---------- --------QE KKS-IYSLLE 121
NVAQFYEHQL PTSQKAKN-- -YFKQRGLSD QTIQFWRLGY APEDWQHL-- ----EKAFPY ---DIEGLKQ 227
NVAQFYEKQL PNSNKAQQ-- -YFKQRGLSA ETIQFWRLGY APEDWQHL-- ----EKAFPY ---DIEGLKQ 235
NVAQFYEQQL PHSQKAKN-- -YFKQRGLTN QTIQFWRLGY APEDWQHL-- ----EKAFPY ---DIDGLKQ 228
NVAQFYEHQL PNSQKAKN-- -YFKQRGLTN QTIQFWRLGY APEDWQHL-- ----EKAFPY ---DIDGLKQ 230
KIQQFYQHNL SIHPHAKH-- -YFLSRGISD EIFETFGLGY APFGWQHL-- ----EHQFPQ ---DIEGLKA 284
QIQQFYQHNL SIHPHAKH-- -YFLSRGISD EIFETFGLGY APFGWQHL-- ----EHQFPQ ---DIEGLKA 280
QIGQFYQNNL RNNLHAMA-- -YFTERGLTD ATINEFGLGY APTGWQHL-- ----EEAFPQ ---DIAGLKA 275
AVHDYYQLML NNFTFAKQ-- -YFLDRGLSE ETIQTFGLGY APDGWQHL-- ----EQVFPQ ---DIEGLKI 255
AAAEFYKQAL KSHPARKAAV NYLKGRGLTG EIARDFGLGF APPGWDNLLK HLGGDNLQLK AMLD-AGL-- 189
AAADFYRQAL KSHPARKAAV DYLKGRGLTG EIARDFGLGF APPGWDNLYK HLSSDTLQQR AMID-AGL-- 188
TAADYYRQAL KSHPARQVAV DYLKGRGLSG VIARDFALGF APPGWDNLLK HLGGDALQQK AMIE-AGL-- 188

















































Figure 4.5: Zinc-binding domain extension in Moraxellaceae. Protein sequence alignment
showing the novel ZBD sequence insertion of the Moraxellaceae compared to the closest
relatives from Pseudomonadales. Alignments were generated using ClustalW (Thompson et al.,
2002) and were manually adjusted. Moraxellaceae species: Abu, Acinetobacter baumannii ; Aby,
Acinetobacter sp. ADP1 (baylyi); Aca, Acinetobacter calcoaceticus; Aol, Acinetobacter oleivorans;
Par, Psychrobacter arcticus; Pcr, Psychrobacter cryohalolentis; P.sp, Psychrobacter sp. PRwf-1; Mca,
Moraxella catarrhalis. Pseudomonadulus species: Pae, Pseudomonas aeruginosa; Pbr, Pseudomonas
brassicacearum; Avi, Azotobacter vinelandii ; Cja, Cellvibrio japonicus. Amino acid residues are shown
in single-letter abbreviations and are coloured: red, acidic; blue, basic; orange, non-polar; green, polar;
yellow, cysteine.
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4.3 Materials and methods
4.3.1 Plasmids for gene truncation of Acinetobacter baylyi DNA
primase
Plasmids were constructed for gene truncation of A. baylyi DnaG by inserting
the dnaG gene from pAR1347 (provided by Andrew Robinson) into pJB1726 and
pJB1732 (Section 3.4.9), to produce pJB1743 and pJB1742 for N- and C-terminal
deletions, respectively (Figure 4.6). pJB1743 allows 5'-terminal gene deletion and
pJB1742 3'-terminal gene deletion with each plasmid providing DNA encoding a
C-terminal His6 tag followed by the EGFP fusion protein for protein purification
and solubility selection. The open reading frame (ORF) for A. baylyi DnaG
was PCR amplified from pAR1347 using oligonucleotide primers 337 and 338
(Appendix C). The PCR primers produced an amplification product with an
appropriate NdeI restriction site at the start of the dnaG ORF and a BamHI
restriction site at the end of the ORF (Section 3.3.2.2). To facilitate truncation
generation using Nt.BbvCI, PCR primer 337 also caused a silent mutation in
the A. baylyi DnaG sequence such that the BbvCI restriction site present at the
start of DnaG was removed. Plasmids pJB1726, pJB1732 and the dnaG PCR
product were digested with NdeI and BamHI, gel purified and ligated. Successful
transformants were selected and extracted plasmids were sequenced to confirm
their identities.

































































Figure 4.6: Plasmids for gene truncation of dnaG. pJB1743 (for N-terminal deletions) and
pJB1742 (C-terminal deletions) were made by placing the A. baylyi dnaG gene from pAR1347 between
the NdeI and BamHI sites of pJB1726 and pJB1732 (Section 3.4.9). The dnaG gene was amplified
by PCR using oligonucleotide primers 337 and 338 (Appendix C), digested with NdeI and BamHI and
gel purified. pJB1726 and pJB1732 direct expression of C-terminal His6 and EGFP fusion proteins for
protein purification and solubility selection.
4.3.2 Library preparation
4.3.2.1 Preparation of plasmid DNA for uni-directional truncation
Gene deletion plasmids containing dnaG were prepared for uni-directional deletion
using exonuclease III. For C-terminal deletion of dnaG, 30 µg of pJB1742 was
digested with 30 U of the nicking endonuclease Nt.BbvCI in NEB restriction
enzyme buffer 4 with 100 µg.mL−1 BSA for 2 h at 37◦C and the enzyme was heat
inactivated by incubation at 80◦C for 20 min.
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For N-terminal deletion of dnaG 20 µg of purified pJB1743 was digested with
20 U of NcoI in NEB restriction enzyme buffer 3 with 100 µg.mL−1 BSA for 2
h at 37◦C, and the enzyme was heat inactivated by incubation at 80◦C for 20
min. The NcoI-digested plasmid was then end protected by adding 40 µM each
of dGTPαS (Glen Research), dATP, dCTP, dTTP and 20 U DNA polymerase
I (Klenow fragment), and the mixture was incubated at 30◦C for 15 min; DNA
polymerase I was then heat inactivated by incubation at 65◦C for 20 min.
Linearised pJB1743 was made susceptible to uni-directional ExoIII digestion
using 20 U NdeI, incubated for 2 h at 37◦C and NdeI was heat inactivated by
incubation at 80◦C for 20 min.
4.3.2.2 Uni-directional truncation using exonuclease III
Exonuclease III reactions were performed in 60 mM Tris-HCl pH 7.6, 5 mM
MgCl2, 1 mM DTT and 100 µg.mL−1 BSA. Reaction mixtures were prepared with
1 µg of target plasmid DNA and 100 U of ExoIII in 20 µL per time point sample.
Exonuclease reactions were performed in a heat block and initiated by introducing
ExoIII to warmed DNA in reaction buffer followed by mixing by pipette.
Exonuclease reactions were terminated by chelation of magnesium and increased
acidity. Each 20 µL time point sample (3' deleted; 15 s intervals between 6
min 30 s and 8 min 45 s and 5' deleted: 15 s intervals between 1 min 25
s and 2 min 40 s) was introduced into a separate pre-prepared tube with
independent 2 µL droplets of 3 M sodium acetate pH 5.2 and 125 mM EDTA,
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such that addition of the exonuclease treated DNA sample mixed the other
two solutions. DNA was immediately precipitated from terminated exonuclease
reactions by addition of 50 µL of 100% ethanol (see Section 2.3.9). After the
DNA pellet had been washed with 70% ethanol and dried, TE was added to
resuspend the truncated DNA. The truncated plasmid DNA from multiple ExoIII
reactions were pooled to make separately a 3' deleted and a 5' deleted gene library.
4.3.2.3 Removal of ssDNA from exonuclease truncated DNA
Resuspended exonuclease truncated plasmid DNA was incubated in a total
volume of 10 µL of 50 mM sodium acetate pH 5, 30 mM NaCl, 1 mM ZnSO4
and 1 U of mung bean nuclease per 1 µg DNA. Mung bean nuclease reactions
were incubated at 30◦C for 30 min and then terminated by placing on ice and
addition of SDS to a final concentration of 0.01%. Truncated plasmid DNA was
precipitated using sodium acetate, EDTA and ethanol (Section 2.3.9), washed
with 70% ethanol and then resuspended in TE.
4.3.2.4 Ligation of the truncated plasmid pool
Mung bean nuclease digested A. baylyi N- and C-terminally deleted plasmid
pools were repaired using DNA polymerase I (Klenow fragment) and then ligated
using T4 DNA ligase. Precipitated DNA pellets were resuspended in TE and then
diluted in a dual purpose DNA polymerase I/T4 DNA ligase reaction buffer (50
mM Tris-HCl pH 7.6, 10 mM MgCl2, 10 mM DTT and 1 mM ATP) to a DNA
concentration of 6 ng.µL−1.
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The truncated DNA in dual purpose buffer was warmed to 37◦C and then DNA
polymerase I (Klenow fragment; 1 U per µg of DNA) was added and the mixture
incubated for 5 min, after which 40 µM each dATP, dCTP, dGTP and dTTP was
added and incubation continued for a further 30 min. The mixtures were then
cooled to 4◦C and T4 DNA ligase (1 U per 300 ng of DNA) was added before
incubation overnight at 4◦C.
To increase transformation efficiency, salt was removed from the ligated gene
truncation plasmid pools. Plasmid pools were diluted to 500 µL in TE and
concentrated by centrifugal ultrafiltration, re-diluted in TE and concentrated a
second time.
4.3.2.5 Library transformation and expression
Ligated gene truncation libraries were transformed into E. coli BL21(λDE3)recA
and cultured on agar plates to induce expression of truncated DnaG-EGFP fusion
proteins (Section 2.2.3). After one h recovery in LB, transformed library pools
were plated onto LB agar or Selection agar (15 g.L−1 agar in 5 g.L−1 yeast extract,
2 mM MgSO4, 50 mM Na2HPO4, 50 mM KH2PO4, 25 mM (NH4)2SO4, 0.1 g.L−1
ampicillin, 0.5 g.L−1 glucose, 2 g.L−1 α-lactose and 5 g.L−1 glycerol). Plated gene
truncation libraries were incubated at 30◦C overnight and stored at 4◦C thereafter.
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4.3.3 Truncation mutation identification
Successful transformants from truncated DnaG-EGFP fusion libraries were
observed under a long-wave UV handheld lamp to excite EGFP and produce
fluorescence. Selected bacterial colonies were clonally isolated on LB agar plates
(Section 2.2.2), with incubation overnight at 30◦C.
Truncated DnaG-EGFP fusion library transformants were screened for insert size
by colony PCR and simultaneously stored as recoverable cultures at −80◦C as
described in Section 2.3.5. Briefly, clonally isolated bacterial colonies were picked
and inoculated into 200 µL LB-Miller with 7% DMSO from which a 1 µL sample
was used for colony PCR. A sample of each identified colony was also inoculated
onto an agar plate grid prior to the storage of bacterial cultures at −80◦C.
Samples of each bacterial culture smeared onto an agar plate grid were incubated
overnight at 30◦C and observed for degree of EGFP fluorescence phenotype by
comparison to an identical culture solely expressing EGFP or not (i.e., containing
pJB1706 or non-truncated deletion plasmid, respectively). Nucleotide sequences
were determined for selected plasmids (Section 2.3.11).
4.3.4 Removal of EGFP sequence from fusion genes
Following library selection for expression of soluble N- or C-terminal deleted
A. baylyi DnaG-EGFP fusion proteins, selected sequenced plasmids were
chosen for expression of truncated DnaG proteins without EGFP. To facilitate
straightforward removal of EGFP from the protein sequence, a stop codon
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was introduced following the His6 sequence for each plasmid (see Section
3.3.2.3). Selected plasmids encoding A. baylyi DnaG truncation mutants were
digested with MfeI, and ligated with the self-complementary oligonucleotide 420
(AATTGTAAGCTTAC; Section 2.3.10). Ligation products were transformed
into BL21(λDE3)recA and selected on expression-inducing Selection agar plates.
Transformants were selected based on the loss of their green fluorescent phenotype
due to the successful introduction of a stop codon preceding the egfp ORF. The
plasmids were then purified and sequenced for confirmation.
4.3.5 Removal of His6-tag and EGFP sequence from fusion proteins
In a similar fashion to removal of the EGFP fusion sequence (Section 4.3.4), some
A. baylyi DnaG truncation mutants were selected for expression without the
His6 or egfp fusion tags (Section 3.3.2.3). The selected plasmids were linearised
with EcoRI and then the sticky ends were filled in using DNA polymerase I
(Klenow fragment) and 40 µM each dNTP in the EcoRI restriction enzyme
buffer for 30 min at 30◦C. The end-filled linear plasmid was transformed
directly into BL21(λDE3)recA and white, non-fluorescent transformants were
selected as above. The plasmids were then purified and sequenced for confirmation.
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4.3.6 Expression, solubility examination and purification of truncation
mutants
To examine the solubility of DnaG truncation mutants identified by solubility
library selection experiments, selected proteins were expressed with a C-terminal
His6-tag in E. coli BL21(λDE3)recA/pLysS by auto-induction (see Section 2.5.1).
Individual 400 mL cultures were incubated with shaking for 24 h at 30◦C.
To compare the solubility of the selected truncation mutants to each other, a
sample of each over-expressed BL21(λDE3)recA culture was then recovered by
centrifugation at 8,000 × g and the bacterial pellets were resuspended to an A600
of 10 AU in 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 20 mM imidazole.
To facilitate efficient lysis of the cultures that overproduced DnaG truncation
mutants and T7 lysozyme, the resuspended bacterial cells were lysed by repeated
freeze-thaw cycles between −80◦C and 4◦C or processed through a French press
cell three times; cell lysate from freeze-thaw lysis was then passed through a
syringe needle to shear DNA. Following cell lysis, the soluble and insoluble cellular
fractions were separated by centrifugation at 30,000 × g for 30 min. Equal samples
of whole cell lysate and soluble cellular fractions for each truncation mutant were
analysed directly by SDS-PAGE (Section 2.5.9), while insoluble cellular fractions
were resuspended in a small volume of 8 M urea and then diluted in SDS-loading
buffer to be in proportion to the total cell lysate, then analysed by SDS-PAGE.
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4.3.6.1 Purification of over-expressed His6-tagged truncated proteins
Cells from 400 mL cultures of isolates that over-expressed DnaG truncation
mutants with C-terminal His6-tags (see Section 4.3.6) were resuspended in 30
mL of immobilised metal ion chromatography (IMAC) binding buffer (50 mM
Tris-HCl pH 8.0, 300 mM NaCl, 20 mM imidazole) and lysed by French press.
The soluble fraction was recovered by centrifugation at 30,000 × g for 30 min.
Once the cleared bacterial lysate had been filtered through a 0.45 µm cassette
(Merck Millipore), it was applied to a 1 mL HisTrap HP column (GE Healthcare
Life Sciences) using an ÄKTApurifier (GE Healthcare Life Sciences). The column
was washed with IMAC binding buffer. Once the A280 reached baseline, the
bound protein was eluted using IMAC binding buffer with a step gradient of
imidazole from 20 mM through 500 mM. Eluted fractions were pooled based on
purity observed by SDS-PAGE; the purified proteins eluted at concentrations
suitable for later experiments. Mass spectrometry analysis (Section 2.5.10) of
His6-tagged DnaG truncated mutants in 0.1% formic acid produced electrospray
ionization (ESI)-mass spectra in excellent agreement with the sequence predicted
masses (results not shown).
4.3.6.2 Improved purification of His6-tagged truncated proteins
In later purifications of His6-tagged proteins, the protocol was modified to include
a wash step for the protein bound column using 10 column volumes (CV) of
IMAC binding buffer with 1 M NaCl to remove non-specifically bound species,
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then 10 CV of IMAC binding buffer, prior to a step elution using 50 mM Tris-HCl
pH 8.0, 300 mM NaCl and 90 mM imidazole. Eluted protein was pooled and
dialysed into 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA and 1 mM DTT.
4.3.7 Circular dichroism of truncated protein
A. baylyi His6-tagged DnaG ZBD truncation mutants purified by the initial
method (Section 4.3.6.1) were dialysed into circular dichroism (CD) buffer (20
mM Tris-HCl pH 8.0, 50 mM NaCl) and filtered using a 0.22 µm cassette (Merck
Millipore) for CD spectroscopy. Far-UV CD spectra were acquired using a Jasco
J-810 spectropolarimeter (Jasco, Victoria, Canada) with a Jasco circulating water
bath at 25◦C. Samples for spectra were diluted in CD buffer to produce useful
spectra (approximately 0.2 mg.mL−1) in a 0.05 cm quartz cell and the following
parameters were used: range, 300–190 nm; recording speed, 100 nm.min−1;
accumulating 4 scans.
4.3.7.1 Purification of DnaG1–165 and DnaG1–170
Untagged A. baylyi DnaG ZBD truncated proteins were over-expressed by
auto-induction (see Section 2.5.1). Cultures of BL21(λDE3)recA/pLysS containing
plasmids that direct expression of DnaG truncations were prepared by shaking at
30◦C until the cultures were saturated. The bacterial cells containing expressed
DnaG1–165 and DnaG1–170 were harvested by centrifugation at 8,000 × g for 10
min. Pelleted bacterial cells (10 g) were resuspended in TBS150 (50 mM Tris-HCl
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pH 8.0, 150 mM NaCl, 1 mM EDTA and 1 mM DTT; 5 mL per g cells) and
lysed using a French press. Soluble proteins were recovered by centrifugation at
30,000 × g for 30 min. The soluble protein fraction was treated with 0.2 g.mL−1
(NH4)2SO4 and the precipitate collected by centrifugation at 30,000 × g for 30
min. The protein pellets containing the DnaG truncation proteins were collected
and resuspended in TBS150, and then dialysed against the same buffer overnight.
The ammonium sulphate isolated protein fractions were then purified in two
aliquots by flowing through a DEAE chromatography column (35 mL Toyopearl
DEAE-650M) equilibrated with TBS150 and connected to an ÄKTApurifier
system; under these conditions contaminants with a very strong negative charge
such as DNA are bound to the DEAE column and the protein of interest flows
through. The protein fractions which did not bind to the DEAE column were
pooled and proteins were precipitated by addition of 0.5 g.mL−1 (NH4)2SO4 and
collected by centrifugation at 30,000 × g for 30 min. The protein pellet containing
the DnaG truncation protein was collected and resuspended in TBS50 (50 mM
Tris-HCl pH 8.0, 50 mM NaCl, 1 mM DTT and 1 mM EDTA) and then dialysed
overnight in the same buffer.
The DEAE flow-through purified protein sample was then clarified by
centrifugation at 30,000 × g for 30 min and then, in two separate purifications,
loaded onto a SuperQ column (30 mL Toyopearl SuperQ-650M) connected to an
ÄKTApurifier system, and the column washed with TBS50. Once the A280 of the
column eluant reached baseline, a linear gradient elution was applied from 50–500
mM NaCl in TBS over 400 mL. Partially purified DnaG1–165 and DnaG1–170 eluted
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at a NaCl concentration of ∼ 160 mM.
Pooled SuperQ fractions were dialysed overnight with TBS50 and then loaded, in
two separate purifications, on to a MonoQ column (8 mL; GE Healthcare Life
Sciences). Pure DnaG1–165 and DnaG1–170 were each eluted as a sharp peak in an
elution gradient of 50–500 mM NaCl over 200 mL. Mass spectrometry analysis of
DnaG DnaG1–165 and DnaG1–170 in 0.1% formic acid produced ESI-mass spectra
in excellent agreement with their predicted masses based on the gene sequence
(data not shown).
Purified A. baylyi DnaG1–165 and DnaG1–170 truncated proteins were dialysed
extensively against 20 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM DTT and 1 mM
EDTA. Protein samples were then concentrated using Amicon Ultra-4 Centrifugal
Filter Units (Merck Millipore) with a MWCO of 4,000 Da.
4.3.8 Nuclear magnetic resonance analysis of Acinetobacter baylyi
DNA primase zinc-binding domain
An aliquot of concentrated A. baylyi ZBD protein was dialysed extensively against
20 mM Tris-HCl pH 7.0, 50 mM NaCl, 1 mM DTT and 1 mM EDTA; dialysis was
completed without EDTA present in the dialysis buffer. Truncated DnaG1–165 was
stored and shipped in liquid nitrogen to Dr Xun-Cheng Su, State Key Laboratory
of Elemento-organic Chemistry, Nankai University, Peoples Republic of China.
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Otherwise, aliquots of DnaG1–165 and DnaG1–170 proteins were dialysed extensively
against 50 mM Tris-HCl pH 7.5 (or pH 7.0), 150 mM NaCl, 1 mM DTT and 1
mM EDTA; dialysis was completed without EDTA present in the dialysis buffer.
Protein aliquots were stored and shipped on dry ice to Dr Kiyoshi Ozawa at the
Australian National University, Canberra, Australia for analysis by TOCSY NMR.
NMR experiments recorded spectra using Bruker Avance 600 MHz NMR
spectrometers with cryoprobes at 25◦C; 80 ms mixing time was applied for 2D
TOCSY spectra.
4.3.9 Protein crystallography of DnaG1–165 and DnaG1–165
Purified DnaG1–165 and DnaG1–170 were subjected to crystallisation trials using
QIAGEN NeXtal JCSG+, PEGs I and PEGs II suites in sitting drop configuration
with Corning 96 well crystallisation plates (reservoir volume 50 µL). Purified,
concentrated protein (1 µL ; 10 mg.mL−1) was mixed with crystallisation solution
(1 µL), and the crystallisation plate sealed and then stored at 4◦C or 16◦C and
occasionally inspected. Later crystallisation trails used DnaG1–165 at 200 mg.mL−1
and DnaG1–170 at 44 mg.mL−1 and the QIAGEN NeXtal JCSG+ suite.
Jeffrey R. Barrett 104
4.3.10 Homology modelling of the Acinetobacter baylyi DNA primase
zinc-binding and RNA polymerase domains
Protein structures were modelled using ModWeb (Eswar et al., 2003), an online
server for protein structure modelling using the MODELLER program (Sali
and Blundell, 1993; Fiser et al., 2000; Martí-Renom et al., 2000; Eswar et al.,
2006) to calculate three-dimensional protein structures against the best available
homologues in the PDB. The ModWeb service outputs model quality assessments
of the predicted protein structure including the GA341 score which accounts for
sequence identity, structural compactness and residue level statistical measures
of contacts, φ/ψ dihedral angles and accessible surfaces (Melo et al., 2002;
Eramian et al., 2008). The GA341 score ranges from 0 to 1 with a score ≥
0.7 suggesting a reliable structure with a probability of the correct fold larger
than 95%. QMEAN scores were calculated using the SWISS-MODEL server
(http://swissmodel.expasy.org/qmean/cgi/index.cgi; Benkert et al., 2008) and
protein structures were visualised using the PyMOL Molecular Graphics System,
Version 1.5.7 (www.pymol.org; Schrödinger, LLC, 2012).
4.4 Results
4.4.1 C-terminal truncation of Acinetobacter baylyi DNA primase
To search for soluble C-terminal truncations representing the A. baylyi ZBD,
an ExoIII gene truncation library was produced from pJB1742 as described in
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Section 4.3.2. Treatment of pJB1742 with Nt.BbvCI produces a single DNA nick
just upstream of the end of dnaG and is separated from dnaG by stop codons in
all three reading frames. ExoIII will uni-directionally truncate from the 3' nick,
proceed through the three-frame stop codons and then through dnaG. Ligation of
limited ExoIII digestions produces plasmids in which truncated genes for dnaG are








Figure 4.7: Methodology for C-terminal truncation of dnaG. Digestion of pJB1742 with
Nt.BbvCI produces a single 3' end (between the sequence CC and TCAGC) for uni-directional deletion
using ExoIII. Initial digestion through three stop codons (red) must occur to allow gene fusion to
the downstream His6 and egfp sequences. Following uni-directional gene deletion and plasmid repair,
one-in-three truncated genes are in-frame with the downstream egfp gene, producing a truncated
DnaG-EGFP fusion protein when expressed in E. coli .
Deletion reactions were carried out at 30◦C for between 6 min 30 s and 8 min 45 s.
Under these reaction conditions, ExoIII progresses with a rate of 200 bp.min−1 and
resulted in a library of genes for the 5'-terminus that span about a third of dnaG
(see Appendix B.1). The samples from all time points were pooled, ligated and
transformed into BL21(λDE3)recA as described in Section 4.3.2. The recovered
transformed BL21(λDE3)recA cells were spread onto 10 Selection agar plates
containing ampicillin. After overnight incubation at 30◦C approximately 2,100
colonies developed, forty-nine of which exhibited a green fluorescent phenotype.
To determine the coverage of the gene library, 15 randomly selected plasmids
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were sequenced, but of these eight mutants were completely un-truncated while
the seven truncated genes ranged in size from 181 to 830 bp. Sequenced green
fluorescent colonies contained truncated genes ranging from 200 to 700 bp
(discussed later). To reduce the number of non-truncated mutants in the A. baylyi
C-terminal deletion library, the library pool was digested with BamHI, a site for
which is present in the template plasmid pJB1742 but should not appear in any
truncated plasmid. The plasmid library was de-salted and BL21(λDE3)recA was
transformed with the new BamHI treated library and transformants recovered
on 11 agar plates. This resulted in approximately 1,300 colonies, 35 of which
were green fluorescent. Twenty randomly selected non-green-fluorescent mutants
were sequenced to determine the coverage of truncated A. baylyi dnaG genes
(Table 4.1). Of the twenty mutants sequenced, two had truncated past the
initiation codon at the start of the gene and one mutant did not appear to
have been truncated. The remaining 17 plasmids contained genes ranging in
size from 115 through 872 bp, representing genes in all three reading frames
relative to the C-terminal fusion gene. Three mutants were also slightly truncated
through the C-terminal fusion gene, missing between one and four nucleotides,
indicating that these had been deleted through the action of ExoIII, mung bean
nuclease or DNA polymerase I (Klenow fragment). The gene deletion library was
considered sufficient to identify those expressing soluble proteins that comprise
the N-terminal ZBD of DnaG.
Thirty-five plasmids expressing in-frame and putatively soluble DnaG-EGFP
fusions — indicated by their green fluorescent colony phenotype — were first
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Table 4.1: Randomly sequenced dnaG C-terminally truncated plasmids. Gene sequences for
deleted DnaG proteins (shown in the correct reading frame for dnaG) are fused to downstream
purification and solubility reporting proteins. Mutants with over-truncated C-terminal fusion tags are
displayed in red.
End of truncated Out of frame Fusion sequence Protein length
dnaG mutant residues (amino acids)
Over truncated −14 TCAGCGGGCTCCTCT −4.7
Over truncated −8 TCAGCGGGCTCCTCT −2.7
ATTCGGGTTGCTGTC CA TCAGCGGGCTCCTCT 38.3
CATTGCTTTGGCTGT ---GCGGGCTCCTCT 62
TCCTAAAGATAACTT T TCAGCGGGCTCCTCT 99.7
ACTTTGAACAAAAGA AA TCAGCGGGCTCCTCT 103.3
TTTCCTATAAGCGCA AT TCAGCGGGCTCCTCT 109.3
ACCATCTCACCATGC T TCAGCGGGCTCCTCT 130.7
GCAATATCCGAATCA TCAGCGGGCTCCTCT 136
CCTCTTACTTTGACG AT TCAGCGGGCTCCTCT 150.3
ACAGTTTGATCAAAG C TCAGCGGGCTCCTCT 158.7
ATCAAAGCTATATGG GT TCAGCGGGCTCCTCT 161.3
GGTTTTGAAGATGCC TCAGCGGGCTCCTCT 166
GACCTATTGGAAAAT TCAGCGGGCTCCTCT 178
TAGCTCAGTTTTATG AA TCAGCGGGCTCCTCT 183.3
CAGTTTTATGAAAAA TCAGCGGGCTCCTCT 185
ACAACGTGGCTTGAG T ----CGGGCTCCTCT 202.67
AAAGGGCGTGTGGTC TCAGCGGGCTCCTCT 267
AGACTCCGAGATTTT C -------GCTCCTCT 290.67
CCTAAGTAACTAACC TCAGCGGGCTCCTCT not truncated
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examined by colony PCR to determine the size of the genes (Figure 4.8). One
mutant failed to produce a PCR amplification product indicating that one of the
two primer sites had been removed. The majority of putative truncated dnaG
genes ranged in size between 50 and 800 bp.
The recovered green fluorescent colonies had varied green fluorescence intensity,
which was easily visible by patching green mutants onto an agar grid (for example,
see Figure 4.9); some strains appeared to lose their green fluorescent phenotype
on successive culturing (data not shown). The intensity of the green fluorescence
phenotype was recorded and aggregated from multiple culture plates and
assigned a score from 0–4 (see Table 4.2); a score of zero was assigned when green
fluorescence could not be visually determined and a score of four when a colony has
the same brightness as His6-EGFP expressed from pJB1706 on the same agar plate.
Precise sites of truncation of the putative soluble DnaG proteins, all 35 mutants
from the BamHI treated library and 11 from the initial library (pre-BamHI
treated), were then determined by dye terminator sequencing of plasmids
designated pJB1765–pJB1791 (Table 4.2). Soluble truncation products comprised
small peptides, or had C-terminal residues close to the end of the unusual
Moraxellaceae sequence insertion/domain linker. No putative soluble truncated
proteins were observed within the sequence insertion region of DnaG, suggesting
that it is important for expressing soluble ZBD constructs.
Multiple sequence alignment of the Moraxellaceae insertion sequence (Figure
4.5) shows that around residue 169 (A. baylyi), the DnaG sequences begins to
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A: Diagram of colony PCR
dnaG egfp
PET3 235
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Figure 4.8: DNA primase C-terminally deleted green fluorescent mutants. Colony PCR was
performed using primers PET3 and 235 to identify the size of genes present in dnaG truncated
mutants. A: Diagram of PCR primer binding sites in gene truncation plasmids; PCR product
contain 138 bp additional to the truncated gene. B: Agarose gel electrophoresis (1%) of truncated
dnaG mutants (1–35), non-truncated pJB1742 (+), EGFP expression plasmid pJB1706(−), and
HyperLadder I molecular size markers (m).
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Figure 4.9: Green fluorescence phenotype of Acinetobacter baylyi DnaG ZBD truncations.
Green fluorescent E. coli colonies expressing C-terminally truncated A. baylyi DnaG-EGFP fusions
were smeared on Selection media plates and incubated overnight at 30◦C. The number identifies the
C-terminal residue of the truncation. Green fluorescent phenotype was examined under a long-wave
UV lamp and assigned a score from 0–4; 0, green fluorescence not visible or 4, expression of His6-EGFP
from pJB1706.
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Table 4.2: Sequenced C-terminally deleted A. baylyi DnaG constructs. Green fluorescent colonies expressing truncated DnaG-EGFP
fusion proteins were sequenced to identify the mutations present. Shown at the top are the DNA and protein sequence of untruncated pJB1742
(wt/WT) that was used to generate truncated DnaG genes fused to EGFP. f0–2 indicate the reading frames present in pJB1742; red, stop
codons in each reading frame which must be removed for truncated proteins to co-express with EGFP; bold, BamHI site which follows the
A. baylyi dnaG sequence, adding the residues Gly-Ser to the protein; blue, BbvCI site used to generate the 3' nick. Shown in the body of
the Table are DNA and protein sequences of truncated mutants. Scores for green fluorescence brightness are on a scale from 0–4 where 0
indicates that green fluorescence could not be visually detected and 4, green fluorescence was similar to colonies expressing His6-EGFP with
no N-terminal fusion. Red, indicates regions of the flexible linker that have been deleted. One dnaG truncated mutant was out of frame with
egfp, one mutant did not produce readable sequencing and four contained no dnaG gene (not shown).
wt TTAAGATTATTATCTGGATCCTAAGTAACTAACC TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC WT
f0 L R L L S G S *
f1 +1 * S A G S S G N S H H H H H
f2 +2 *
DNA sequence Plasmid
Score Protein sequence Mutation
CCTCAGCATACCATTGATCAAATTCTAGATCGGACT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1775
(4) P Q H T I D Q I L D R T S A G S S G N S H H H H H 1–15
CAGCATACCATTGATCAAATTCTAGATCGGACTGAT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1774
(4) Q H T I D Q I L D R T D S A G S S G N S H H H H H 1–16
ATTGATCAAATTCTAGATCGGACTGATCTGGTTGAG TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1767
(4) I D Q I L D R T D L V E S A G S S G N S H H H H H 1–19
CAAATTCTAGATCGGACTGATCTGGTTGAGTTAATA GCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1768
(3) Q I L D R T D L V E L I A A G S S G N S H H H H H 1–21
CAAATTCTAGATCGGACTGATCTGGTTGAGTTAATA TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1753
(3) Q I L D R T D L V E L I S A G S S G N S H H H H H 1–21
ATTCTAGATCGGACTGATCTGGTTGAGTTAATAGGC TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1782
(2) I L D R T D L V E L I G S A G S S G N S H H H H H 1–22
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Table 4.2 – continued from previous page
wt TTAAGATTATTATCTGGATCCTAAGTAACTAACC TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC WT
f1 +1 * S A G S S G N S H H H H H
DNA sequence Plasmid
Score Protein sequence Mutation
CGGACTGATCTGGTTGAGTTAATAGGCCAGAGAGTC TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1791
(1) R T D L V E L I G Q R V S A G S S G N S H H H H H 1–25
CGGACTGATCTGGTTGAGTTAATAGGCCAGAGAGTC TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1754
(1) R T D L V E L I G Q R V S A G S S G N S H H H H H 1–25
ATAGGCCAGAGAGTCAAACTAAAAAAAACAGGTAGA TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1778
(0) I G Q R V K L K K T G R S A G S S G N S H H H H H 1–32
ATAGGCCAGAGAGTCAAACTAAAAAAAACAGGTAGA TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1783
(0) I G Q R V K L K K T G R S A G S S G N S H H H H H 1–32
TGTCCATTTCATCAAGAAAAAAGCCCTTCTTTCCAT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1786
(1) C P F H Q E K S P S F H S A G S S G N S H H H H H 1–49
TGTCCATTTCATCAAGAAAAAAGCCCTTCTTTCCAT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1755
(1) C P F H Q E K S P S F H S A G S S G N S H H H H H 1–49
TGTCCATTTCATCAAGAAAAAAGCCCTTCTTTCCAT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1756
(1) C P F H Q E K S P S F H S A G S S G N S H H H H H 1–49
CCATTTCATCAAGAAAAAAGCCCTTCTTTCCATGTA TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1777
(1) P F H Q E K S P S F H V S A G S S G N S H H H H H 1–50
CCATTTCATCAAGAAAAAAGCCCTTCTTTCCATGTA TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1787
(1) P F H Q E K S P S F H V S A G S S G N S H H H H H 1–50
AAAAGCCCTTCTTTCCATGTATATCGAGACAAGGGC TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1757
(2) K S P S F H V Y R D K G S A G S S G N S H H H H H 1–55
AGCCCTTCTTTCCATGTATATCGAGACAAGGGCTAT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1770
(2) S P S F H V Y R D K G Y S A G S S G N S H H H H H 1–56
Continued on next page. . .
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wt TTAAGATTATTATCTGGATCCTAAGTAACTAACC TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC WT
f1 +1 * S A G S S G N S H H H H H
DNA sequence Plasmid
Score Protein sequence Mutation
CATGTATATCGAGACAAGGGCTATTACCATTGCTTT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1758
(1) H V Y R D K G Y Y H C F S A G S S G N S H H H H H 1–60
CATGTATATCGAGACAAGGGCTATTACCATTGCTTT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1759
(1) H V Y R D K G Y Y H C F S A G S S G N S H H H H H 1–60
TATCGAGACAAGGGCTATTACCATTGCTTTGGCTGT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1788
(0) Y R D K G Y Y H C F G C S A G S S G N S H H H H H 1–62
TATCGAGACAAGGGCTATTACCATTGCTTTGGCTGT CCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1789
(0) Y R D K G Y Y H C F G C P A G S S G N S H H H H H 1–62
ATTGATGGGCGTAACTTTATTGATGTCATGCAGGAA TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1765
(0) I D G R N F I D V M Q E S A G S S G N S H H H H H 1–86
GCACAGTTTGATCAAAGCTATATGGGTTTTGAAGAT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1772
(3) A Q F D Q S Y M G F E D S A G S S G N S H H H H H 1–165
GCACAGTTTGATCAAAGCTATATGGGTTTTGAAGAT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1790
(3) A Q F D Q S Y M G F E D S A G S S G N S H H H H H 1–165
GCACAGTTTGATCAAAGCTATATGGGTTTTGAAGAT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1760
(3) A Q F D Q S Y M G F E D S A G S S G N S H H H H H 1–165
GCACAGTTTGATCAAAGCTATATGGGTTTTGAAGAT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1761
(3) A Q F D Q S Y M G F E D S A G S S G N S H H H H H 1–165
AGCTATATGGGTTTTGAAGATGCCCCTCAAGAAGGC TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1776
(3) S Y M G F E D A P Q E G S A G S S G N S H H H H H 1–170
AGCTATATGGGTTTTGAAGATGCCCCTCAAGAAGGC TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1781
(3) S Y M G F E D A P Q E G S A G S S G N S H H H H H 1–170
Continued on next page. . .
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wt TTAAGATTATTATCTGGATCCTAAGTAACTAACC TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC WT
f1 +1 * S A G S S G N S H H H H H
DNA sequence Plasmid
Score Protein sequence Mutation
TATATGGGTTTTGAAGATGCCCCTCAAGAAGGCAAT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1769
(3) Y M G F E D A P Q E G N S A G S S G N S H H H H H 1–171
TATATGGGTTTTGAAGATGCCCCTCAAGAAGGCAAT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1762
(3) Y M G F E D A P Q E G N S A G S S G N S H H H H H 1–171
AATCTTTATGACCTATTGGAAAATGTAGCTCAGTTT -----GGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1771
(2) N L Y D L L E N V A Q F - - G S S G N S H H H H H 1–182
AATCTTTATGACCTATTGGAAAATGTAGCTCAGTTT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1763
(2) N L Y D L L E N V A Q F S A G S S G N S H H H H H 1–182
AAACAGCTGCCAAATAGTAATAAGGCACAGCAATAT ---GCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1773
(2) K Q L P N S N K A Q Q Y - A G S S G N S H H H H H 1–195
GAAAAACAGCTGCCAAATAGTAATAAGGCACAGCAA TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1764
(2) E K Q L P N S N K A Q Q S A G S S G N S H H H H H 1–195
TGGCGTTTGGGTTATGCACCCGAAGACTGGCAGCAC CCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1780
(1) W R L G Y A P E D W Q H P A G S S G N S H H H H H 1–221
TCAAGTGATAGTGGACGTGACTTTGACCTGCTACGT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1766
(2) S S D S G R D F D L L R S A G S S G N S H H H H H 1–252
TCAAGTGATAGTGGACGTGACTTTGACCTGCTACGT TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1785
(2) S S D S G R D F D L L R S A G S S G N S H H H H H 1–252
ACATTATTTAAACAGAACTCTAGAATCACGATTGCC TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1784
(0) T L F K Q N S R I T I A S A G S S G N S H H H H H 1–357
CAGCTCAATGAATTAAGCAAACAGATCAACTTAAGA TCAGCGGGCTCCTCTGGGAATTCTCATCACCATCAC pJB1779
(1) Q L N E L S K Q I N L R S A G S S G N S H H H H H 1–626
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be conserved, suggesting that the RPD begins around residue 169, which is 12
residues preceding the Pfam assignment for homology to the RPD. Putative
soluble N-terminal fragments 1–165, 1–170 and 1–175 had a strong green
fluorescent phenotype and deletion end-points were clustered in this region, while
slightly longer mutants containing short portions of the RPD were also identified
as putatively soluble (see Figure 4.21A in Discussion).
4.4.2 Examination of soluble N-terminal DNA primase mutants
To investigate if the truncated proteins identified by the EGFP solubility selection
screen were in fact soluble, those proteins which might represent a useful ZBD
protein were modified to no longer express an EGFP C-terminal fusion, but to
still possess a C-terminal His6-tag (pJB1793–pJB1790; Table 4.3; Section 4.3.4).
The genes were over-expressed by auto-induction in BL21(λDE3)recA/pLysS.
Since no proteins corresponding to just the predicted ZBD (∼ 100 residues;
Figures 4.4, 4.5 and 4.21A) were obtained by screening for a green fluorescent
phenotype, mutants were selected which might represent the smallest soluble
construct containing the ZBD and the following insertion sequence.
The T7 lysozyme containing, mutant DnaG over-expressed cells were collected
by centrifugation and resuspended to equal concentration of cells, lysed by
repeated freeze-thaw cycles and then centrifuged to separate soluble and insoluble
components, which were analysed by SDS-PAGE (Figure 4.10). Each plasmid
directed over-expression of a protein of the expected size and the amount of
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Table 4.3: Plasmids for expression of putatively soluble DNA primase N-terminal fragments.
Selected A. baylyi DnaG ZBD mutant plasmids were modified to direct expression of C-terminal
His6-tagged protein without EGFP fusion.





















Figure 4.10: Soluble over-expression of DNA primase C-terminal deletion mutants. N-terminal
fragments of A. baylyi DnaG were over-expressed in BL21(λDE3)recA by auto-induction at 30◦C.
Following cell lysis, the cellular, C; soluble, Sol and insoluble, In fractions were each analysed by
SDS-PAGE. HyperPage molecular size markers are indicated. The arrow indicates the over-expressed
protein.
protein expression varied significantly among the mutants. In general, the yield
of soluble over-expressed truncated DnaG corresponded to the green fluorescence
intensity of cells expressing these proteins as fusions to EGFP; where a brighter
green fluorescent colony coincided with higher soluble protein yield. Of the
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mutants examined, DnaG1–165, DnaG1–170 and DnaG1–171 produced a substantial
proportion of soluble over-expressed protein and showed bright green fluorescence
when expressed as a fusion to EGFP. Of these three proteins, DnaG1–170 showed
a lower level of over-expression, yet produced similar yields of soluble protein.
DnaG1–182 and DnaG1–195 produced less soluble protein than the preceding
mutants and had correspondingly less bright green fluorescence when fused to
EGFP. DnaG1–182 over-expressed poorly but appeared to be very soluble at this
level of protein expression, whereas, DnaG1–195 over-expressed well but was poorly
soluble. DnaG1–221 produced no detectable soluble protein when over-expressed;
this mutant had a very weakly fluorescent EGFP fusion. Most of the soluble
proteins were also evident in the insoluble cellular fraction, but this might be
expected when a protein is highly over-expressed, or cell lysis may not have been
complete.
4.4.3 Purification of soluble N-terminal fragments of DNA primase
To further confirm the solubility and foldedness of the truncation mutants
identified, each was purified by one step IMAC (Figure 4.11). Each of DnaG1–165,
DnaG1–170, DnaG1–171, DnaG1–182 and DnaG1–195, which appear in the soluble
cellular fraction were purified by IMAC and remained in solution. On the other
hand, DnaG1–221, which does not appear in the soluble cell fraction was not
enriched using IMAC. These results highlight that truncated DnaG mutants
identified by expression of the corresponding EGFP fusion protein are actually
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Figure 4.11: Purification of DNA primase C-terminally truncated proteins. C-terminal-His6
tagged fragments of DnaG: A; DnaG1–165, B; DnaG1–170,C; DnaG1–171, D; DnaG1–182, E; DnaG1–195,
F; DnaG1–221, were over-expressed in BL21(λDE3)recA by auto-induction at 30◦C. The soluble cellular
fraction was purified by one-step IMAC and analysed by SDS-PAGE. Shown on gels are F, IMAC
unbound fraction and 1–5, successively eluted IMAC fractions. Migration of HyperPage molecular
size markers are indicated.
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4.4.4 Circular dichroism of the DNA primase zinc-binding domain
We wished to examine whether the N-terminal domain fragments of DnaG were
folded. To help asses the foldedness of the ZBD-extension proteins, low resolution
structural information was obtained by recording circular dichroism (CD)
spectra for each soluble truncated DnaG mutant. CD is a technique to acquire
information on the secondary structures present in a protein. Each secondary
structural element differentially absorbs left- and right-handed circularly polarised
light and gives rise to characteristic CD spectra (Kelly et al., 2005). The CD
spectra produced for all mutants (Figure 4.12) were comparable, consistent with
them being folded and indicating that the proteins share secondary structural
elements. In particular, the weak negative elipticity at wavelengths < 210 nm
indicated the presence of α-helix and β-sheet structures in the ZBDs (cf. Figure
4.3).
4.4.5 Examination of the foldedness of C-terminally truncated DNA
primase by nuclear magnetic resonance spectroscopy
Further characterisation of protein foldedness in truncated A. baylyi DnaG
proteins was performed using NMR spectroscopy. 1D proton NMR can infer if a
protein is in a folded state. In an unfolded protein, methyl protons are solvent
exposed and all will produce similar NMR signals. However, when a protein is
folded, some of these methyl groups are sequestered in the hydrophobic protein
core, where they will produce unique (sharp) NMR signals related to their unique
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Figure 4.12: Circular dichroism of DNA primase zinc-binding domain-extension proteins.
Circular dichroism spectra were recorded for purified His6-tagged A. baylyi ZBD-extension proteins in
20 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM DTT and 1 mM EDTA. Circular dichroism spectra were
converted to molar ellipticity ([θ]). CD spectra: (•), DnaG1–165; (•), DnaG1–170; (•), DnaG1–171;
(•), DnaG1–182; (•), DnaG1–195.
chemical environment (−0.5 to 1.5 ppm; McDonald and Phillips, 1967; Christendat
et al., 2000). Further information on protein conformation can be inferred from
the presence of Cα (5–6 ppm) proton chemical shifts which are indicative of
β-sheet hydrogen bonds (McDonald and Phillips, 1967; Christendat et al., 2000;
Rehm et al., 2002). The 1D NMR spectrum of non-His6-tagged DnaG1–165 (Figure
4.13) shows well dispersed signals in the methyl and amide regions, but not
Cα, consistent with the protein possessing a folded and predominantly α-helical
structure, as predicted from the known ZBD structures (Figure 4.3). In addition
to indicating that DnaG1–165 contains a folded α-helical region, the 1D NMR
spectrum showed sharp amide resonances (7–9 ppm) suggestive of a folded
structure.
2D TOtal Correlation SpectroscopY (TOCSY) NMR introduces a secondary
spectral axis, whereby under the right conditions, the chemical shifts for each
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Figure 4.13: One dimensional nuclear magnetic resonance spectrum of DnaG1–165. To see if
purified DnaG1–165 was folded, 1D NMR was recorded in 20 mM Tris-HCl pH 7.0, 50 mM NaCl and 1
mM DTT by the research group of Dr Xun-Cheng Su at the State Key Laboratory of Elemento-organic
Chemistry, Nankai University, Peoples Republic of China.
proton in a spin-system can be observed within distinct amino acids. These
spin-system chemical shifts can be seen perpendicular to each other in both
spectral axes and can be used to identify responsible residues. As proteins
increase in size, the number of proton resonances increases, resulting in chemical
shift overlap in NMR spectra. Further, as the protein molecules tumble more
slowly as the proteins increase in size, chemical shift signals broaden (Jardetzky
and Roberts, 1981). The result of these two effects is that, in 2D experiments,
chemical shifts from protons within large molecules broaden to the point that
they are indistinguishable from the background (Lecroisey et al., 1997). However,
flexible regions within a protein move more quickly, sharpening their resonances
to detectable levels. Thus, an appropriate 2D NMR approach can produce a
“flexible” residue spectrum, whereby chemical shifts are visible only for mobile
residues in larger molecules. In addition to defining flexible residues, this 2D
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NMR experiment can offer insight into the conformation of these flexible,
NMR-observable residues. When in a disordered conformation, amino acids show
resonances at characteristic random-coil values (Wishart et al., 1995; Wishart,
2011) and the contribution of random-coil chemical shifts in “flexible” NMR
spectra then indicate if these regions of a protein are disordered or not.
2D TOCSY NMR spectra were recorded for His6-tagged DnaG1–165 (pH 7.5)
and DnaG1–170 (pH 7.0; Figure 4.14) and these “flexible” NMR spectra show a
significant number of residues with random-coil chemical shifts. Comparison of
spectra for the two similar proteins indicates the appearance of an additional
glutamic acid random-coil chemical shift in the spectrum of DnaG1–170. The
additional C-terminal residues of DnaG1–170-His6, compared to DnaG1–165-His6,
contain this additional Glu, strongly suggesting that the flexible residues are
present at the C-terminus of these proteins (see Figure 4.5).
4.4.6 N-terminal fragments of DNA primase bind zinc
One of the defining features of ZBDs in primase is that they bind tightly to
zinc. To test the ability of the DnaG N-terminal proteins to bind zinc, A. baylyi
ZBD-extension mutants were analysed by ESI-mass spectrometry under both
denaturing and native conditions. Proteins maintained in acidic buffers, which
promote protein unfolding (denaturation), lose non-covalently bound species as
the folded regions to which they associate are no longer present. However, proteins
maintained in ammonium acetate buffers can often retain their natively folded
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A: A. baylyi DnaG: DnaG1–165-His6 TOCSY
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Figure 4.14: Two dimensional TOCSY NMR spectra of DnaG1–165-His6 and DnaG1–170-His6.
To see if purified ZBD-extension proteins were folded, TOCSY NMR spectra were recorded by Dr
Kiyoshi Ozawa at the Australian National University. 2D TOCSY NMR spectra (80 ms mixing time)
were recorded for: A, DnaG1–165-His6 (pH 7.0; 50 mM Tris, 150 mM NaCl, 1 mM DTT, 1 mM
EDTA) resulting in some precipitation of the protein over the course of the experiment; and B,
DnaG1–170-His6 (pH 7.5; 50 mM Tris, 150 mM NaCl, 1 mMDTT). Red dashed lines indicate the
range of random-coil values for: vertical, amide proton and horizontal, Cα proton chemical shifts
(Wishart et al., 1995; Wishart, 2011)
conformations (Felitsyn et al., 2002; Hernández and Robinson, 2007), and so can
be observed in mass spectrometry with ligands still intact.
To determine if A. baylyi ZBD-extension mutants contain a folded ZBD,
non-His6-tagged DnaG1–165 and DnaG1–170 were purified (Sections 4.3.5 and
4.3.7.1; Figure 4.15) and the proteins were prepared for mass spectrometry.
Contaminating metals were removed from the samples by dialysis against 1 mM
EDTA before analysis. The electrospray mass spectra of denatured DnaG1–165
and DnaG1–170 in 0.1% formic acid showed that the proteins were complete, each























Figure 4.15: Purified untagged DnaG1–165 and DnaG1–170. Two ZBD-extension proteins were
expressed without His6 or EGFP fusions (Sections 4.3.5 and 4.3.7.1). Purified: A, DnaG1–165and B,
DnaG1–170 were analysed by SDS-PAGE and stained with Coomassie blue.
























Denatured: 19259.29 Da ± 0.24
Native     : 19323.51 Da ± 0.24
∆ 64.2 ± 0.48























Denatured: 19738.67 Da ± 0.06
Native     : 19802.94 Da ± 0.13
             ∆ 64.3 ± 0.19
Figure 4.16: Positive ion electrospray mass spectrum of denatured and native DNA primase
zinc-binding domain-extension mutants. Denatured mass analysis (blue) was performed in
formic acid and native mass analysis (green) was performed in 100 mM ammonium acetate pH
for: A, DnaG1–165 and B, DnaG1–170. The mass obtained is consistent with the predicted mass the
respective proteins. Native protein samples contain additional mass (64.2 and 64.3 Da) consistent
with a single bound zinc ion.
0.1%
7.2
giving a mass in close agreement with the predicted mass without N-terminal
methionine (DnaG1–165, 19,257.4 Da and DnaG1–170, 19,739.9 Da; Figure 4.16).
However, under native mass spectrometry conditions both DnaG1–165 and
DnaG1–170 displayed a mass higher by 64 Da than under denaturing conditions,
consistent with a single bound zinc (atomic mass 65.4 Da), supporting that A.
baylyi ZBD-extension mutants contain a folded ZBD.
4.4.7 Crystallisation of DnaG1–165 and DnaG1–170
To attempt to determine the three-dimensional structures of the A. baylyi
ZBD-extension proteins, numerous attempts to crystallise both DnaG1–165 and
DnaG1–170 were made, but were unsuccessful, even using highly concentrated
protein samples (up to 10 mM in the case of DnaG1–165). Many protein
properties can contribute to failed protein crystallisation. In the case of the A.
baylyi ZBD-extension proteins, the C-terminal extensions may be flexible. The
Moraxellaceae sequence insertion shows poor conservation (Figure 4.5) suggesting
that it may be unstructured. This is supported by NMR data that show significant
portions of the proteins are in a random-coil conformation (Figure 4.14).
4.4.8 N-terminal truncation of Acinetobacter baylyi DNA primase
To search for soluble N-terminal truncations complementing those identified in
Section 4.4.1, an N-deleted gene truncation library was produced using pJB1743
as described in Section 4.3.2. NcoI linearised pJB1743 was end filled using
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dGTPαS, dATP, dCTP, dTTP and the Klenow fragment of DNA polymerase
I. Digestion of α-S protected pJB1742 with NdeI removed the dGTPαS end
adjacent to the start codon of dnaG and allowed uni-directional deletion using
ExoIII (Figure 4.17). The α-S protected NcoI site initiates translation in pJB1743
and following ligation of limit ExoIII truncations directs over-expression of
N-terminally truncated DnaG-EGFP fusion proteins when a mutant is in the
appropriate reading frame. Truncating a protein composed of globular domains
from both the N- and C-termini would be expected to produce similar protein









Figure 4.17: Methodology for N-terminal truncation of DNA primase. NcoI linearised pJB1743
was protected with dGTPαS (red) and dATP, dCTP and dTTP (green) and then digested with NdeI to
allow uni-directional deletion through the N-terminus of A. baylyi dnaG. The filled NcoI site provides
the start codon for truncated genes. Following limit digests of pJB1743 using ExoIII and plasmid
repair, one-in-three truncated genes are in-frame with the start codon and so direct over-expression
of N-terminally deleted DnaG proteins fused with the downstream EGFP when expressed in E. coli .
Deletion reactions were carried out at 30◦C for between 1 min 25 s and 2
min 40 s. These conditions should have resulted in a library of genes with the
N-terminal domain removed and sampled through the ZBD-extension (the library
was focussed to provide deletion end-points approximately between nucleotides
300 and 600 of dnaG; see Appendix B.2). Truncated library samples were
pooled, ligated and transformed into BL21(λDE3)recA as described in Section
4.3.2. Library transformed BL21(λDE3)recA cells were spread onto 12 Selection
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agar plates containing ampicillin. After overnight incubation at 30◦C a total of
approximately 4,000 colonies developed, 63 of which showed green fluorescece.
After the agar plates had been stored at 4◦C for 24 h, a further 39 green fluorescent
colonies became apparent.
Twenty randomly selected non-fluorescent colonies were chosen and the mutant
plasmids purified and sequenced (Table 4.4). The genes present for N-terminally
deleted DnaG were truncated by between 246 and 720 nucleotides, represented all
three reading frames and did not appear to have truncated at the α-S protected
end. The N-terminal deletion library likely provided sufficient coverage of the
region of interest. The size of the genes present in the 102 green fluorescent
N-terminally deleted DnaG mutants was determined by colony PCR and mostly
revealed genes ranging between 350 and 1,900 bp (data not shown; full-length
dnaG is 1,890 bp). Twenty mutants appeared to contain small < 200 bp genes
and these were not investigated further.
The identities of the remaining 82 putative soluble EGFP fusion proteins were
then determined by DNA sequencing and the mutants were scored based on the
brightness of their green fluorescent phenotype (Table 4.5). Firstly, multiple genes
for proteins starting at residues 168–170 of DnaG had a bright green fluorescent
phenotype, suggesting that they represent soluble proteins. These DnaG mutants
have terminal residues very close to those identified by C-terminal deletion of
DnaG and appear to be at the start of homology for the RPD (Figure 4.5).
However, in contrast to the C-terminal deletion library, N-terminal deletions
were putatively soluble when truncation occurred at the end of the ZBD and
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throughout the Moraxellaceae sequence insertion/domain linker residues 101
through 168 (of A. baylyi DnaG; Figure 4.21B in Discussion).
Table 4.4: Randomly sequenced N-terminally truncated DNA primase plasmids. The fusion
sequence, which provides a start codon containing αS protected dGMP (bold) is fused to truncated
dnaG genes (shown in the correct reading frame for dnaG).
Fusion Out of frame End of truncated Protein length
sequence residues dnaG mutant (amino acids)
CCATG C GCTCAAGTGATAGTG 389.7
CCATG AG TGCAGAAACTATTCA 426.3
CCATG GC ACAGCAATATTTTAA 436.3
CCATG GT AGCTCAGTTTTATGA 450.3




CCATG GA CGATCCATTCGCACA 479.3
CCATG GCACCCTCTTACTTT 485
CCATG GG TTTACAAGCACCCTC 487.3
CCATG GAACAGATTGACGGT 492
CCATG CA TGCTGCAATATCCGA 499.3
CCATG CA CCATGCTGCAATATC 500.3
CCATG A CTGAAAAATCTGCAC 507.7
CCATG ACTGAAAAATCTGCA 508
CCATG GAACAAAAGAAACTT 529
CCATG AA AGATAACTTTGAACA 532.3
CCATG TC GGGCGTTGAACTTCC 538.3
CCATG G ATGTCATGCAGGAAC 547.7
As previously observed, the recovered colonies had varied green fluorescence
intensity for the genes of various sizes. Several mutants with very poor green
fluorescence brightness were produced that had truncations within the ZBD of
A. baylyi DnaG, where production of only part of the ZBD folding unit should
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Table 4.5: Sequenced N-terminally deleted A. baylyi DnaG. Plasmids from green fluorescent colonies expressing truncated DnaG-EGFP
fusion proteins were sequenced to identify the mutations present. Displayed at the top are the DNA and protein sequences of untruncated
pJB1743 (wt/WT) that was used to generate truncated dnaG genes fused to egfp; shown in red are the nucleotides removed during linearisation
for uni-directional truncation. f0–1 indicate the reading frames present in pJB1743; f0; reading frame of initiation codon, f1; reading frame of
non-truncated dnaG in pJB1743. Scores for green fluorescence brightness are on a scale from 0–4 where 0 indicates that green fluorescence
could not be visually detected and 4, green fluorescence was similar to colonies expression His6-EGFP with no N-terminal fusion. One mutant
did not provide useful DNA sequencing data (not shown).
wt CCATGGCGACCTCGTGA-/19 bp ATGGCTATTCCTCAGCATACCATTGATCAA WT
f0 M A T S *
f1 M A I P Q H T I D Q
DNA sequence Plasmid
Score Protein sequence Mutation
CCATG ATGGCTATTCCTCAGCATACCATTGATCAAATTCTA pJB1866
(2) M M A I P Q H T I D Q I L 1–629
CCATG ATGGCTATTCCTCAGCATACCATTGATCAAATTCTA pJB1869
(2) M M A I P Q H T I D Q I L 1–629
CCATG CCTCAGCATACCATTGATCAAATTCTAGATCGGACT pJB1822
(1) M P Q H T I D Q I L D R T 4–629
CCATG GGTAGAACCTATTCGGGTTGCTGTCCATTTCATCAA pJB1810
(0) M G R T Y S G C C P F H Q 31–629
CCATG CGAGACAAGGGCTATTACCATTGCTTTGGCTGTCAG pJB1858
(1) M R D K G Y Y H C F G C Q 52–629
CCATG GATATTGATGGGCGTAACTTTATTGATGTCATGCAG pJB1823
(3) M D I D G R N F I D V M Q 74–629
CCATG GGGCGTAACTTTATTGATGTCATGCAGGAACTGTCT pJB1845
(2) M G R N F I D V M Q E L S 77–629
CCATG GATGTCATGCAGGAACTGTCTAGTAAATCGGGCGTT pJB1857
(2) M D V M Q E L S S K S G V 82–629
Continued on next page. . .
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Table 4.5 – continued from previous page
wt CCATGGCGACCTCGTGA-/19 bp ATGGCTATTCCTCAGCATACCATTGATCAA WT
f0 M A T S *
DNA sequence Plasmid
Score Protein sequence Mutation
CCATG CAGGAACTGTCTAGTAAATCGGGCGTTGAACTTCCT pJB1837
(2) M Q E L S S K S G V E L P 85–629
CCATG CTGTCTAGTAAATCGGGCGTTGAACTTCCTAAAGAT pJB1805
(3) M L S S K S G V E L P K D 87–629
CCATG TCGGGCGTTGAACTTCCTAAAGATAACTTTGAACAA pJB1841
(2) M S G V E L P K D N F E Q 91–629
CCATG CTTCCTAAAGATAACTTTGAACAAAAGAAACTTTCC pJB1827
(2) M L P K D N F E Q K K L S 95–629
CCATG GAACAAAAGAAACTTTCCTATAAGCGCAATACACAA pJB1826
(1) M E Q K K L S Y K R N T Q 101–629
CCATG CAAAAGAAACTTTCCTATAAGCGCAATACACAAAAA pJB1876
(1) M Q K K L S Y K R N T Q K 102–629
CCATG CTTTCCTATAAGCGCAATACACAAAAACCAGAACCG pJB1816
(1) M L S Y K R N T Q K P E P 105–629
CCATG TATAAGCGCAATACACAAAAACCAGAACCGAAACCT pJB1853
(2) M Y K R N T Q K P E P K P 107–629
CCATG TATAAGCGCAATACACAAAAACCAGAACCGAAACCT pJB1854
(2) M Y K R N T Q K P E P K P 107–629
CCATG AAGCGCAATACACAAAAACCAGAACCGAAACCTGTT pJB1815
(2) M K R N T Q K P E P K P V 108–629
CCATG CAAAAACCAGAACCGAAACCTGTTGTAAATACTGAA pJB1846
(1) M Q K P E P K P V V N T E 112–629
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Table 4.5 – continued from previous page
wt CCATGGCGACCTCGTGA-/19 bp ATGGCTATTCCTCAGCATACCATTGATCAA WT
f0 M A T S *
DNA sequence Plasmid
Score Protein sequence Mutation
CCATG CCTGTTGTAAATACTGAAAAATCTGCACCATCTCAC pJB1821
(3) M P V V N T E K S A P S H 118–629
CCATG GTTGTAAATACTGAAAAATCTGCACCATCTCACCAT pJB1803
(2) M V V N T E K S A P S H H 119–629
CCATG AATACTGAAAAATCTGCACCATCTCACCATGCTGCA pJB1880
(1) M N T E K S A P S H H A A 121–629
CCATG AAATCTGCACCATCTCACCATGCTGCAATATCCGAA pJB1850
(2) M K S A P S H H A A I S E 124–629
CCATG TCTCACCATGCTGCAATATCCGAATCATCGGAACAG pJB1832
(2) M S H H A A I S E S S E Q 128–629
CCATG CACCATGCTGCAATATCCGAATCATCGGAACAGATT pJB1807
(2) M H H A A I S E S S E Q I 129–629
CCATG CACCATGCTGCAATATCCGAATCATCGGAACAGATT pJB1808
(2) M H H A A I S E S S E Q I 129–629
CCATG CACCATGCTGCAATATCCGAATCATCGGAACAGATT pJB1813
(2) M H H A A I S E S S E Q I 129–629
CCATG CACCATGCTGCAATATCCGAATCATCGGAACAGATT pJB1829
(2) M H H A A I S E S S E Q I 129–629
CCATG CACCATGCTGCAATATCCGAATCATCGGAACAGATT pJB1856
(2) M H H A A I S E S S E Q I 129–629
CCATG GCTGCAATATCCGAATCATCGGAACAGATTGACGGT pJB1831
(2) M A A I S E S S E Q I D G 131–629
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wt CCATGGCGACCTCGTGA-/19 bp ATGGCTATTCCTCAGCATACCATTGATCAA WT
f0 M A T S *
DNA sequence Plasmid
Score Protein sequence Mutation
CCATG GCAATATCCGAATCATCGGAACAGATTGACGGTTTA pJB1872
(2) M A I S E S S E Q I D G L 132–629
CCATG TCCGAATCATCGGAACAGATTGACGGTTTACAAGCA pJB1849
(1) M S E S S E Q I D G L Q A 134–629
CCATG TCATCGGAACAGATTGACGGTTTACAAGCACCCTCT pJB1852
(2) M S S E Q I D G L Q A P S 136–629
CCATG TCATCGGAACAGATTGACGGTTTACAAGCACCCTCT pJB1873
(2) M S S E Q I D G L Q A P S 136–629
CCATG TCGGAACAGATTGACGGTTTACAAGCACCCTCTTAC pJB1817
(3) M S E Q I D G L Q A P S Y 137–629
CCATG TTACAAGCACCCTCTTACTTTGACGATCCATTCGCA pJB1811
(2) M L Q A P S Y F D D P F A 143–629
CCATG TTACAAGCACCCTCTTACTTTGACGATCCATTCGCA pJB1833
(2) M L Q A P S Y F D D P F A 143–629
CCATG CCCTCTTACTTTGACGATCCATTCGCACAGTTTGAT pJB1818
(2) M P S Y F D D P F A Q F D 146–629
CCATG CCCTCTTACTTTGACGATCCATTCGCACAGTTTGAT pJB1870
(2) M P S Y F D D P F A Q F D 146–629
CCATG TACTTTGACGATCCATTCGCACAGTTTGATCAAAGC pJB1809
(2) M Y F D D P F A Q F D Q S 148–629
CCATG TACTTTGACGATCCATTCGCACAGTTTGATCAAAGC pJB1878
(2) M Y F D D P F A Q F D Q S 148–629
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wt CCATGGCGACCTCGTGA-/19 bp ATGGCTATTCCTCAGCATACCATTGATCAA WT
f0 M A T S *
DNA sequence Plasmid
Score Protein sequence Mutation
CCATG CAGTTTGATCAAAGCTATATGGGTTTTGAAGATGCC pJB1839
(2) M Q F D Q S Y M G F E D A 155–629
CCATG CAAGAAGGCAATCTTTATGACCTATTGGAAAATGTA pJB1806
(3) M Q E G N L Y D L L E N V 168–629
CCATG CAAGAAGGCAATCTTTATGACCTATTGGAAAATGTA pJB1812
(3) M Q E G N L Y D L L E N V 168–629
CCATG CAAGAAGGCAATCTTTATGACCTATTGGAAAATGTA pJB1814
(3) M Q E G N L Y D L L E N V 168–629
CCATG CAAGAAGGCAATCTTTATGACCTATTGGAAAATGTA pJB1838
(2) M Q E G N L Y D L L E N V 168–629
CCATG CAAGAAGGCAATCTTTATGACCTATTGGAAAATGTA pJB1848
(3) M Q E G N L Y D L L E N V 168–629
CCATG CAAGAAGGCAATCTTTATGACCTATTGGAAAATGTA pJB1855
(3) M Q E G N L Y D L L E N V 168–629
CCATG CAAGAAGGCAATCTTTATGACCTATTGGAAAATGTA pJB1861
(3) M Q E G N L Y D L L E N V 168–629
CCATG CAAGAAGGCAATCTTTATGACCTATTGGAAAATGTA pJB1877
(3) M Q E G N L Y D L L E N V 168–629
CCATG GAAGGCAATCTTTATGACCTATTGGAAAATGTAGCT pJB1819
(2) M E G N L Y D L L E N V A 169–629
CCATG GAAGGCAATCTTTATGACCTATTGGAAAATGTAGCT pJB1844
(2) M E G N L Y D L L E N V A 169–629
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wt CCATGGCGACCTCGTGA-/19 bp ATGGCTATTCCTCAGCATACCATTGATCAA WT
f0 M A T S *
DNA sequence Plasmid
Score Protein sequence Mutation
CCATG GGCAATCTTTATGACCTATTGGAAAATGTAGCTCAG pJB1804
(3) M G N L Y D L L E N V A Q 170–629
CCATG GGCAATCTTTATGACCTATTGGAAAATGTAGCTCAG pJB1843
(3) M G N L Y D L L E N V A Q 170–629
CCATG GGCAATCTTTATGACCTATTGGAAAATGTAGCTCAG pJB1851
(3) M G N L Y D L L E N V A Q 170–629
CCATG GGCAATCTTTATGACCTATTGGAAAATGTAGCTCAG pJB1875
(3) M G N L Y D L L E N V A Q 170–629
CCATG TTGGAAAATGTAGCTCAGTTTTATGAAAAACAGCTG pJB1825
(1) M L E N V A Q F Y E K Q L 176–629
CCATG GAAAAACAGCTGCCAAATAGTAATAAGGCACAGCAA pJB1820
(0) M E K Q L P N S N K A Q Q 184–629
CCATG AAACAGCTGCCAAATAGTAATAAGGCACAGCAATAT pJB1842
(1) M K Q L P N S N K A Q Q Y 185–629
CCATG AAGGCACAGCAATATTTTAAACAACGTGGCTTGAGT pJB1834
(2) M K A Q Q Y F K Q R G L S 192–629
CCATG AAGGCACAGCAATATTTTAAACAACGTGGCTTGAGT pJB1836
(2) M K A Q Q Y F K Q R G L S 192–629
CCATG AAACAACGTGGCTTGAGTGCAGAAACTATTCAATTC pJB1828
(2) M K Q R G L S A E T I Q F 198–629
CCATG CAACGTGGCTTGAGTGCAGAAACTATTCAATTCTGG pJB1824
(0) M Q R G L S A E T I Q F W 199–629
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wt CCATGGCGACCTCGTGA-/19 bp ATGGCTATTCCTCAGCATACCATTGATCAA WT
f0 M A T S *
DNA sequence Plasmid
Score Protein sequence Mutation
CCATG ATTCAATTCTGGCGTTTGGGTTATGCACCCGAAGAC pJB1868
(2) M I Q F W R L G Y A P E D 207–629
CCATG GCACCCGAAGACTGGCAGCACCTTGAAAAAGCCTTT pJB1859
(2) M A P E D W Q H L E K A F 215–629
CCATG TTAAAGCAAGTGGGACTCATCCGCTCAAGTGATAGT pJB1847
(1) M L K Q V G L I R S S D S 233–629
CCATG AGTGATAGTGGACGTGACTTTGACCTGCTACGTGAG pJB1864
(1) M S D S G R D F D L L R E 242–629
CCATG CGTGAGCGTGTCATCTTCCCGATTCGTGATCATAAA pJB1862
(2) M R E R V I F P I R D H K 252–629
CCATG CGTGAGCGTGTCATCTTCCCGATTCGTGATCATAAA pJB1865
(2) M R E R V I F P I R D H K 252–629
CCATG CGTGAGCGTGTCATCTTCCCGATTCGTGATCATAAA pJB1867
(2) M R E R V I F P I R D H K 252–629
CCATG CGTGAGCGTGTCATCTTCCCGATTCGTGATCATAAA pJB1871
(2) M R E R V I F P I R D H K 252–629
CCATG CGTGAGCGTGTCATCTTCCCGATTCGTGATCATAAA pJB1879
(3) M R E R V I F P I R D H K 252–629
CCATG AAACTCAAGGCAAAAGACTGGTTAATGGTAGAAGGC pJB1874
(2) M K L K A K D W L M V E G 305–629
CCATG GCAACCTTAGGCACAGCCAGTAATGCTGATCACTTA pJB1863
(2) M A T L G T A S N A D H L 333–629
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wt CCATGGCGACCTCGTGA-/19 bp ATGGCTATTCCTCAGCATACCATTGATCAA WT
f0 M A T S *
DNA sequence Plasmid
Score Protein sequence Mutation
CCATG CAGAACTCTAGAATCACGATTGCCTTTGATGGCGAT pJB1830
(0) M Q N S R I T I A F D G D 350–629
CCATG ATTGCCTTTGATGGCGATGCAGCAGGGCAAAAAGCG pJB1860
(0) M I A F D G D A A G Q K A 356–629
CCATG GACATCTCTACGCCTGAGGGCAAAAGTCAGGTCATG pJB1835
(2) M D I S T P E G K S Q V M 431–629
CCATG CTTTATATTCACTTCGAGGCTTTGCGGGCTTTTATT pJB1840
(0) M L Y I H F E A L R A F I 508–629
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lead to protein misfolding and/or aggregation. Truncation at residue 74 (which
is near the end of the ZBD) produced a mutant colony phenotype suggesting a
well expressed and soluble protein. Compared to the G. stearothermophilus ZBD
structure (Figure 4.3B), truncation at residue 74 leaves only the complete final
twelve residue α-helix of the ZBD; presence of the corresponding region in the A.
baylyi DnaG truncation mutant appears to not perturb protein folding or produce
significant aggregation. Mutants were also identified with truncation end-points
in the RPD, where they appear to dissect this domain in loop regions, discussion
of which can be found in Section 4.4.10.
The size and high quality of the library of transformants suggests that each
mutant within the region where the ExoIII deletions were focussed (i.e. between
residues 100 and 250; Appendix B.2) should be observed more than once. The
mutants with the strongest green fluorescence brightness were over-represented
in the mutants identified, likely due to the ease with which these mutants are
observed on agar plates. On the other hand, of all the green fluorescent mutants
sequenced, 39 were represented only once, and of these, most had a very poor
green fluorescence phenotype and/or were outside of the focussed region, making
them less likely to be visually identified. However, two mutants with strong green
fluorescent phenotypes (score of 3/4; Table 4.5) and which were expected to be
represented more than once in the library were recovered only once (DnaG118–629
and DnaG137–629). Aside from these two, the recovery of identical putatively
soluble DnaG mutants, and the gene sizes identified by sequencing randomly
selected mutants, supports that the library recovered most of the possible
truncated proteins detectable by this method.
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4.4.9 Solubility of N-terminally deleted DNA primase mutants
To confirm the solubility of the mutants identified by N-terminal deletion of
DnaG, a range of putatively soluble mutants was selected and they were modified
to no longer express an EGFP C-terminal fusion, but still possess a C-terminal
His6-tag (pJB1951–1960; Table 4.6). These proteins were over-expressed by
auto-induction in BL21(λDE3)recA.
Table 4.6: Plasmids for expression of putative soluble DNA primase C-terminal fragments.
Plasmids for putative soluble mutants of A. baylyi DnaG deleted from the N-terminus were modified
to express them as C-terminal His6-tagged proteins without EGFP fusion.









Cells from cultures of strains predicted to express N-terminally deleted A.
baylyi DnaG fragments were collected by centrifugation and resuspended to
equal concentrations of cells, and lysed by being passed through a French press
three times; the cell lysate was then centrifuged to separate the soluble and
insoluble fractions, then analysed by SDS-PAGE (Figure 4.18A). Each mutant
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A: Solubility of N-terminally deleted DNA primase
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Figure 4.18: Over-expression and protein solubility of DNA primase N-terminally deleted
mutants. All proteins were over-expressed in BL21(λDE3)recA by auto-induction at 30◦C. A:
Following cell lysis the C, cellular; Sol, soluble and In, insoluble fractions were each analysed by
SDS-PAGE. Molecular size markers are indicated. B: Four soluble expressed N-terminally truncated
DnaG proteins were purified by one-step IMAC and pooled, eluted protein analysed by SDS-PAGE.
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plasmid directed over-expression of a protein of the expected size, but with varied
levels of protein over-expression. Of the mutants examined, strains containing
DnaG74–629, DnaG85–629, DnaG119–629 and DnaG118–629 showed a high proportion
of soluble over-expressed protein and produced a strong green fluorescence
phenotype when expressed as EGFP fusion proteins in E. coli. Strains producing
DnaG95–629, DnaG137–629, DnaG168–629 produced a substantial proportion of soluble
over-expressed protein but also a significant proportion of over-expressed protein
was collected in the insoluble cellular fraction, while DnaG146–629 appeared almost
exclusively in the insoluble fraction. These observations are consistent with the
green fluorescent phenotype of these mutants when expressed as fusions to EGFP.
Each mutant strain identified as producing putatively soluble DnaG truncations
using EGFP as a solubility reporter produced soluble over-expressed protein in
proportion to its EGFP brightness phenotype. To further confirm the solubility
of these proteins, four truncated proteins, DnaG74–629, DnaG119–629, DnaG137–629
and DnaG168–629 were purified by one-step IMAC and were enriched and soluble
(Figure 4.18B).
4.4.10 Modelled protein structures of the Acinetobacter baylyi
zinc-binding and RNA polymerase domains
As crystallisation trials of N-terminal ZBD-extension mutants did not yield useful
protein crystals, hypothetical protein structures were modelled for the A. baylyi
DnaG ZBD and also the RPD. In a general sense, protein homology models are
Jeffrey R. Barrett 140
produced by aligning the sequence of the protein of interest against the known
structure of a related protein (Sali and Blundell, 1993; Fiser et al., 2000; Haas et al.,
2013). The backbone of the protein of interest is then reproduced from the known
structure, which then allows insertion of side-chain atoms and model optimisation.
Optimisation of a model can allow improvement of protein models by adjusting
atom positions to minimise collisions. The most robust information provided by
modelled protein structures is the position of backbone atoms while side-chain
positions are less certain (Schwede et al., 2009), and of course comparative protein
modelling is unreliable for regions of proteins with no known structural homologue.
MODELLER is a comparative protein structure modelling program (Sali and
Blundell, 1993; Fiser et al., 2000) that produces homology models of protein
structures by satisfying/optimising spatial restraints of structures based on
template structures and de novo modelling of protein loops (Eswar et al., 2006;
Martí-Renom et al., 2000), resulting in a calculated protein structure for the
position of all non-hydrogen protein atoms. A web interface for comparative
protein structure modelling — MobWeb — allows automated generation of
structural templates from structures in the PDB that have sequence based
similarity to the protein of interest (ModPipe v2.2.0; Eswar et al., 2003).
Models are then comparatively built for each conserved sequence template with
MODELLER to satisfy spatial restraints (MODELLER v9.11, released Sep. 6,
2012; Fiser et al., 2000; Sali and Blundell, 1993). ModWeb then evaluates the
resulting models using several model scoring methods to generate an aggregate
measure of model quality.
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Having generated a protein structure model, one needs to obtain an indication
of the likelihood that the structure is realistic. To meet this goal, many methods
have been developed to evaluate model protein structures (Melo and Feytmans,
1998; Samudrala and Moult, 1998; Martí-Renom et al., 2000; Zhou and Zhou,
2002; Wallner and Elofsson, 2003; Pettitt et al., 2005; Tosatto, 2005; Benkert
et al., 2008; Eramian et al., 2008; Randall and Baldi, 2008). One such homology
structure evaluation algorithm, QMEAN, compares modelled secondary structures
with secondary structure predicted from the primary amino acid sequence, long
range atomic interactions, local backbone geometry and the likelihood of reside
burial, ultimately to arrive at a reliability score for fold likelihood (Benkert et al.,
2008, 2011). QMEAN returns a value for the likelihood of the fold ranging from 0
to 1 where higher values indicate a better quality structure.
The distantly related A. aeolicus and G. stearothermophilus ZBD structures are
highly conserved (Figure 4.3; Pan and Wigley, 2000; Corn et al., 2005) suggesting
that the bacterial ZBD should be well suited to comparative protein structure
modelling. The larger RPD is also well conserved among bacteria, especially so
at the two N-terminal sub-domains (A. aeolicus and E. coli Cα RMSD: whole
RPD, 4.05 Å over 288 residues; N-terminal sub-domain, 2.14 Å over 112 residues;
toprim sub-domain, 1.90 Å over 120 residues; and C-terminal sub-domain, 3.46 Å
over 48 residues; Keck et al., 2000; Corn et al., 2005).
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4.4.10.1 Modelled protein structure of the Acinetobacter baylyi zinc-binding domain
The most reliable structural model for the DnaG ZBD (Figure 4.19A) was built
using the G. stearothermophilus ZBD (Cα RMSD: 0.19 Å; 1D0Q chain A; Figure
4.19B; Pan and Wigley, 2000). However, a model based on the ZBD of A. aeolicus
also produced a high probability structure (Cα RMSD: 0.59 Å; 2AU3; Corn
et al., 2005). The model structures of the ZBD had GA341 (confidence) scores
of 1, indicating that the protein conformations were structurally favourable and
well supported. Neither model produced predictions for the poorly conserved and
likely flexible ZBD-extension sequence. In addition to the GA341 scores produced
by ModWeb, a QMEAN score of 0.716 was also calculated for the modelled A.
baylyi ZBD structure, indicating a significantly reliable model structure. The A.
baylyi DnaG ZBD modelled structure presented here represents residues 2–101,
which correspond to residues 4–103 in the G. stearothermophilus ZBD structure
(48% sequence identity).
ModWeb does not incorporate ligands into the models it produces. To include the
zinc molecule which should be present in the A. baylyi ZBD structure, a single
zinc atom was modelled into the predicted ZBD structure by aligning the four
zinc coordinating side-chain atoms from the G. stearothermophilus ZBD (PDB:
1D0Q) with the corresponding atoms in the predicted A. baylyi structure. A zinc
atom was then introduced and bonds added as in 1D0Q. The distances for the
modelled Cys (sulphur)-Zn and His (nitrogen)-Zn bonds are within the ranges
observed in crystal structures for other Cys (sulphur)-Zn and His (nitrogen)-Zn
bonds (Hsin et al., 2008) and the zinc coordination geometry is tetrahedral.
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Figure 4.19: Structural model of DNA primase zinc-binding domain. Protein structure models
for the DnaG ZBD were produced using ModWeb (Eswar et al., 2003). A statistically significant
structural model was produced using the ZBD of G. stearothermophilus as the template (1D0Q; Pan
and Wigley, 2000). A: A. baylyi ZBD structure, and B: G. stearothermophilus ZBD structure. ZBD
structures are represented as ribbons under transparent surface with the C-terminus at the top-left
and zinc coordinating residues in ball-and-stick representation and zinc atom in orange.
The predicted structure of the A. baylyi DnaG ZBD — in close agreement with
the G. stearothermophilus structure against which it was modelled — contains
a central four-stranded antiparallel β-sheet region from Lys28 to Cys59, where
the zinc coordinating residues Cys38, His41, Cys59 and Cys62 are present in
loops extending from the ends of the second and fourth β-strands. Flanking the
antiparallel β-sheet region are two α-helices at the N-terminus and three α-helices
at the C-terminus.
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4.4.10.2 Modelled protein structure of Acinetobacter baylyi RNA polymerase
domain
Modelling of the RPD of A. baylyi DnaG returned a protein structure (Figure
4.20A) based on the E. coli RPD structure (Cα RMSD: 0.88 Å; 1DD9 chain A;
Figure 4.20B; Keck et al., 2000). The A. baylyi model contains residues 171 to 475
modelled against E. coli DnaG residues 115–424 (40% sequence identity). The
significance of the model is further supported by a GA341 of 1 and QMEAN score
of 0.785. The modelled A. baylyi RPD structure contains the three sub-domains
characteristic of bacterial primase RPDs (Keck et al., 2000). At its centre, the
metal binding toprim fold is flanked by an N-terminal mixed α/β fold and a
C-terminal fold made from three anti-parallel α-helices.
4.4.11 N-terminal DNA primase deletion mutants and predicted
protein structure
Even though truncation within the RPD — with its three distinct sub-domains
— was not intended, some N-terminally deleted mutants were over truncated,
identifying intra-RPD mutants that make soluble proteins. When comparing
these intra-RPD mutants to the predicted structure of the A. baylyi domain,
several of these appear at rational positions. Pfam prediction of the RPD of A.
baylyi DnaG begins at residue Phe182, yet alignment of DnaG sequences closely
related to A. baylyi show high similarity from around residue 169 (Figure 4.5);
the first residue in the modelled structure is residue 171. Soluble N-terminal
deletion mutants beginning at the start of the RPD (Table 4.7) remove the first
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A: Acinetobacter baylyi RNA polymerase domain model
B: Escherichia coli RNA polymerase domain structure
Figure 4.20: Structural model of DNA primase RNA polymerase domain. The protein structure
was modelled using ModWeb (Eswar et al., 2003). A highly supported structural model was produced
using the E. coli RPD as the template (1DD9; Keck et al., 2000). A: A. baylyi RPD structure, and
B: E. coli RPD structure are represented as ribbons under transparent surface with the N-terminus
at the left-hand side.
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Table 4.7: Putatively soluble N-terminally
deleted mutants of DNA primase. Identity of
putative soluble protein mutants that are truncated










































Figure 4.20: N-terminal breakpoints of truncated DNA primase. A. baylyi models of A: ZBD
and B: RPD. Terminal residues of putative soluble mutants are coloured yellow (ZBD) or red (RPD)
and the N-terminal residues are coloured blue and labelled N. ZBD structures show zinc coordinating
residues in ball-and-stick representation with the zinc atom in orange. Dashed lines indicate the
boundaries of distinct RPD sub-domains.
(DnaG192–629), second (DnaG198–629) and third (DnaG207–629) α-helices (Figure
4.20D). Truncation at residue 252 separates the three C-terminal β-strands from
the N-terminal sub-domain and apparently allows production of soluble protein.
Further truncation through DnaG reveals protein end-points near the ends of the
RPD sub-domains; DnaG305–629 and DnaG333–629 appear to separate, roughly, the
central toprim fold from the N-terminal fold, and DnaG431–629 the toprim fold
from the C-terminal fold.
Soluble N-terminally deleted DnaG mutants that truncate within the ZBD occur
at the end of the domain and are not very interesting. DnaG74–629, DnaG77–629,
DnaG82–629, DnaG85–629, DnaG87–629 and DnaG91–629, incorporate residues of the
last α-helix and short loop of the ZBD into the expressed protein (Figure 4.20C).
4.4.11.1 C-terminal DNA primase deletion mutants and predicted protein structure
Few soluble C-terminally deleted DnaG mutants have truncations that map to
regions of the modelled structures. Of the truncations terminating inside the
ZBD, only two, short, putatively soluble mutants were identified, DnaG1–55 and
DnaG1–56 (Table 4.9), which contain the three zinc-binding anti-parallel β-sheets
and two short N-terminal α-helices (Figure 4.20E). Each of these proteins contain
the important zinc-binding region but may be too small to fold. The next
shortest soluble C-terminally deleted DnaG mutants contain the whole ZBD and
inter-domain linker, which is likely unstructured.
For C-terminally truncated proteins terminating in the RPD, DnaG1–195 contains
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Table 4.9: Putatively soluble C-terminally
deleted mutants of DNA primase. Identity
of putatively soluble protein mutants that are


















Figure 4.20: C-terminal breakpoints of truncated DNA primase. A. baylyi models of A: ZBD
and B: RPD. Terminal residues of putative soluble mutants coloured yellow (ZBD) or red (RPD)
and N-terminal of structure are coloured blue and labelled N. ZBD structures show zinc coordinating
residues in ball-and-stick representation with the zinc atom in orange.
the complete first N-terminal α-helix (Figure 4.20B) and DnaG1–182 contains the
first 12 residues of this helix. Interestingly, the C-terminus of DnaG1–252 — that
ends at the same position as the N-terminally deleted mutant DnaG252–629 —
separates completely the three C-terminal β-strands from the N-terminal fold of
the RPD.
4.5 Discussion
The aim of the work in this Chapter was to use the new technique presented in
Chapter 3 to identify the domain boundary of the A. baylyi DnaG ZBD and to
produce soluble domain constructs for the N-terminal ZBD and RPD-HBD of
DNA primase, which we had otherwise not been able to produce.
To achieve these aims, libraries of N- or C-terminally deleted A. baylyi dnaG
genes were prepared using ExoIII and mung bean nuclease. Once expression
plasmid pools for truncated dnaG were prepared, transformation and culture
of these plasmids in the E. coli expression strain BL21(λDE3)recA allowed
co-expression of the truncated genes with a 3'-egfp fusion for indicating solubility
of the truncated proteins. EGFP is not fluorescent when first synthesised; protein
folding must first occur, and then slow chemical steps generate the internal
chromophore required for fluorescence (Section 1.6.2). These processes that
mature non-fluorescent EGFP are slow and sensitive to protein solubility, making
EGFP useful as a reporter of solubility of proteins to which it is fused. The
EGFP solubility screening methodology used here is pragmatic and makes the
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assumption that intact protein domains are well structured and therefore are more
likely to be soluble. The other side of this coin is that truncated proteins which
contain incompletely folded domains are likely to not fold properly and perturb
maturation of EGFP fluorescence, producing different colony phenotypes for cells
expressing soluble and insoluble EGFP-fusions. Shortened protein mutants that,
when expressed, allow the C-terminal EGFP to become fluorescent were proposed
to be truncated between domain boundaries. Still, some complete protein domains
are not necessarily soluble when expressed alone and although this methodology
is not of use in producing these proteins in soluble form, insoluble domains are of
little experimental use. In this sense, our selection procedure is pragmatic.
4.5.1 C-terminal deletions of DNA primase
This work was unsuccessful in producing genes encoding canonical, soluble ZBD
for A. baylyi DnaG primase. However, in A. baylyi, DnaG contains an unusual
69 residue insertion at the end of the predicted ZBD boundary (Figure 4.5). A.
baylyi dnaG ZBD genes which incorporate this linker region can direct expression
of soluble proteins that remain soluble when purified (Figure 4.21A). This work
reports experiments confirming that these proteins are indeed soluble, incorporate
zinc and that at least a portion of the proteins are structured.
When the ZBD-extension proteins were first produced they contained a C-terminal
EGFP fusion, which is not necessarily useful in further experiments and may in
fact act to help solubilise the proteins. When EGFP was genetically removed,
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Figure 4.21: Soluble truncated DNA primase. A: Soluble N-terminal (ZBD) fragments of DnaG, B:
soluble C-terminal (RPD-HBD) fragments of DnaG. Coloured rectangles are Pfam domain annotations
for A. baylyi DnaG: (•), ZBD; (•), RPD and (•), HBD. Arrows above (C-terminally deleted DnaG)
and below (N-terminally deleted DnaG) indicate termini of truncation mutants identified in this study;
green arrows indicate mutants with strong green fluorescence phenotype. Thinner representations
below show data for truncated proteins for which protein solubility was determined without fusion to
EGFP; included are SDS-PAGE gels showing whole cell, soluble and insoluble fractions. Grey cartoon
indicates proteins for which no soluble protein was produced.
protein solubility was retained and the proteins could be purified. Purified
DnaG1–165, DnaG1–170, DnaG1–171, DnaG1–182 and DnaG1–195 displayed similar
CD spectra and these spectra were consistent with the proteins being at least
partially structured. Further examination of two of the ZBD-extension proteins
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using 1D and TOCSY NMR supports the conclusion that the proteins are at
least partially folded and composed of mostly α-helices, but also contain unfolded
regions. Attempts to crystallise DnaG1–165 and DnaG1–170 were unsuccessful,
which may be due to the presence of unstructured regions in the ZBD extension.
Examination of the identities of putatively soluble C-terminally deleted mutants
of DnaG (Figure 4.21A) suggest that truncations within the Moraxellaceae ZBD
extension do not produce soluble ZBD proteins. The sequence insertion within A.
baylyi DnaG appears, by sequence alignment to related species (Figure 4.5), to
end at residues 168, where interestingly, DnaG1–165, DnaG1–170 are the shortest
soluble proteins identified. The Pfam annotation of A. baylyi DnaG places residue
182 at the start of the RPD, although all 14 residues from 169–182 are well
conserved in the Moraxellaceae species. The shortest of these DnaG mutants —
DnaG1–165 — terminates just before the end of the Moraxellaceae extension, and
two more very soluble proteins DnaG1–170 and DnaG1–171 terminate at the very
start of the RPD. Mutants longer than these proteins have reduced solubility (or
over-express poorly), which would seem to be in agreement with the start of the
folded RPD being around residue 169, since incomplete folding segments of the
RPD should reduce solubility of these proteins. The discrepancy between Pfam
assignment of the RPD and the extra 14 conserved Moraxellaceae residues might
help explain why previous work to produce truncated proteins at this domain
boundary were unsuccessful.
Investigation of DnaG1–165 and DnaG1–170 by mass spectrometry revealed that
these two proteins bind zinc tightly. Analysis of these mutants, after extensive
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dialysis against EDTA, revealed an additional mass consistent with bound zinc
in buffer which supports natively folded protein conformations but the additional
mass was not found when DnaG1–165 and DnaG1–170 were prepared in formic acid.
Previous studies have shown that the complete primase ZBD structure is required
for strong zinc-binding; a short 35 residue, partially folded zinc-binding peptide
(K34–G69) from E. coli DNA primase binds zinc very weakly compared to the
full length primase (K34–G69, KD∼ 10–100 nM and primase, KD<1 pM; Griep
and Lokey, 1996; Griep et al., 1997). The weaker zinc-binding by the partially
folded K34–G69 peptide allows removal of zinc from the peptide by chelation
with EDTA, whereas it is not removed from full length primase. The fact that
DnaG1–165 and DnaG1–170 can tightly hold onto zinc during dialysis against EDTA
suggests that these ZBD-extension mutants have a natively-folded ZBD, and that
therefore, it is the 69 residue extension sequence that contains the unstructured
regions observed by NMR.
Although structures of DNA primase ZBDs are known, and limited proteolysis
liberates the E. coli ZBD from primase (Tougu et al., 1994), previous members
of our research group have unsuccessfully attempted to make ZBD truncations of
both the E. coli and A. baylyi proteins (Nicholas Dixon and Andrew Robinson;
personal communication). In both E. coli and G. stearothermophilus DNA
primases, the ZBD is liberated more slowly by limited proteolysis than the other
domains of DnaG (Tougu et al., 1994; Bird et al., 2000), suggesting that the
ZBD may be closely associated with the RPD. The ZBD is in fact observed on
the surface of the primase RPD in the A. aeolicus structure (Corn et al., 2005).
The close association of the ZBD and RPD may, in many species, have either I)
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resulted in stabilisation of the ZBD by association with the RPD, or II) aided
folding of the ZBD, which may explain the difficulties in producing soluble ZBD
constructs. The thermophilic nature of G. stearothermophilus may have provided
selection pressure for increased stability/folding efficiency of its ZBD.
In that case, the absence of distinct and soluble ZBD mutants of A. baylyi DnaG
from recovered shortened genes would also suggest that the ZBD of A. baylyi
DnaG is either not soluble, or is unable to efficiently fold, in isolation. Yet,
soluble ZBD mutants containing also the Moraxellaceae insertion sequence can
be expressed as folded, soluble proteins. Thus, in A. baylyi — and likely also in
the other Moraxellaceae species — the extension following the ZBD may have
adapted to add stability to the ZBD, or take part in the folding pathway of the
ZBD, allowing over-expression of folded and soluble ZBD. The fact that when
the ZBD is proteolytically removed from E. coli DnaG, it is not soluble, would,
if the relationship is general for many bacteria, suggest that ZBD stabilisation,
rather than folding, is important for isolated ZBD solubility. In this case, the
extension to the ZBD of A. baylyi — and maybe the rest of the Moraxellaceae —
has been selected over time to stabilise the ZBD. As the original insertion into
the ancestral DNA primase must have been tolerated, the closer proximity of the
extension sequence to the ZBD — at least when not associated with the RPD
— may have provided the selective pressure for reassignment of the stabilising
interaction from the RPD to the extension.
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4.5.2 N-terminal deletions of DNA primase
An N-terminal deletion library, complementary to the C-terminal library, was
produced to identify soluble RPD-HBD proteins (Figure 4.21B). Very soluble
N-terminally deleted A. baylyi DnaG proteins were identified starting at residues
168 and 170, which is directly where the Moraxellaceae sequences begin to be
well conserved (Figure 4.5), and this likely marks the start of the RPD. Several
truncated, putatively soluble mutants began slightly into the N-terminus of the
RPD (truncated at residues 192, 198 and 207) and three were spaced within the
RPD (residues 252, 305 and 333). On the whole, few putatively soluble truncation
mutants were observed encroaching into the start of the RPD of primase, which
we should expect if the methodology selects for complete domains which fold well.
However, in contrast to the C-terminal deletion, N-terminal deletion produced
soluble mutants that start in the ZBD-extension and even in the ZBD (Figure
4.21A). The large number of soluble mutants beginning in the ZBD-extension
may support that this region is unstructured. In the end, comparison of mutants
obtained by N-terminal and C-terminal deletion strongly suggests that the
N-terminal domain boundary of the RPDs is at residues 168–170, and this will be
the region targeted in further work.
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4.5.3 DNA primase truncation mutations and modelled protein
structures
This Chapter provides well supported homology models for the ZBD and RPD
of A. baylyi DnaG. Mapping the end-points of soluble truncated DnaG mutants
onto modelled ZBD and RPD structures suggests that truncation breakpoints of
soluble proteins can occur in the first few secondary structural elements of the
domain (at specific positions). Identification of soluble proteins using a solubility
reporting fusion protein selects proteins that over-express well and are soluble.
Based on these selection criteria, proteins with truncated secondary structures
— that may or may not be folded —and portions of natively unfolded flexible
extensions do not necessarily negatively affect selection.
Soluble N-terminally deleted DnaG mutants were also identified that truncate
the known sub-domains of the RPD. This was interesting as these truncations
were unexpected. Unlike at the start of the RPD, where several mutants were
identified, sub-domain mutants did not have varied end-points, but since these
regions were not targeted by the deletion study, it stands to reason that these
were likely under represented in the library. It might be expected that a deletion
library focussed at these regions would reveal more soluble intra-RPD mutants.
Nonetheless, these adventitious non-targeted soluble mutants are an added bonus,
providing further insight into the available soluble variants of the protein.
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4.5.4 General discussion
Attempting to reconcile the divergence of solubility between C-terminally and
N-terminally shortened DnaG proteins, where truncation occurs in the sequence
insertion following the ZBD, is not straightforward. C-terminally shortened
proteins containing the whole ZBD are not expressed solubly without the
whole extension, but many different truncations within the extension from the
complementary N-terminally deleted library were soluble. It appears that the
ZBD of A. baylyi requires the full ZBD-extension for solubility, but that this
region is unstructured and unimportant for the solubility of the RPD.
In the experiments presented here, the green fluorescence phenotype of E. coli
cells expressing truncated DnaG-EGFP fusion proteins is shown to correlate
strongly with protein solubility when the EGFP is removed; these data are thus
consistent with previous reports (Waldo et al., 1999; Pédelacq et al., 2005).
Examining all mutants identified using the EGFP solubility reporter shows that
many of the possible protein constructs are soluble, the majority of which appear
to truncate to regions outside of known structural elements. Whether or not all of
these proteins are fully folded is unknown, but seems unlikely. It is probable that
some contain unfolded extensions and were identified because these extensions do
not lead to significant levels of protein aggregation. Proteins which produce the
brightest green fluorescent phenotype when over-expressed as fusions to EGFP,
however, appeared at fewer truncation positions and paint a clearer picture, where
they strongly correlate with the domain boundary at the N-terminus if the RPD.
This technique for protein truncation and solubility selection has proven useful
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for identifying soluble protein constructs, which previously were not produced by
means of rational design.
From a pragmatic viewpoint, having a way to produce soluble versions of small
domains enables study of their structures and functions that would otherwise be
impossible. For example, the extent of unstructured regions at the termini can
readily be identified by NMR, but this can only be done if samples of soluble
proteins can be produced in the first place.
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Chapter 5
Soluble domain constructs of
Staphylococcus aureus septation ring
formation regulator (EzrA)
5.1 Introduction
5.1.1 Cell division and Z-rings
Cell division in bacteria is a tightly controlled process, in which many proteins
work in concert to segregate the required cellular components for daughter cell
production, and to facilitate separation of the new cells (Adams and Errington,
2009). Integral to division of the cell, FtsZ polymerisation forms a ring structure
around the perimeter of the cell centre known as the Z-ring (Bi and Lutkenhaus,
1991; Adams and Errington, 2009). With the Z-ring in place, complementary
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proteins are mobilised to the mid-cell to form the divisome which coordinates cell
membrane synthesis, cell wall synthesis and cell division (Figure 5.1; Goehring
and Beckwith, 2005; Adams and Errington, 2009).
FtsZ
Z-ring






Figure 5.1: Cell division and the divisome. Bacterial cell division occurs by cell elongation at a
structure known as the Z-ring, which is a polymer of the FtsZ protein. On the inside of a cell, a group
of proteins known as the divisome facilitates the process of cell division. On the outside of the cell,
a second group of proteins synthesise and cross link peptidanoglycans for synthesis of new cell wall.
The divisome and cell wall synthesis proteins drive cell elongation and over time constriction of the
Z-ring separates the daughter cells. Image inspired by Adams and Errington (2009).
In both Bacillus subtilis and E. coli, Z-ring formation is observed to be
independent of FtsZ concentration. Throughout the cell cycle FtsZ maintains a
constant concentration, and in fact experimentally increasing the concentration
of FtsZ does not alter the regulation of Z-ring formation (Weart and Levin,
2003). The tight regulation of Z-ring formation in bacterial cell division therefore
indicates the action of other participants.
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5.1.2 EzrA has two Z-ring regulating roles
One candidate for regulation of Z-ring formation in the medically relevant
Firmicutes bacteria is the membrane anchored protein EzrA (extra Z-rings; Levin
et al., 1999). Bacillus subtilis EzrA contains an N-terminal membrane anchor
and occurs throughout the cell membrane where it appears to guard against
FtsZ polymerisation. In ezrA null mutants, Z-rings lose septal specificity, with
Z-rings then occurring anywhere from the poles to mid-cell (Levin et al., 1999),
whereas mild over-expression of EzrA inhibits FtsZ assembly (Haeusser et al.,
2004). Removal of the N-terminal membrane anchor abolishes the ability of
EzrA to negatively control Z-ring formation (Haeusser et al., 2004). Although B.
subtilis ezrA null strains lose spatial control of Z-ring formation, the proportion
of growing populations containing Z-rings is unchanged, indicating that EzrA is
not involved in the cell-cycle switch for Z-ring formation (Levin et al., 1999).
EzrA is well suited for negative regulation of Z-ring formation, with cellular
concentrations around 10,000–20,000 molecules per cell (Haeusser et al., 2004).
It associates tightly with the cell membrane (2/3 of EzrA is extracted with
membranes; Bhavsar et al., 2005). With a cell membrane area of 3.9 × 106 nm2
(rod with two hemispheres of r = 0.415 µm and h = 2.45 µm; Maass et al., 2011),
EzrA may be spaced as closely as one EzrA molecule per 300–700 nm2 of cell
membrane, thus providing a dense packing to block FtsZ polymerisation (Figure
5.2).
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Figure 5.2: EzrA spacing and FtsZ polymer size. EzrA is densely packed on the internal face of
the cell membrane in B. subtilis. Inside the average B. subtilis cell, the internal surface area is up to
3.9 × 106 nm2 (Maass et al., 2011), with between 10,000 and 20,000 molecules of EzrA (Haeusser
et al., 2004) associating tightly with the cell membrane (over 2/3 of EzrA is membrane associated;
Bhavsar et al., 2005). A grid of EzrA monomers (yellow balls), each occupying an area of 400 nm2
is shown to scale, along with a 10 subunit FtsZ polymer of 4 × 40 nm (pink rod; Romberg et al.,
2001). EzrA monomers (62 kDa) are depicted to scale as a spherical and globular protein (diameter
of ≈ 5 nm). Inset top right: electron micrograph of B. subtilis FtsZ polymers with scale bar of 40 nm
(Adapted from Haeusser et al., 2004).
However, as somewhat of a contradiction to the apparent Z-ring inhibition role of
EzrA, it has also been shown to co-localise with Z-rings and this occurs even when
the N-terminal membrane anchor is deleted (Haeusser et al., 2004). This mid-cell
localisation of EzrA has been suggested to occur through a short conserved
C-terminal region (the QNR patch) that, when removed, eliminates its ability to
localise to mid-cell. ezrA∆QNR mutants experience delayed — but not absent —
cell division, and still negatively regulate FtsZ polymerisation (Haeusser et al.,
2007).
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5.1.3 Cell wall synthesis
EzrA is also involved in coordinating cell wall synthesis. The bacterial cell wall,
enlightened mostly from experiments in B. subtilis, is composed of a single massive
molecule of cross-linked peptidoglycan polymers and is important for maintaining
cellular integrity. For successful cell division, this massive structure must be
remodelled to allow daughter cell production, requiring careful choreography of
the many proteins associated with the divisome.
Cell wall synthesis in the Firmicutes occurs in two distinct modes, mediated by
two spatially distinct pathways: I) cell division (septum formation), common
to both coccoid and rod-shaped species, and II) cell elongation (lateral wall
synthesis), occurring only in, and responsible for the unique morphology of
rod-shaped cells (Jones et al., 2001; Daniel and Errington, 2003; Scheffers and
Pinho, 2005; Carballido-López, 2006). Cell septum peptidoglycan synthesis —
depletion of which can produce defects in daughter cell production — is more
important than lateral wall peptidoglycan synthesis, where deletion of genes
encoding important cell elongation proteins can convert rod-shaped species to
have viable coccoid phenotypes (Begg and Donachie, 1985; Henriques et al., 1998).
Septal cell wall synthesis occurs mainly through the action of the septum specific
peptidoglycan synthesising penicillin-binding proteins (PBPs), located on the
outer surface of the cytoplasmic membrane (Scheffers and Pinho, 2005). Class A
PBPs facilitate both crosslinking between and elongation of peptidoglycans while
class B PBPs catalyse cross-linking only (Ghuysen, 1991). Localisation of cell
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division PBPs is dependent on the presence of Z-rings as Z-ring depletion results
in dispersal of septal PBPs. The septal localisation of division PBPs suggests
communication from the intra-cellular divisome proteins arranged at the Z-ring
to the PBPs positioned on the outside of the cell membrane, but this relationship
is poorly understood (Scheffers and Pinho, 2005).
5.1.4 EzrA helps coordinate cell wall synthesis at the site of cell
division
Bacterial-two-hybrid analysis in B. subtilis indicates two cell division proteins
which interact with the essential septal PBP1 (ponA; also called PBP1A, not to
be confused with a related protein known as PBP1a), EzrA and GpsB (guiding
PBP1 shuttling), which also appear to interact with each other. Neither EzrA nor
GpsB is individually essential in B. subtilis but gene mutations are synthetically
almost inviable in combination (Kobayashi et al., 2003; Claessen et al., 2008).
PBP1 takes part in both lateral cell wall and septal peptidoglycan synthesis,
localising to mid-cell at the onset of cell division, but otherwise is distributed
throughout the cell wall; this spatial pattern of localisation is shared by GpsB.
Depletion of EzrA removes GpsB and PBP1 localisation to mid-cell (Figure 5.3)
and results in a thinner cell phenotype, suggesting a role for EzrA in coordinating
these components of cell wall synthesis to the divisome.







Figure 5.3: Coordination of cell wall synthesis at the divisome. Currently PBP2 is thought to
be the enzyme required for cell wall synthesis in Staphylococcus aureus. The B. subtilis homologue of
PBP2, PBP1, has been shown by bacterial-two-hybrid experiments to associate with EzrA and GpsB
at mid-cell during cell division (Claessen et al., 2008). Depletion of EzrA stops GpsB and PBP1 from
localising at the mid-cell.
5.1.5 The importance of EzrA in cell division in Staphylococcus
aureus
Cell wall synthesis in the major human pathogen Staphylococcus aureus occurs at
the division septum only (Pinho and Errington, 2003; Scheffers and Pinho, 2005).
Here, the cell wall synthesis apparatus localises and is coordinated by the cell
division apparatus, that alternates, in turn, among the three perpendicular axes
of the cell.
Due to the simplified cell wall synthesis methodology applied by S. aureus,
the proteome contains a minimal complement of PBPs, where PBP2 (ponA;
homologous function to PBP1 in B. subtilis) localises to the cell septum (Pinho
and Errington, 2003), and is the only PBP present that can both elongate and
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cross-link peptidoglycans (Pinho and Errington, 2003; Scheffers and Pinho, 2005).
Localisation of the divisome and coordination of cell wall synthesis is imperative
in S. aureus, as eliminating Z-rings through FtsZ depletion delocalises PBP2,
and upon loss of this septal localisation, peptidoglycan synthesis continues in a
distributed fashion. This results in a sickly cell phenotype where the cells continue
to enlarge until they are too large and lyse (Pinho and Errington, 2003). A similar
defect occurs through application of methicillin, which delocalises S. aureus PBP2
and leads to cell death (Pinho et al., 2001). Dissection of the mechanism for
coordinating the internal cell division machinery with external cell wall synthesis
might suggest novel antibiotic targets. Previous evidence that EzrA plays a role
in localising the B. subtilis PBP2 homologue to the divisome makes EzrA an
intriguing target for study.
Indeed, ezrA has been established by multiple studies to be an essential gene in
S. aureus. Transposon mutagenesis has identified ezrA (SAV1717 in the Mu50
reference genome; Bae et al., 2004) as an essential gene in both the Newman
and SH1000 strains (Chaudhuri et al., 2009) and this conclusion was supported
by an antisense RNA screen in a wild-type but otherwise unidentified S. aureus
strain (named ytwP in this study; Ji et al., 2001). Steele and colleagues (2011)
showed evidence for the essentiality of ezrA in S. aureus SH1000 by deleting the
291 C-terminal codons from chromosomal ezrA in a strain complemented with
plasmid encoded full-length EzrA under stringent control; this strain could not
grow in the absence of expression of full length EzrA.
However, controversy exists as to whether ezrA is indeed an essential gene in S.
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aureus, as not all systematic studies to identify essential genes have identified
ezrA. Moreover, the work of Jorge and colleagues (2011) directly contradicts the
previous studies that identified EzrA as being an essential protein. They present
evidence that S. aureus can survive when EzrA is I) depleted using antisense
RNA to inhibit ezrA expression, II) not expressed through withholding inducer
from a strain that expresses ezrA under the strictly controlled pspac promoter,
and III) eliminated in null mutants of the COL, NCTC8325-4, Newman, RN4220
and SH1000 strains. The data presented for both the antisense RNA and pspac
experiments indicate that a small proportion of residual EzrA remains in vivo,
which might help explain the lack of lethality. However, the inviability of null
mutants is hard to reconcile. Two further genome wide studies of genes essential in
S. aureus failed to identify ezrA; however, this was because ezrA was not identified
specifically due to low homology with ezrA from other species (< 30% identity
at the protein level c.f. B. subtilis, Enterococcus faecalis, E. coli, Streptococcus
pneumoniae and Pseudomonas aeruginosa; Ji et al., 2001; Ko et al., 2006).
The conflicting results of Jorge et al. (2011), compared with those of other
groups (Ji et al., 2001; Bae et al., 2004; Chaudhuri et al., 2009; Steele et al.,
2011), are hard to reconcile, and no obvious strain or methodological difference
is identifiable. Nonetheless, Jorge et al. (2011) do report sickly cell phenotypes
when EzrA is not expressed, including larger cells, delocalised cell wall synthesis
and delocalised Z-rings.
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5.1.6 EzrA as a potential protein–protein interaction hub
Recent evidence implicates EzrA as an interaction hub in S. aureus, where
bacterial two-hybrid experiments have indicated that it interacts directly with 12
cell division/peptidoglycan synthesis proteins, of which at least 10 are encoded
by essential genes (Table 5.1; Bae et al., 2004; Chaudhuri et al., 2009; Steele
et al., 2011). The implication of these many interactions is that EzrA may play
an important role in coordination of many functions of the divisome in addition
to regulating Z-ring formation and localisation of cell wall synthesis.
Using a S. aureus strain expressing an EzrA-GFP fusion from the native ezrA
promoter and inducible FtsZ, Steele et al. (2011) were able to show that EzrA
co-localises with Z-rings. Further experiments with an inducible ezrA strain
showed that EzrA is necessary for localisation of GspB-GFP and PBP2-GFP to
the septum and in fact, for active peptidoglycan synthesis. These results provide
strong evidence that de-coupling of cell wall synthesis from cell division is lethal
in S. aureus and that divisome construction — initiated by Z-ring formation — is
coordinated by EzrA through the cell membrane to the peptidoglycan synthesising
PBP2. Regardless of the conflicting reports of ezrA essentiality in S. aureus,
clearly cells depleted of EzrA are sickly, if not inviable. Further examination of
protein interactions with EzrA should provide insight into the coordination of
bacterial cell division, and has the potential to yield novel antibiotic targets. Of
initial interest are the EzrA interactions with FtsZ and PBP2, where disruption of
the EzrA–FtsZ interaction should banish PBP2 (and potentially other proteins)
from the divisome and lead to cell lysis by delocalisation of peptidoglycan
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Table 5.1: Essentiality of proteins suspected of interacting with EzrA. List of proteins that
were identified as interacting with S. aureus EzrA by bacterial-two-hybrid assay (Steele et al., 2011).
Proteins are named as in S. aureus, and alternate names are in footnotes. Protein functions are
described by as per Lutkenhaus and Addinall (1997); Henriques et al. (1998); Mercer and Weiss
(2002); Scheffers and Pinho (2005); Adams and Errington (2009).
Essential
Protein Known role(s) S. aureus1 B. subtilis2
EzrA3 Negative regulator of Z-ring formation away
from septum. Regulates Z-ring dynamics
when localised to mid-cell.
√4,5 X, √ (GpsB− /
FtsL− / SepF−)
DivIB Unclear role in septal peptidoglycan
synthesis
√4 √
DivIC Unclear role in septal peptidoglycan
synthesis
√4 √
FtsA FtsZ membrane anchor. Required for Z-ring
assembly, organisation and ancillary protein
recruitment
√4 √
FtsL Unclear role in septal peptidoglycan
synthesis
√4 √
FtsW Unclear role in stabilisation of Z-rings
and recruitment of septal peptidoglycan
synthesis enzymes
√4 √
FtsZ Structural unit of Z-ring √4 √
GpsB6 Recruitment of PBP2 (B. subtilis PBP1)
to mid-cell during cell division (and
non-division lateral cell wall synthesis in rod
shaped species)
√4 X, √ (EzrA−)7
PBP18 Cell division specific peptidoglycan synthesis √4 √
PBP29 Peptidoglycan synthesis √4 X
PBP3 Cell division specific peptidoglycan synthesis X NA
RodA Required for rod cell morphology in B.
subtilis, unknown role in S. aureus
X (√)4,5 √
SepF10 Required for proper septal morphology √4 X, √ (EzrA−)11
1 Chaudhuri et al. (2009) 2 Kobayashi et al. (2003)
3 EzrA was previously named YtwP and SAV1717 4 Bae et al. (2004)
5 Ji et al. (2001) 6 GpsB gene name is ypsB
7 Claessen et al. (2008) 8 Named PBP2B in B. subtilis
9 Named PBP1 in B. subtilis 10 SepF gene name is ylmF
11 Hamoen et al. (2005) 170
synthesis, while disruption of the EzrA–PBP2 interaction should disable cell wall
growth.
Of these two interactions, that between EzrA and FtsZ is most intriguing as an
antibacterial target. The number of different putative interactions of EzrA suggest
that it may localise other proteins to mid-cell, and the cell lysis phenotype would
be promising from the standpoint of recruiting the immune system in infected
patients.
5.1.7 Little is currently known about the structure of EzrA
EzrA is a relatively recently identified participant in cell division (Levin et al.,
1999) where ezrA mutants of B. subtilis were observed to possess extra Z-rings.
Since the discovery of EzrA, there have been very few in vitro biochemical studies
of it. After beginning this work, soluble N-terminally deleted EzrA mutants
have been identified by limited proteolysis (EzrA164–564, EzrA250–564; Son and
Lee, 2013), but other domain boundaries are unknown and its interactions are
in question. No three-dimensional structural information is currently published
for any EzrA protein and no structurally known domains occur within EzrA
according to Pfam (Finn et al., 2010), but five coiled-coil domains are predicted
to be present (Figure 5.4).
The N-terminal membrane anchor of EzrA is dispensable for the interaction
with the divisome and PBP2; instead, the membrane anchor serves the purpose
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IQYGNRY
Bsu EzrA (∆501−511) regulates
Z-ring formation away from
mid-cell only
Bsu EzrA i) localises to divisome
ii) negatively regulates Z-ring 
formation away from mid-cell
Bsu EzrA (∆1−26) localises
to divisome only
Sau EzrA 
100–138 203–223 277–297 350–370 471–491
Figure 5.4: Known phenotypes of ezrA mutants. Displayed are S. aureus and B. subtilis EzrA
proteins with known in vivo B. subtilis ezrA phenotypes (Haeusser et al., 2007). Predicted coil-coil
domains as annotated in Pfam are shown as purple boxes, the N-terminal membrane anchor is shown
as a pink box and the QNR patch is shown in green. The full length B. subtilis protein is 562 amino
acids long and S. aureus 564.
of embedding EzrA in the cell membrane to guard against aberrant Z-ring
polymerisation (Figure 5.4). The well conserved near-C-terminal seven amino
acid QNR patch (residues 506–512 in S. aureus) has been shown to be important
in mid-cell localisation but not inhibition of FtsZ assembly by in vivo deletion
studies (Haeusser et al., 2007).
5.2 Aims
EzrA is an interesting target for antibacterial development as two protein–protein
interactions in which it is involved are known and many more are suspected,
and most of these interaction partners are essential for growth and/or cell
survival in S. aureus (Table 5.1). Since EzrA is likely to be composed of several
protein domains but is poorly conserved and has no homologues with solved
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protein structures, we were interested in searching for soluble protein truncations
using the methodology described in Chapter 3. In addition to interest in the
proposed FtsZ-interacting C-terminal EzrA domain, the numerous suspected
protein–protein interactions may occur elsewhere in the protein, and use of a range
of soluble protein constructs would facilitate study of the sites of these interactions.
The aims of this Chapter were to perform both I) 5'-terminal and II) 3'-terminal
deletion of S. aureus ezrA to produce libraries of truncated genes with truncation
points distributed throughout. This strategy should allow identification of soluble
proteins that are useful for direct study and determination of protein break points
that suggest domain boundaries throughout the protein. After identification of
soluble truncated EzrA proteins, the further aims were to III) examine if the
truncated proteins are folded, and IV) identify EzrA fragments that can still
interact with FtsZ.
5.3 Materials and methods
5.3.1 Preparation of Staphylococcus aureus ezrA truncation libraries
E. coli codon optimised S. aureus ezrA was ordered from DNA2.0 (USA) without
the 23 residue N-terminal membrane anchor (EzrA24–564) in plasmid pJExpress411
(pJB1974). The initiation codon occurs at the unique NdeI restriction site and
the TAA stop codon is immediately preceded by a unique BamHI site which adds
two amino acids (Gly-Ser) to the C-terminus of the expressed EzrA24–564 protein.
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The gene for EzrA24–564 was inserted between the NdeI and BamHI sites of the
C- and N-terminal deletion plasmids pJB1720 and pJB1726 (Figures 3.15B and
























































Figure 5.5: Plasmids for gene truncation of Staphylococcus aureus ezrA. pJB1977 (for
N-terminal deletion) and pJB1975 (for C-terminal deletion) were made by placing the S. aureus
ezrA24–564 gene from pJB1974 into the NdeI and BamHI sites of pJB1726 and pJB1720. pJB1974
was digested with NdeI and BamHI and the ezrA fragment was gel purified. pJB1726 and pJB1720
express C-terminal His6 tags and EGFP fusion proteins for protein purification and solubility selection.
To make N- and C- terminal deletion libraries of ezrA, 20 µg of purified pJB1977
or pJB1975 were digested with 20 U of NcoI in NEB restriction enzyme buffer 3
with 100 µg.mL−1 BSA for 2 h at 37◦C and then the enzyme was heat inactivated
by incubation at 80◦C for 20 min. Linear plasmids were then end protected with
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40 µM each of dGTPαS (Glen Research), dATP, dCTP, and dTTP, 20 U DNA
polymerase I (Klenow fragment) at 30◦C for 15 min. After heat inactivation of
DNA polymerase I at 65◦C for 20 min, pJB1977 and pJB1975 were prepared for
uni-directional ExoIII digestion using 20 U NdeI or BamHI, by incubation for 2
h at 37◦C and then the enzymes were heat inactivated by incubation at 80◦C.
Plasmids containing ezrA were then truncated with ExoIII (by taking samples of
the reaction at 5.0 and 6.5 min), repaired, transformed into E. coli and identified
as described in Sections 4.3.2 and 4.3.3.
5.3.2 Preparation of EzrA truncation-His6 tagged expression plasmids
Plasmids for expression of truncated EzrA without EGFP were prepared
by linearising the selected plasmids with MfeI and then ligation of the
self-complementary oligonucleotide 420 (AATTGTAAGCTTAC) to form an
in-frame stop codon. The resulting plasmids expressed a C-terminal fusion
sequence to EzrA of GSSGNSHHHHHHQL* for N-terminal deletion mutants and
HGSSGNSHHHHHHQL* for C-terminal mutants.
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5.3.3 Expression, examination of protein solubility and purification of
truncation mutants
5.3.3.1 Protein expression and examination of protein solubility
Truncated EzrA mutants identified from library experiments were expressed
with a C-terminal His6-tag in E. coli BL21(λDE3)recA/pLysS by auto-induction
(Section 2.5.1). Individual 400 mL cultures were incubated with shaking for 24
h at 30◦C, after which cells were recovered by centrifugation at 8,000 × g and
portions of the bacterial pellets were resuspended to an A600 of 10 AU in IMAC
buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 20 mM imidazole) and lysed by
passing three times through a chilled French press (Section 2.5.2). Following cell
lysis, the soluble and insoluble cellular fractions were separated by centrifugation
at 30,000 × g for 30 min.
Samples of whole cell lysate and soluble protein for each mutant were analysed
directly by SDS-PAGE (Section 2.5.9) and insoluble cellular protein was
resolubilised in a small volume of 8 M urea then diluted with SDS-loading buffer
in proportion to cell lysate and analysed by SDS-PAGE.
5.3.3.2 Purification of truncated EzrA proteins
EzrA mutants were purified by resuspension of cells (∼ 4 g) from over-expressed
cultures in IMAC buffer (15 mL per g of cells) and then lysed by passage
three times through a chilled French press. Cellular extract was clarified by
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centrifugation at 30,000 × g for 30 min, filtered through a 45 µm syringe filtration
device (Merck Millipore) and loaded onto a 1 mL HisTrap HP column (GE
Healthcare Life Sciences) connected to an ÄKTApurifier system (GE Healthcare
Life Sciences). The column was washed with 10 mL of IMAC buffer, then 10
mL of IMAC buffer with 1 M NaCl and 10 mL further IMAC buffer. Purified
truncated EzrA proteins were then eluted immediately using IMAC buffer with
500 mM imidazole, and fractions were pooled (typically 2–5 mL) and diluted to
40 mL in ion exchange buffer TBS0 (50 mM Tris-HCl pH 8.0, 1 mM DTT and 1
mM EDTA). EzrA proteins were then applied to an 8 mL MonoQ column (GE
Healthcare Life Sciences) connected to an ÄKTApurifier and equilibrated with
TBS0, then eluted with a gradient of 0–400 mM NaCl in TBS0 over 20 column
volumes.
5.3.3.3 Concentration and storage of truncated EzrA proteins
Purified EzrA truncation mutants were dialysed extensively against 20 mM
Tris-HCl pH 8.0, 50 mM NaCl, 1 mM DTT and 1 mM EDTA. Protein samples
were then concentrated using Amicon Ultra-4 Centrifugal Filter Units (Merck
Millipore) with a MWCO of 4,000 Da.
5.3.3.4 Purification of pooled libraries of truncated EzrA
EzrA protein library pools were prepared by mixing plasmids for various
His6-tagged truncated EzrA proteins. The EzrA plasmid pools were then
transformed into BL21(λDE3)recA by electroporation and the transformation
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pools directly inoculated into 400 mL auto-induction medium (Section 2.5.1).
The cultures were grown for 24 h at 30◦C and the pool of proteins purified as
described in Section 5.3.3.2.
5.3.4 Nuclear magnetic resonance analysis of truncated EzrA
Some EzrA mutants, when purified by anion-exchange chromatography, eluted in
two distinct peaks at A280, containing proteins of identical mass; for these proteins
the early eluting species were prepared for NMR analysis. Aliquots of concentrated
truncated EzrA mutants (Table 5.2) were dialysed extensively against 20 mM
Tris-HCl pH 7.0, 50 mM NaCl, 1 mM DTT and 1 mM EDTA, with EDTA
absent from the final dialysis buffer. Truncated EzrA protein aliquots were stored
and shipped at liquid nitrogen temperature to Dr Xun-Cheng Su, State Key
Laboratory of Elemento-organic Chemistry, Nankai University, Peoples Republic
of China. NMR experiments analysed 1D and TOCSY spectra using a Bruker
Avance 600 MHz NMR spectrometer with 100 ms mixing times for TOCSY spectra.
5.3.5 Plasmids for over-expression of wild type and biotinylated
Staphylococcus aureus cell division protein FtsZ
A synthetic plasmid containing the E. coli codon optimised protein coding
sequence for S. aureus FtsZ was ordered from DNA2.0 in plasmid pJExpress414
(pJB2095); this vector directs expression of FtsZ from a T7 phage promoter, and
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the ftsZ gene has an NdeI site at the start codon. To incorporate DNA encoding
the E. coli biotinylation sequence (MAGLNDIFEAQKbioIEWHEH; Beckett et al.,
1999) from pKO1285 (a derivative of pKO1274 which has the E. coli tus gene
inserted; Jergic et al., 2007) at the start of the coding sequence for FtsZ, the
small XbaI-NdeI restriction fragment of pKO1285 — encoding ribosome-binding
site, initiation codon and biotin ligase recognition sequence — was gel purified
and substituted for the equivalent fragment from pJB2095, producing pJB2096
(Figure 5.6). The resulting fusion protein, FtsZbio, when biotinylated, incorporates
one biotin molecule per molecule of protein.































Figure 5.6: Plasmid for over-expression of N-terminally biotinylated Staphylococcus aureus
FtsZ. The ribosome binding site, initiation codon and E. coli biotin ligase recognition sequence from
pKO1285 were liberated by digestion with XbaI and NdeI and ligated between the XbaI and NdeI
sites of pJB2095. pJB2096 directs over-expression of full-length S. aureus FtsZ with an N-terminal
E. coli biotin ligase recognition sequence.
5.3.6 Purification of biotinylated Staphylococcus aureus FtsZ
pJB2096 was transformed into BL21(λDE3)recA and a selected transformant was
inoculated into 2.1 L of auto-induction medium and cultured, with shaking, for 24
h at 30◦C (Section 2.5.1). FtsZbio containing cells were harvested by centrifugation
at 8,000 × g and resuspended in TBS150 (50 mM Tris-HCl pH 8.0, 150 mM NaCl
and 1 mM EDTA; 15 mL per g of cells), lysed using a chilled French press (Section
2.5.2) and the soluble cell fraction cleared by centrifugation at 30,000 × g for 30
min at 4◦C.
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A previous study identified two FtsZ populations when E. coli FtsZ was
over-expressed in a similar manner to that used here (Lu et al., 1998). The
two populations have differing GTPase activity and were discovered as they
precipitate at differing ammonium sulphate concentrations (low activity, 0.11
g.mL−1; high activity, 0.14 g.mL−1). The source of the difference between the
two populations of FtsZ is unknown as the two populations gave identical mass
by ESI mass spectrometry, and exhibited identical polymerisation characteristics
(Lu et al., 1998). Our intent for the FtsZ protein was to identify protein–protein
interactions, so the FtsZ purification procedure did not intend to separate the
two species (if they exist for the S. aureus protein). FtsZbio was precipitated from
the clarified cell lysate by addition of 0.2 g.mL−1 ammonium sulphate, which
precipitates the majority of over-expressed FtsZbio. Precipitated protein was
separated by centrifugation at 30,000 × g for 30 min at 4◦C and then resuspended
in 160 mL of TBS150.
DNA was removed from 40 mL portions of the recovered FtsZbio containing
solution by flowing it through a 35 mL DEAE chromatography column (Toyopearl
DEAE-650M) in TBS150 using an ÄKTApurifier and the FtsZbio containing
unbound fraction was collected. The relatively pure FtsZbio solution was then
pooled, concentrated by precipitation with 0.5 g.mL−1 ammonium sulphate and
then collected by centrifugation at 30,000 × g for 30 min. Ammonium sulphate
precipitated FtsZbio was resuspended in TBS150 with 1 mM DTT and 1 mM
EDTA and then dialysed against the same buffer before freezing in aliquots in
liquid nitrogen and storage at −80◦C.
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5.3.6.1 Purification of N-terminally His6 tagged Escherichia coli biotin ligase
N-terminally His6 tagged E. coli biotin ligase (BirA) was expressed from pKO1298
(Jergic et al., 2007) in BL21(λDE3)recA by auto-induction, with shaking, for 24 h
at 30◦C in a 400 mL culture (Section 2.5.1). Cells were collected by centrifugation
at 8,000 × g and resuspended in IMAC buffer (50 mM Tris-HCl, 300 mM NaCl
and 20 mM imidazole; pH 8.0; 15 mL per g of cells) and lysed using a chilled
French press (Section 2.5.2). Insoluble components were separated from the
soluble cell lysate by centrifugation at 30,000 × g for 30 min at 4◦C.
Clarified cell lysate (30 mL) containing BirA was filtered through a 45 µm syringe
filtration device and applied to a 1 mL HisTrap HP column, washed with 10
column volumes of IMAC buffer, then washed with 10 column volumes of IMAC
buffer with 1M NaCl, a further 5 column volumes of IMAC buffer and then eluted
using IMAC buffer with 500 mM imidazole. Fractions containing His6-BirA were
pooled, immediately adjusted to 1 mM EDTA and 1 mM DTT and then dialysed
against 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA and 1 mM DTT (pH 8.0).
Purified His6-BirA aliquots were frozen in liquid nitrogen and stored at −80◦C.
5.3.6.2 In vitro biotinylation of Staphylococcus aureus FtsZ
FtsZbio was dialysed to 50 mM Bicine pH 8.3 for conjugation to biotin using E.
coli biotin ligase. In vitro biotinylation of 40 µM FtsZbio was performed in 10 mL
of 50 mM Bicine pH 8.3, 10 mM ATP, 10 mM Mg(OAc)2, 50 µM d-biotin with 100
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µg BirA for 30 min at 30◦C (Kay et al., 2009). Following in vitro biotinylation,
FtsZbio was dialysed to 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM DTT and
1 mM EDTA.
5.3.6.3 In vitro EzrA pull-down using biotinylated-FtsZ bait
To identify EzrA fragments that are capable of interacting with full length
FtsZ, in vitro biotinylated FtsZbio was attached to streptavidin-coated resin and
incubated with various EzrA mutants (Section 5.3.3.4). Pull-down assays using
FtsZ-coated resin were performed in 600 µL sample tubes and buffers exchanged
by centrifugation of the samples in a small bench-top centrifuge at 2,000 × g for
5 s, then removing the supernatant with a pipette. FtsZbio was incubated with
7.5 µL Pierce High-capacity streptavidin resin (maximal binding capacity up to
37.5 µg biotinylated FtsZ) and incubated on ice in TBS150 (50 mM Tris-HCl pH
8.0, 150 mM NaCl) for 30 min, then thoroughly washed with TBS150. To reduce
non-specific protein interactions with the streptavidin resin, FtsZbio-coated beads
were then incubated with 4 nmol d-biotin and 40 mg BSA for 30 min on ice,
then thoroughly washed with TBS150. FtsZbio-coated resin was then exchanged to
ice-cold TBS50 (50 mM Tris-HCl pH 8.0, 50 mM NaCl). Samples of EzrA proteins
were added in excess and incubated in TBS50 for 30 min on ice, after which resin
was collected by centrifugation at 2,000 × g for 5 s, and the buffer exchanged
for fresh ice-cold TBS50 twice. Once the FtsZ-coated resin had been sufficiently
washed, 15 µL SDS-loading dye was added and the mixture incubated at 80◦C for
10 min prior to analysis by SDS-PAGE.
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5.4 Results
5.4.1 Genetic truncation of Staphylococcus aureus EzrA
In order to gain insight into the domain organisation of EzrA, both N- and
C-terminal truncation was performed. EzrA is annotated in Pfam as containing
five coiled-coil domains (Figure 5.4), hinting that it contains up to six distinctly
folded regions. In the protein truncation libraries characterised in Chapter 4,
truncations targeting removal of the N-terminal domain of DnaG unexpectedly
provided soluble proteins outside of the region targeted by the limited ExoIII
digest; gene deletion using ExoIII is known to produce mutants that are
disproportionately over and under truncated (Hoheisel, 1993; Ostermeier, 2003).
To elucidate soluble EzrA protein domains, a truncation methodology was chosen
such that the majority of gene products of truncation would be for protein sizes
likely to comprise one or two terminal folded domains. This methodology alone
should provide domain break points for up to four EzrA domains. With sufficient
mutant sampling, identification of under-truncated soluble protein should then
hint at soluble truncations for the remaining protein domain(s), if they exist.
N- and C-terminal EzrA deletion libraries were produced from limited-ExoIII
digests of linearised pJB1977 and pJB1975 (5.0 and 6.5 min with a rate of 200
bp.min−1) as described in Section 5.3.1. NcoI digested pJB1977 and pJB1975
were protected from ExoIII hydrolysis at both ends by incorporation of dGTPαS
and made sensitive to ExoIII by removing a single protected end using NdeI
or BamHI (Figure 5.7). For N-terminal deletion of EzrA, the remaining α-S
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protected NcoI site initiates translation in pJB1977 and following ligation of limit
ExoIII truncation (pooled 5.0 and 6.5 min samples), directs over-expression of
N-terminally truncated EzrA-EGFP fusion proteins (Figure 5.7A). For C-terminal
deletion of EzrA, removal of the NcoI–BamHI DNA fragment deletes stop
codons from all three reading frames as well as the α-S protected NcoI site of
pJB1975; ligation of products of limit ExoIII truncation produces plasmids where
3'-terminally truncated ezrA genes are fused in-frame to the downstream egfp
sequence (Figure 5.7B).




















Figure 5.7: Methodology for 5'- and 3'-truncation of Staphylococcus aureus ezrA.
A, 5'-terminally and B, 3'-terminally deleted genes were prepared from pJB1977 or pJB1975
(respectively) digested with NcoI and then protected with dGTPαS (red) and dATP, dCTP and
dTTP (green). These linearised plasmids were then digested with NdeI (N-terminal deletion) or
BamHI (C-terminal deletion) to remove the protected end most adjacent to the ezrA gene to allow
uni-directional deletion. The remaining filled NcoI site provides the start codon for 5'-terminally
truncated genes or the start of the 3'-terminal gene fusion for 3'-terminally truncated genes. After
limit digests using ExoIII and plasmid repair, one-in-three truncated gene open-reading-frames are
in-frame with the downstream egfp gene, producing a truncated EzrA protein fused to EGFP when
expressed in E. coli .
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Separately, limit ExoIII digests of pJB1977 and pJB1975 were ligated and
transformed into BL21(λDE3)recA, recovered in LB, then spread onto 10
Selection agar plates (Section 4.3.2.5) and incubated overnight at 30◦C. The
transformed cultures were stored at 4◦C for 48 h as previous evidence suggests that
colonies further develop their green fluorescent phenotype during this time. The
N-terminally deleted library made from pJB1977 produced 4,381 transformants,
of which 140 had a green fluorescent phenotype, while the C-terminally deleted
library produced from pJB1975 gave 2,955 colonies, of which 73 produced a green
fluorescent phenotype. Previous protein truncation libraries produced in this
work (see Chapter 4), showed a correlation between green fluorescent phenotype
and protein solubility, and this is supported by previous reported work (Waldo
et al., 1999; Pédelacq et al., 2005). Relying on the principle that interrupting
protein folding units should reduce protein solubility, sequencing of truncated
ezrA mutants with the strongest green fluorescent phenotypes was expected to
provide insight into the domain architecture of EzrA. As a result 49 5'-terminally
deleted (Table 5.3) and 33 3'-terminally deleted (Table 5.4) ezrA mutants with
a bright green fluorescent phenotype were sequenced to identify the truncated
proteins they express.
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Table 5.3: N-terminally deleted S. aureus EzrA mutants. Plasmids from green colonies expressing truncated EzrA-EGFP fusion proteins
were sequenced to identify the mutations present. Displayed at the top are the DNA and protein sequences of untruncated pJB1977 (wt/WT)
that was used to generate truncated ezrA genes fused to egfp; shown in red are the nucleotides removed during linearisation for uni-directional
truncation. f0–1 indicate the reading frames present in pJB1977; f0; reading frame of initiation codon, f1; reading frame of non-truncated ezrA
in pJB1977. Shown in the body are DNA and protein sequences of truncated EzrA mutants. Six mutants did not provide useful DNA sequence
and 12 contained no or short ezrA sequences (not shown).
wt CCATGGCGACCTCGTGA-/19 bp ATGGCTATTCCTCAGCATACCATTGATCAA WT
f0 M A T S *




M Q I I E K A I E R K N E 29–564
CCATG GTGGAAGGTTACGATCTGGATCATGTGAAAGTTGACAGC pJB2029
M V E G Y D L D H V K V D 244–564
CCATG CTGGAAGAGGCGAACGATAAACTGGCGAACATCAACGAC pJB2046
M L E E A N D K L A N I N 277–564
CCATG GCGAACGATAAACTGGCGAACATCAACGACAAGCTGGAC pJB2045
M A N D K L A N I N D K L 280–564
CCATG GTGAAAGCCAAGAACGACGTCGAAGAAACCAAGGATATC pJB2050
M V K A K N D V E E T K D 302–564
CCATG GTTCAGGACAACTTGCAGTACCTGGAGGATCACGTTACC pJB2024
M V Q D N L Q Y L E D H V 381–564
CCATG ACCGTAATCAACGATAAGCAGGAGAAGTTGCAAAACCAT pJB2042
M T V I N D K Q E K L Q N 393–564
CCATG TCGAAGAAAGAAGAAGTGTATCGTCGCTTGCTGGCTTCC pJB2044
M S K K E E V Y R R L L A 425–564
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wt CCATGGCGACCTCGTGA-/19 bp ATGGCTATTCCTCAGCATACCATTGATCAA WT




M P E R F I I M K N E I D 443–564
CCATG AAAAACGAGATTGATCATGAGGTTCGTGACGTTAATGAG pJB2036
M K N E I D H E V R D V N 450–564
CCATG ATTGATCATGAGGTTCGTGACGTTAATGAGCAGTTTTCT pJB2021
M I D H E V R D V N E Q F 453–564
CCATG ATTCACGTCAAGCAGCTGAAGGATAAAGTCTCTAAGATT pJB2051
M I H V K Q L K D K V S K 469–564
CCATG GATAAAGTCTCTAAGATTGTCATTCAAATGAACACCTTC pJB2025
M D K V S K I V I Q M N T 476–564
CCATG GTCTCTAAGATTGTCATTCAAATGAACACCTTCGAGGAC pJB2038
M V S K I V I Q M N T F E 478–564
CCATG CAAATGAACACCTTCGAGGACGAAGCGAACGACGTGCTG pJB2039
M Q M N T F E D E A N D V 484–564
CCATG AGCAACGTTGACAAGTCTTTGAATGAGGCGGAGCGTCTG pJB2040
M S N V D K S L N E A E R 517–564
CCATG GTTGACAAGTCTTTGAATGAGGCGGAGCGTCTGTTTAAG pJB2028
M V D K S L N E A E R L F 519–564
CCATG GACAAGTCTTTGAATGAGGCGGAGCGTCTGTTTAAGAAC pJB2035
M D K S L N E A E R L F K 520–564
CCATG TCTTTGAATGAGGCGGAGCGTCTGTTTAAGAACAATCGT pJB2022
M S L N E A E R L F K N N 522–564
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wt CCATGGCGACCTCGTGA-/19 bp ATGGCTATTCCTCAGCATACCATTGATCAA WT




M K N N R Y K R A I E I A 531–564
CCATG AAGAACAATCGTTACAAACGCGCCATTGAAATCGCTGAA pJB2041
M K N N R Y K R A I E I A 531–564
CCATG AAGAACAATCGTTACAAACGCGCCATTGAAATCGCTGAA pJB2047
M K N N R Y K R A I E I A 531–564
CCATG AATCGTTACAAACGCGCCATTGAAATCGCTGAACAGGTG pJB2026
M N R Y K R A I E I A E Q 533–564
CCATG AATCGTTACAAACGCGCCATTGAAATCGCTGAACAGGTG pJB2032
M N R Y K R A I E I A E Q 533–564
CCATG CGCGCCATTGAAATCGCTGAACAGGTGCTGGAGAGCGTT pJB2027
M R A I E I A E Q V L E S 537–564
CCATG GAAATCGCTGAACAGGTGCTGGAGAGCGTTGAACCGGGC pJB2020
M E I A E Q V L E S V E P 540–564
CCATG GAAATCGCTGAACAGGTGCTGGAGAGCGTTGAACCGGGC pJB2043
M E I A E Q V L E S V E P 540–564
CCATG GTGCTGGAGAGCGTTGAACCGGGCGTCACGAAACACATC pJB2023
M V L E S V E P G V T K H 545–564
CCATG AGCGTTGAACCGGGCGTCACGAAACACATCGAAGAAGAG pJB2048
M S V E P G V T K H I E E 548–564
CCATG AGCGTTGAACCGGGCGTCACGAAACACATCGAAGAAGAG pJB2049
M S V E P G V T K H I E E 548–564
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wt CCATGGCGACCTCGTGA-/19 bp ATGGCTATTCCTCAGCATACCATTGATCAA WT




M K H I E E E V I K Q 555–564
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Table 5.4: C-terminally deleted S. aureus EzrA. Plasmids from green colonies expressing truncated EzrA-EGFP fusion proteins were
sequenced to identify the mutations present. Shown at the top are the DNA and protein sequence of untruncated pJB1975 (wt/WT) that was
used to generate truncated ezrA genes fused to egfp. f0–2 indicates the reading frames present in pJB1975. Shown in red are the nucleotides
removed during linearisation for uni-directional truncation. Shown in the body are DNA and protein sequences of truncated EzrA mutants.
Seven mutants did not produce readable DNA sequence and two contained non-truncated EzrA (not shown).
wt GAGGTGATCAAGCAAGGATCCTAAGTAACTAAC CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT WT






S N K R Q I I E K A I E H G S S G N S H H H H H 24–36
GAAAAAGCAATAGAGAGAAAGAATGAAATTGAAACC CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB2004
E K A I E R K N E I E T H G S S G N S H H H H H 24–43
GCGCAACTGAGCAAACTGAATTTGAAAGGTGAAACC CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB2013
A Q L S K L N L K G E T H G S S G N S H H H H H 24–62
GCGCAACTGAGCAAACTGAATTTGAAAGGTGAAACC CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB1995
A Q L S K L N L K G E T H G S S G N S H H H H H 24–62
GCGCAACTGAGCAAACTGAATTTGAAAGGTGAAACC CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB1998
A Q L S K L N L K G E T H G S S G N S H H H H H 24–62
GCGCAACTGAGCAAACTGAATTTGAAAGGTGAAACC CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB2002
A Q L S K L N L K G E T H G S S G N S H H H H H 24–62
GCGCAACTGAGCAAACTGAATTTGAAAGGTGAAACC CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB2003
A Q L S K L N L K G E T H G S S G N S H H H H H 24–62
CTGAGCAAACTGAATTTGAAAGGTGAAACCAAAACT CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB1994
L S K L N L K G E T K T H G S S G N S H H H H H 24–64
Continued on next page. . .
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wt GAGGTGATCAAGCAAGGATCCTAAGTAACTAAC CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT WT




K Y L A P V E E K I H N H G S S G N S H H H H H 24–90
GCACCTGTTGAAGAGAAAATTCACAATGCCGAAGCG CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB1982
A P V E E K I H N A E A H G S S G N S H H H H H 24–93
GAGAAAATTCACAATGCCGAAGCGCTGCTGGATAAG CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB1990
E K I H N A E A L L D K H G S S G N S H H H H H 24–97
CACAATGCCGAAGCGCTGCTGGATAAGTTTAGCTTC CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB2006
H N A E A L L D K F S F H G S S G N S H H H H H 24–100
GACAGCTATGAGCAGAGCTACCAGCAGCAACTGGAG CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB1986
D S Y E Q S Y Q Q Q L E H G S S G N S H H H H H 24–126
TATGAGCAGAGCTACCAGCAGCAACTGGAGGACGTT CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB2010
Y E Q S Y Q Q Q L E D V H G S S G N S H H H H H 24–128
GAGCAGAGCTACCAGCAGCAACTGGAGGACGTTAAC CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB2005
E Q S Y Q Q Q L E D V N H G S S G N S H H H H H 24–129
GTTAACGAGATCATCGCACTGTACAAAGATAACGAC CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB1988
V N E I I A L Y K D N D H G S S G N S H H H H H 24–139
GCGGCACTGAATGAGCAAATGAAACAGCTGCGTAGC CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB2012
A A L N E Q M K Q L R S H G S S G N S H H H H H 24–212
CTGAATGAGCAAATGAAACAGCTGCGTAGCTATATG CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB1989
L N E Q M K Q L R S Y M H G S S G N S H H H H H 24–214
CTGATTCGTGAAACCCAAAAAGAACTGCCGGGTCAA CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB2011
L I R E T Q K E L P G Q H G S S G N S H H H H H 24–231
Continued on next page. . .
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wt GAGGTGATCAAGCAAGGATCCTAAGTAACTAAC CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT WT




E L P G Q F Q D L K Y G H G S S G N S H H H H H 24–238
GATCATGTGAAAGTTGACAGCACCTTGCAGAGCCTG CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB1984
D H V K V D S T L Q S L H G S S G N S H H H H H 24–261
GAGCCGCTGATTAGCCGTCTGGAACTGGAAGAGGCG CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB1981
E P L I S R L E L E E A H G S S G N S H H H H H 24–280
GATATGTATGATTTGATTGAGCACGAGGTGAAAGCC CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB2009
D M Y D L I E H E V K A H G S S G N S H H H H H 24–304
TCTGAACGCCCGATTCACGTCAAGCAGCTGAAGGAT CATGGCTCCTCTGGGAATTCTCATCACCATCACCAT pJB1992
S E R P I H V K Q L K D H G S S G N S H H H H H 24–476
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As expected, many of the truncated EzrA mutants producing a green fluorescent
phenotype when expressed as a fusion to EGFP are clustered at the ends of the
protein where the libraries were focussed (Figure 5.8). Strikingly, many truncations
within EzrA produce putatively soluble proteins, and with few exceptions, fusion
proteins of putatively soluble mutants are within 30 amino acids of one-another.
These results indicate that many possible truncation mutations in S. aureus EzrA
can be tolerated, which may suggest that it is actually a poorly-structured protein
throughout much of its length.
EzrA24−564
IQYGNRY
Figure 5.8: EzrA truncations. Truncation end points of EzrA truncation libraries with a C-terminal
EGFP protein-solubility reporter. Arrows indicate: above, fluorescence-selected N-terminal deletions
and below, fluorescence-selected C-terminal deletions of EzrA. Also shown: N-terminal membrane
anchor in pink, predicted coiled-coil-folds in purple and QNR patch in green.
5.4.2 Examination of solubility of truncated EzrA mutants
To explore the solubility of expressed, truncated EzrA mutants, a variety of the
truncated ezrA plasmids were modified to no longer express the C-terminal EGFP
fusion, but still contain a C-terminal His6-tag (N-terminal deletions of EzrA,
pJB2082–pJB2093; C-terminal deletions of EzrA, pJB2070–pJB2081; Table 5.5).
These proteins were over-expressed by auto-induction in BL21(λDE3)recA.
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Table 5.5: Identity of putatively soluble truncated Staphylococcus aureus ezrA plasmids.
Plasmids directing expression of selected S. aureus EzrA mutants were modified to express a
C-terminal His6-tag without an EGFP fusion. C-terminal protein sequences are: for EzrA24–564
and N-terminally deleted EzrA, GSSGNSHHHHHHQL* and for C-terminally deleted EzrA
HGSSGNSHHHHHHQL*. EzrA mutants are numbered as in the full-length S. aureus protein.


























Individual cultures of strains that over-expressed truncated EzrA mutants were
collected by centrifugation and lysed using a French press. The cell lysates
were separated into soluble and insoluble components by centrifugation and
then examined by SDS-PAGE (Figure 5.9). All mutants directed expression of
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A: N-terminally deleted EzrA proteins
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Figure 5.9: Over-expression and protein solubility of EzrA N- and C-terminally deleted mutants. A, N-deleted and B, C-deleted EzrA
mutants were over-expressed in BL21(λDE3)recA by auto-induction at 30◦C. After cell lysis by French press, the: C; cellular; Sol; soluble and
In; insoluble fractions were each analysed by SDS-PAGE. Migration of Precision Plus Protein Dual Color molecular size markers are indicated.
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soluble protein of the expected sizes except for EzrA24–231, which did not produce
detectable protein over-expression (not shown).
Full-length EzrA24–564 was over-expressed well and appeared almost exclusively
in the soluble protein fraction. Of the N-terminally truncated EzrA mutants, the
largest fragments examined — EzrA277–564 and EzrA280–564 — are ∼ 35 kDa in
size, and wholly contain the three predicted C-terminal coiled-coil domains and
the QNR patch; EzrA302–564 is truncated slightly into the first predicted coiled-coil
fold of these mutants. EzrA277–564 was over-expressed very well with good yields
of soluble protein, whereas EzrA280–564 was expressed poorly in comparison and
had a reduced proportion of soluble EzrA. Expression of EzrA302–564 was poorer
still. EzrA381–564 and EzrA393–564 are missing two predicted coiled-coil domains
with respect to EzrA277–564; these proteins were over-expressed well and significant
amounts of soluble protein were present in the cell extracts, with about 50% of
each present in the insoluble protein fraction.
EzrA425–564 (18 kDa) was over-expressed at high levels, with an apparent
proteolytic fragment (1–2 kDa smaller) also apparent in the soluble fraction,
but not in the insoluble fraction. The proteolytic fragment of EzrA425–564 was
similar in size to EzrA443–564 (16 kDa) and EzrA453–564 (15 kDa), which were also
over-expressed well and were soluble. The presence solely in the soluble fraction of
the proteolytic fragment of EzrA425–564 would imply that the insoluble EzrA425–564
produced by over-expression is aggregated and therefore inaccessible to cellular
proteases. Cleavage of the soluble fraction at a flexible region produces the more
compact proteolysed fragment, and this fragment remains soluble. The remaining
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C-terminal EzrA fragments EzrA453–564, EzrA469–564, EzrA476–564 and EzrA484–564
were over-expressed in soluble form but their N-termini are not clustered near
distinct regions. EzrA484–564 also showed evidence of proteolysis.
Of the C-terminally deleted EzrA proteins examined, the small 10–15 kDa
mutants EzrA24–97, EzrA24–100, EzrA24–126, EzrA24–128, EzrA24–129 and EzrA24–139
were over-expressed to moderate levels, and were predominantly found in the
soluble cellular fraction. The larger EzrA24–214 (24 kDa), EzrA24–238 (27 kDa) and
EzrA24–476(55 kDa) proteins were also expressed well and were mostly produced
as soluble proteins.
5.4.3 Purification of soluble N- and C-terminal fragments of EzrA
To study the properties of the truncated EzrA proteins, 19 mutants were
purified by one step IMAC and 18 were further fractionated by high resolution
ion-exchange chromatography (Figure 5.10: A–R; mass spectra of purified proteins
are shown in Appendix E 1–17; EzrA476–564 precipitated in high concentration
imidazole buffer when eluted from IMAC). All mutants presumed to be soluble
by using EGFP fusion to report solubility remained soluble following purification
except EzrA476–564, supporting the hypothesis that truncated EzrA mutants
identified as soluble EGFP fusion proteins are soluble by themselves.
For unknown reasons, EzrA277–564, EzrA280–564 and EzrA302–564 eluted from the
anion-exchange column in two distinct peaks, yet mass spectra of both the













































































































Figure 5.10: Purification of N- and C-terminally deleted EzrA mutants. Soluble N-terminally
truncated EzrA proteins were purified by IMAC and then by anion-exchange chromatography (A
C-terminally truncated EzrA proteins were purified by IMAC and then K; cation-exchange or
anion-exchange chromatography. SDS-PAGE gels were stained with Coomassie blue. Shown for each
protein are chromatographic fractions in order of elution with sample A280 (mAU) overlaid in blue

















































































































Figure 5.10: Purification of N- or C-terminally deleted EzrA mutants— continued from previous
page. 200
early and late eluting peaks for EzrA277–564 (Appendix E.1A and E.1B) and
EzrA302–564 (Appendix E.3A and E.3B) were identical. This suggests some
structural variability between the distinct populations rather than differences in
sequence; the remaining, shorter, N-terminally deleted EzrA mutants EzrA381–564,
EzrA393–564, EzrA425–564, EzrA443–564, EzrA453–564, EzrA476–564 and EzrA484–564
eluted as single populations when purified by anion-exchange.
Purification of EzrA425–564 by sequential IMAC and anion-exchange
chromatography recovered both full length EzrA425–564 and the 1–2 kDa
smaller proteolysis fragment (Figure 5.10F). As all the truncated EzrA proteins
were expressed with a C-terminal His6-tag and purified initially by IMAC, the
recovered proteolytic fragment must be missing the N-terminus of EzrA425–564.
Analysis by mass spectrometry of denatured EzrA425–564 and its large proteolysis
product revealed a mass difference of 1.8 kDa that is consistent with the loss
of the 15 N-terminal residues (Figure 5.11). The large proteolytic fragment of
EzrA425–564 is therefore just four amino acids larger than EzrA443–564, which
was also identified as being soluble (Figure 5.9A). The fact that both domain
truncation using our methodology and in vivo proteolysis recover proteins that
begin in the same region suggests a folding unit boundary at this position in the
sequence of EzrA. The larger N-terminally deleted EzrA mutants EzrA277–564,
EzrA280–564 and EzrA302–564 do not proteolyse in this manner, suggesting that
EzrA425–564 might be partially unfolded at its N-terminus, allowing access to a
proteolytic enzyme.
Purification of some C-terminally deleted EzrA mutants also revealed evidence of


















EzrA 425−564: 18109.85 Da











Figure 5.11: N-terminal proteolysis of EzrA425–564. Positive ion electrospray mass spectrum of
denatured, EzrA425–564 and a co-purified, in vivo proteolysis product. The C-terminus of proteolytic
fragments are retained as EzrA425–564 contains a C-terminal His6-tag. Species observed in mass
spectra reveal residual fragments consistent with proteolysis between residues 338–339, liberating
the N-terminal fragment MSKKEEVYRRLLASN. Full length proteins are coloured blue, residual
proteolysed EzrA425–564 purple and a separately identified soluble EzrA truncation mutant EzrA393–564
green. Calculated peptide masses are indicated in brackets.
proteolysis; i.e., in EzrA24–126, EzrA24–128 and EzrA24–129. These proteins contain
proteolytic fragments that elute in a later, second peak during anion-exchange
chromatography (Figure 5.10L, M, N). Mass spectrometry under denaturing
conditions showed the mass of the full length mutants and a proteolytic fragment
consistent with loss of the 35 N-terminal amino acids from each mutant (Figure
5.12). This proteolysis event did not occur for EzrA24–139, EzrA24–214, EzrA24–238
or EzrA24–476 although EzrA24–238 suffered minor proteolysis of the N-terminal 48
and 49 residues (Appendix E.16B).









EzrA 24-128: 14022.02 Da
















EzrA 24-126: 13807.55 Da





















Figure 5.12: N-terminal proteolysis of EzrA24–126, EzrA24–128 and EzrA24–129. Positive ion
electrospray mass spectrum of denatured EzrA24–126, EzrA24–128 and EzrA24–129 and co-purified
in vivo proteolysis products. Only C-terminal proteolytic fragments are retained as EzrA24–126,
EzrA24–128 and EzrA24–129 contain a C-terminal His6-tag. Species observed in mass spectra reveal
residual fragments consistent with proteolysis between residues 58–59, liberating a 35 amino acid
N-terminal fragment from each. Full length proteins are coloured blue, residual proteolysed EzrA24–126
and EzrA24–128 purple. The mass spectrum is not shown for EzrA24–129, which is coloured yellow.
Calculated peptide masses are indicated in brackets.
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5.4.4 Examination of the foldedness of N- and C-terminally truncated
Staphylococcus aureus EzrA
To establish the foldedness of the soluble truncated EzrA mutants, the proteins
were prepared for proton NMR and sent to Dr Xun-Cheng Su at the State Key
Laboratory of Elemento-organic Chemistry, Nankai University, Peoples Republic
of China, to measure 1D and 2D TOCSY NMR spectra. 1D proton NMR gives
various indications of protein foldedness (Section 4.4.5); in particular, chemical
shift data for buried methyl protons (−0.5 to 1.5 ppm), β-sheet Cα (5–6 ppm)
and backbone amide (6–10 ppm) proton regions are useful (McDonald and
Phillips, 1967; Christendat et al., 2000; Rehm et al., 2002). In the case of a
wholly unfolded protein, every amino acid residue is solvent exposed and the
chemical environments are essentially identical, resulting in each distinct amino
acid producing highly similar proton NMR signals. In contrast, a folded protein
imposes stricter conformational constraints, and consequently, unique chemical
environments which give rise to distinct spectral peaks in NMR spectra.
In the 2D NMR experiments performed here, spectra of large proteins show
chemical shifts for flexible residues only, as large folded portions of proteins
rotate too slowly in solution to give non-background signals (Section 4.4.5).
However, as protein size decreases – and rotation speeds up — resonances
from the folded core of a protein become visible in the “flexible” spectrum.
In the case of these smaller proteins, the characteristics of observed chemical
shifts can be useful in determining whether a protein is disordered, as evidenced
by characteristic random-coil chemical shifts (Wishart et al., 1995; Wishart, 2011).
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One dimensional and 2D TOCSY NMR spectra was recorded for EzrA277–564,
EzrA280–564, EzrA302–564, EzrA381–564, EzrA425–564, EzrA443–564, EzrA484–564,
EzrA24–564, EzrA24–97, EzrA24–126, EzrA24–128, EzrA24–129, EzrA24–139, EzrA24–214,
EzrA24–238 and EzrA24–476 (1D and complete TOCSY spectra, see Appendices
E.1–E.6 and E.10–E.17). While some EzrA mutants appeared to be well folded
by NMR, analysis of the TOCSY spectra makes unambiguous residue assignment
difficult as the chemical shifts — which when flexible are very likely to be
disordered — are at or near random-coil values and obscure each other due to
poor spectral dispersion.
Truncated EzrA mutants, representing approximately the first domain (EzrA24–97,
10.4 kDa; EzrA24–126, 13.8 kDa; EzrA24–128, 14.0 kDa; EzrA24–129, 14.1 kDa), did
not have methyl proton signals in their 1D NMR spectra (Appendices E.10B,
E.11C, E.12C, E.13C), indicating that these are not folded. The 2D TOCSY
spectra display significant signals at amino acid chemical shifts in the random-coil
range (amide–αC proton correlations for C-terminally deleted EzrA mutants
as shown in Figure 5.13). As these proteins are small, and no non-random-coil
resonances are visible, they are likely completely unfolded. N-terminal proteolysis
of these proteins (Section 5.4.3), would easily occur if they are poorly, or not folded.
Interestingly, EzrA24–139 (15.3 kDa) appeared to be partially folded, as methyl
signals are visible in the 1D NMR spectrum (Appendix E.14C). However, the
protein also showed a significant random-coil signal in the TOCSY spectrum
(Figure 5.13E). EzrA24–139 does not undergo proteolysis between residues 58 and
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Figure 5.13: Two-dimensional TOCSY NMR fingerprint region in spectra of C-terminally
deleted EzrA mutants. Cα–NH correlations in NMR spectra recorded for truncated EzrA mutants.
2D TOCSY NMR spectroscopy (mixing time 80 ms) was performed on EzrA mutants (A–H) and
full-length cytoplasmic EzrA (I) in H2O with 20 mM Tris-HCl pH 7.0, 50 mM NaCl and 1 mM DTT
by the research group of Dr Xun-Cheng Su,Nankai University, Peoples Republic of China. Red dashed
lines indicate random-coil values for: vertical, amide proton and horizontal, α-C proton chemical shifts
(Wishart et al., 1995; Wishart, 2011).
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59 unlike EzrA24–126, EzrA24–128, and EzrA24–129, which is further evidence that
the N-terminus of EzrA that incorporates this site is folded in EzrA24–139; no
information can be inferred about the C-terminus of this protein.
On the other hand, EzrA24–214 (24.2 kDa) seemed to be well folded, with methyl
signals in the 1D spectrum, and a minimal contribution of random-coil signals
in the TOCSY spectrum (Figure 5.13F). Some of the resonances observed for
EzrA24–214 are likely from glutamic acid, and although unclear, several methyl
containing residues may also also have peaks in the TOCSY spectrum. It is
not possible to distinguish if the flexible regions in EzrA24–214 are at the N-
or C-terminus from the NMR spectrum alone as such residues are present at
both ends. The TOCSY spectrum of EzrA24–238 (27.1 kDa) was highly similar
to EzrA24–214 (in addition to the 1D spectrum indicating that this protein
is folded; Figure 5.13G; Appendix E.16C). However, EzrA24–238 shows some
additional random-coil chemical shifts at around 1.5 ppm/8.1–8.3 ppm (F1/F2).
The additional unstructured residues cannot be positively identified, although, as
resonances are not present in the spectrum of the shorter EzrA24–214 mutant, the
C-terminus of EzrA24–238 is likely to contain a short, additional flexible region.
The large size of EzrA24–476 (55.2 kDa) reduces the usefulness of NMR for
investigating its structure, yet some random-coil resonances are still visible in
the TOCSY NMR spectrum of this protein, indicating that not all of it is well
folded (Figure 5.13H). Although not all, some of the resonances observed in the
TOCSY spectrum of EzrA24–476 are also observed in the spectrum of EzrA24–214
and EzrA24–238, which may indicate that some of the flexible residues of EzrA24–476
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are at the N-terminus, but these observations cannot rule out that the C-terminus
of EzrA24–476 is also poorly structured.
EzrA277–564 (35.8 kDa), EzrA280–564 (35.4 kDa) and EzrA302–564 (32.8 kDa) are
predicted to contain the complete three C-terminal domains and each mutant
produced clear 1D NMR methyl peaks, indicative of them being folded proteins
(Appendices E.1C, E.2B, E.3C). The TOCSY spectrum of EzrA302–564 indicates
that this protein is well folded, with only a single valine resonance in the
random-coil region (amide–αC proton correlations for N-terminally deleted
EzrA mutants are shown in Figure 5.14). Two Val residues are present near the
N-terminus of the protein and one at the C-terminus, which makes it impossible
to assign the location of the flexible region. However, all C-terminal EzrA
fragments showed a Val resonance at an NH shift of ≈ 7.95 ppm (and indeed, full
length EzrA has a similar signal), which may indicate that V561, at the extreme
C-terminus of EzrA is mobile. EzrA280–564 shows additional resonances in the
TOCSY spectrum (Figure 5.14B), very likely due to the additional N-terminal
residues compared to EzrA302–564, and EzrA277–564 has a further two flexible Glu
resonances (E277, E278: Figure 5.14C).
Mutants further N-terminally truncated (EzrA381–564, 23.5 kDa; EzrA425–564,
18.2 kDa; EzrA443–564, 16.2 kDa) contain folded protein cores as indicated by
their 1D NMR methyl chemical shifts (Appendices E.4B, E.5B, E.6B), but also
showed resonances in their flexible TOCSY spectra (Figures 5.14D, E, F). As
the proteins get progressively shorter at the N-terminus, flexible resonances
disappear from the TOCSY spectrum, where EzrA381–564 has a larger contribution
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Figure 5.14: Two-dimensional TOCSY NMR fingerprints of N-terminally deleted EzrA
mutants. Cα–NH correlations in NMR spectra recorded for truncated EzrA mutants. 2D TOCSY
NMR spectroscopy (mixing time 80 ms) was performed on N-terminally truncated EzrA mutants
(A–G) and full-length cytoplasmic EzrA (H) in H2O with 20 mM Tris-HCl pH 7.0, 50 mM NaCl and
1 mM DTT by the research group of Dr Xun-Cheng Su. Red dashed lines indicate random-coil values
for: vertical, amide proton and horizontal, α-C proton chemical shifts (Wishart et al., 1995; Wishart,
2011).
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of flexible residues while EzrA443–564 seems to be well folded, indicating that the
unstructured regions in these mutants is at the N-terminus. The sample used
to record the spectrum of EzrA425–564 contained a mixture of the full-length
protein and the proteolytic fragment lacking 15 N-terminal residues (fragmented
between residues 438 and 439), so its spectra are difficult to interpret. The
TOCSY spectra of EzrA443–564, EzrA425–564 and EzrA381–564 have a readily
identified Val resonance at an NH shift of ≈ 7.95 ppm, consistent with the
other C-terminal fragments of EzrA. One-dimensional NMR indicates that
EzrA484–564 (11.2 kDa) has a folded protein core and the TOCSY spectrum —
due to its small size — displays numerous resonances, the majority of which are
not at random-coil values, indicating that EzrA484–564 is well folded (Figure 5.14G).
Due to the large size of EzrA24–564 (65.4 kDa; Appendix E.18C and D) these NMR
experiments can provide only limited detail about the full length cytoplasmic
fragment. However, the structure appears predominantly α-helical, based on the
absence of Cα β-sheet proton signals (this is also the case for folded truncated
EzrA mutants). Some Glu resonances are visible in the TOCSY spectrum of
EzrA24–564 that — assuming the flexibility is at an end of the protein — are
possibly for residues E558, E559 and E560, as the N-terminus of EzrA is more
sparsely populated with Glu. However, the EzrA24–564 TOCSY spectrum also
contains several methyl resonances that are hard to identify and these, along with
the flexible Glu resonances, are absent from the TOCSY spectrum of EzrA302–564,
which shares the same C-terminus. In comparison, spectra of the well folded
N-terminal fragments EzrA24–214 and EzrA24–238 contain similar methyl resonances
to EzrA24–564 and a single Glu, suggesting that — these flexible residues at least
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— are located in the N-terminal region of EzrA.
5.4.5 Probing the EzrA–FtsZ interaction using affinity pull-down
Having produced a range of soluble, truncated EzrA proteins, we wished to utilise
these to try to identify the site of interaction between EzrA and FtsZ. Aside from
the terminal domains of EzrA, the proteins available from these EzrA libraries
are not distinct domains, and instead many contain a series of presumably folded
units, that are not by themselves useful for identifying which regions of the protein
interacts with FtsZ. The advantage of using libraries of EzrA is that comparison
of the relative binding of mutants from complementary N- and C-terminal deletion
libraries should allow the site of interaction to be identified. In this case I used
a synthetic library of the already-identified truncated genes, but in principle the
same procedure could be used with naive libraries of truncations.
To identify the EzrA–FtsZ interactions a protein “pull-down” assay was used.
Resin immobilised FtsZ was mixed with various pools of, or individual EzrA
mutants and the resin then removed and washed; any EzrA proteins co-purified
with the resin-bound FtsZ are therefore likely to have bound to FtsZ. The pools of
soluble truncated EzrA were prepared in a straightforward manner (Figure 5.15A)
by I) preparing truncated EzrA plasmid libraries with a C-terminal His6-tag.
The protein libraries were then II) expressed, and the mixture of truncated EzrA
mutants were III) purified from lysed cultures by IMAC.
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analyse by SDS-PAGE
Figure 5.15: Screening for FtsZ interaction using EzrA fragment libraries. EzrA fragment
libraries were made by A: I–II, over-expressing an EzrA-His6 fragment library from plasmid pools
in single cultures and III, purifying soluble over-expressed EzrA fragment proteins by IMAC. EzrA
fragment libraries were then screened for mutants that bind to resin-immobilised FtsZ B: IV,
N-terminally biotinylated FtsZ was incubated with streptavidin-coated resin and then unbound FtsZ
was washed free. V, EzrA fragment libraries were incubated with resin-immobilised FtsZ on ice. Then
VI, resin with attached FtsZ was separated from the EzrA library by centrifugation, and, fresh, protein
free, ice cold buffer was added to wash unbound EzrA and the resin collected again. EzrA mutants
bound to immobilised FtsZ were identified by VII, boiling streptavidin-coated resin in denaturing
buffer and then analysis by SDS-PAGE.
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With a pool of variable sized EzrA proteins, a simple pull-down experiment
can then be used to identify fragments that interact with FtsZ. In these
pull-down experiments, N-terminally biotinylated FtsZ “bait” was prepared by
immobilisation on resin coated by streptavidin (IV; Figure 5.15B). V) The EzrA
“prey” is then applied to the immobilised FtsZ, mixed and incubated on ice for 30
min to allow any interactions to form. As FtsZ is immobilised, VI) centrifugation
of streptavidin resin can then separate and wash away the unbound EzrA.
To confirm that EzrA interacts with FtsZ, and that this pull-down technique
is able to co-purify EzrA with immobilised FtsZ, a pull-down experiment was
performed with EzrA24–564, and indeed, EzrA24–564 was bound to FtsZ immobilised
streptavidin resin, but not FtsZ naïve resin (Figure 5.16A). To then identify
candidate EzrA fragments that interact strongly with FtsZ, purified N- and
C-terminal libraries were investigated for interactions (Figure 5.16B–C). Of the
proteins in the EzrA fragment libraries, only EzrA24–476 appears to bind strongly
to the FtsZ-immobilised resin. To validate the FtsZ-EzrA24–476 interaction, the
pull-down experiment was repeated using purified EzrA24–476 (Figure 5.16F).
As previous reports placed the EzrA–FtsZ interaction site at the C-terminus of
EzrA (Haeusser et al., 2007) and yet Son and Lee (2013) suggested that the
N-terminus of EzrA may be important for interaction with FtsZ, pull-down
experiments were also performed with EzrA24–214, EzrA24–238 (Figure 5.16D–E),
EzrA277–564 and EzrA280–564 (Figure 5.16G–H). Only EzrA24–476 bound FtsZ,
suggesting that — compared to EzrA24–238 and EzrA277–564 — the region between
residues 238 and 276 may be necessary for interaction with FtsZ.









































































































































































Figure 5.16: Identification of FtsZ–EzrA interaction by pull-down assay. To identify candidate
EzrA regions that interact with FtsZ, streptavidin- (13.2 kDa) coated resin was incubated with
N-terminally biotinylated FtsZ (43.2 kDa), then free biotin and BSA (66.5 kDa). FtsZ-coated resin
was then washed and incubated with EzrA and its truncation mutants on ice for 30 min. EzrA
containing buffer was then separated from FtsZ-coated resin by centrifugation, and to remove free
EzrA, twice replaced with TBS50, mixed and FtsZ-coated resin recovered again. FtsZ-coated r
and any bound EzrA, was then incubated in SDS at 80◦C for 10 min and analysed by SDS-P
Polyacrylamide gels show purified protein samples marked FtsZ or EzrA and pull-down experiments.
A: −/−, streptavidin resin incubated with BSA and free biotin only; F/− streptavidin resin incubated
with biotinylated FtsZ, then BSA and free biotin. A–H: pull-down experiments performed with −/E,
streptavidin resin was incubated with BSA and free biotin, washed, and then incubated with EzrA
mutant, or F/E, streptavidin resin was incubated with biotinylated FtsZ, then BSA and free biotin,






5.5.1 Truncated EzrA and solubility
In this work both N- and C-terminally deleted libraries of S. aureus EzrA
were made. The truncation strategy applied allowed identification of many
soluble variants of EzrA and of these, several were selected for purification and
determination of protein foldedness by NMR, showing that the selected mutant
genes encode soluble proteins, some of which are very well folded (Figure 5.17).
EzrA is predicted to contain five coiled-coil regions and some, but not all, soluble
fragments of EzrA are truncated at the borders of these motifs. In general, the
truncated proteins appear to have flexible residues at the non-truncated termini
— as is common in proteins — and the truncated ends may be flexible even if
not at a domain boundary. This is to be expected as the pragmatic solubility
selection scheme used to identify these proteins is not biased for those without
flexible tails.
Of the truncated mutants examined by NMR, EzrA24–214, EzrA302–564, and
EzrA484–564 were very well folded and likely truncated to the boundaries of
domains. Recently, truncation of S. aureus EzrA by limited proteolysis was
reported (EzrA164–564, EzrA250–564 and EzrA278–564; Son and Lee, 2013). The
authors, however, were not able to make soluble C-terminally truncated EzrA
proteins by limited proteolysis, or produce the same degree of protein length
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variation as the technique used here.
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Figure 5.17: Overview of soluble truncated Staphylococcus aureus EzrA mutant proteins. At
the top is a representation of the full length cytosolic part of EzrA (without the 23 residue N-terminal
membrane anchor) with predicted coiled-coil domains coloured in purple and the QNR patch proposed
to bind to FtsZ by Haeusser et al. (2007) in green. Arrows above and below the diagram of full length
EzrA indicate the identity of putatively soluble truncated EzrA mutants. Also shown are truncated
mutants of EzrA that have been over-expressed and purified; SDS-PAGE analysis of cellular, soluble
and insoluble cell fractions from over-expressing cells are shown for each mutant. Protein foldedness
as judged by NMR is indicated by colour: blue, unstructured and green, well structured; proteins
not studied by NMR are coloured yellow. N-terminally proteolysed fragments are coloured red and
EzrA469–564 grey, as this mutant precipitated after purification.
Overall, a short segment at the extreme N-terminus of EzrA is likely to be flexible
since full-length cytoplasmic EzrA (EzrA24–564), EzrA24–214, and EzrA24–238 appear
to be well folded proteins, yet all appear to contain similar flexible residues in their
TOCSY NMR spectra. However, this unstructured N-terminus does not extend
past residue 58 as the partially folded EzrA24–139 and longer mutants are protected
from adventitious proteolysis at this site, unlike the poorly structured smaller
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mutants. The extreme C-terminus of EzrA may also be slightly disordered as all
C-terminal fragments of EzrA contain a flexible Val residue (V561; note that there
is no Val residue in the presumably flexible purification tag). There appears to be
little inter-domain flexibility in EzrA as EzrA24–214 and EzrA302–564 — representing
all but the third predicted domain — contain no flexible residues other than those
at the N- or C-termini of EzrA.
5.5.2 Structural insights into EzrA truncations
Members of our extended research group (Greg Harm, supervised by Dr Aaron
Oakley) have successfully produced diffraction quality protein crystals of
EzrA24–214 (Figure 5.18), and the structure has now been solved (Dr Aaron
Oakley, personal communication). These data support NMR observations that
this mutant is well folded.
We were recently supplied with the coordinates of a crystal structure of B. subtilis
A B C
Figure 5.18: Preliminary crystallography of EzrA24–214. Purified EzrA24–214 was subjected to
protein crystallisation trials using the QIAGEN NeXtal JCSG+ suite in sitting drop configuration by
Greg Harm. Bona fide protein crystals have been recovered in conditions: A, D3 (0.2 M NaCl, 0.1 M
Na/K phosphate pH 6.2, 50% (v/v) PEG 200); B, D5 (0.1 M HEPES pH 7.5, 70% (v/v) MPD) and
C, D8 (0.1 M Tris pH 8.0, 40% (v/v) MPD).
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EzrA from the group of Professor Richard J. Lewis, University of Newcastle,
United Kingdom (Figure 5.19; Cleverly et al., 2014). EzrA has an extended
coiled-coil structure, forming a half-ring composed exclusively of α-helices that
form six identifiable domains. Strikingly, many of the mutants identified using
our truncation methodology map to positions between helical domains where the
structure kinks around the ring (domain 1 ends at residue 129, domain 2 at residue
214, domain 3 at residue 300, domain 4 near residue 411 and domain 5 ends at 485).
Of the proteins examined by NMR, EzrA24–214, EzrA302–564 and EzrA484–564 are
very well folded and are truncated nicely at inter-domain bends in the EzrA
structure (Figure 5.19B, D, F). Although EzrA24–129 appears to be disordered
by NMR, this protein is truncated distinctly to the apparent boundary between
the first and second domains of EzrA (as are EzrA24–126 and EzrA24–128). This
suggests that the long helix that extends across domains 1 and 2 is necessary to
stabilise domain 1. The solubility selection methodology using EGFP fusion to
report on protein solubility is proposed to be useful in identifying protein domains
(in combination with gene truncation), as insoluble and/or aggregation-prone
proteins should drag EGFP into aggregates in vivo where it can neither fold nor
develop green fluorescence. If this were the case with EzrA24–129, mutants slightly
shorter than this (also likely to be unfolded), would not be expected to perturb
development of EGFP fluorescence. Yet, it appears this was not the case for
C-terminally deleted proteins truncating within the first EzrA domain. Perhaps,
in vivo, where molecular crowding is higher, the domain represented by EzrA24–129
may be able to form, whereas proteins representing only part of this domain may
perturb development of mature EGFP.
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Figure 5.19: Cytoplasmic EzrA domain architecture. The unpublished crystal structure o
cytoplasmic regions of B. subtilis EzrA was kindly provided by Professor Richard J. Lewis (Unive
of Newcastle, United Kingdom; Cleverly et al., 2014). To examine the identity of truncations of S.
aureus EzrA produced in this work, B. subtilis and S. aureus EzrA protein sequences were aligned
with ClustalW (Thompson et al., 2002) to approximate the S. aureus residue positions. Truncated
mutants of EzrA (A–F) express well and appear to be truncated at or near domain boundaries. G:
complete EzrA structure (blue) and folds delineated by breakpoints identified in this Chapter (pink).





Interestingly, no soluble EzrA mutant was identified at the boundary of domains
4 and 5. Like the other domains (1–4), these are joined by a long α-helix that
extends through both domains. Nevertheless, mutants including (EzrA393–564)
or excluding most of (EzrA425–564; nine residues of the helix are included) this
helix were identified as soluble (Figure 5.19G). Some molecules of EzrA425–564
were proteolysed between residues 438–439 but EzrA381–564 was not. Although
EzrA381–564 contains a flexible N-terminus, it seems that these residues are
protected from proteolysis. EzrA24–476 completely contains the first four domains
of EzrA, and a C-terminal extension containing, what appears to be, the majority
of the fifth domain (Figure 5.19C). This protein contains significant flexibility
(by NMR) which is very likely attributed to the fifth domain. That domain 5
appears to be short, folded in EzrA443–564 but not in EzrA24–476 may point to a
requirement for its stabilisation by domain 6 to become structured, or the least
residues 477 to ∼ 483.
At the N-terminus of EzrA, EzrA24–126, EzrA24–128 and EzrA24–129 appear not
to be folded, yet addition of just a few residues, as is the case with EzrA24–139,
produces a protein that is partially structured based on observations by NMR.
This is interesting as residues 130–139 represent an extension into domain 2 of
the α-helix at the base of the α-helical bundle making up domain 1 (Figure
5.19G). These additional α-helical residues may help stabilise the fold of domain
1, although the domain is still apparently somewhat unstable. Further support for
this proposition is that EzrA24–126, EzrA24–128 and EzrA24–129, but not EzrA24–139,
proteolysed between residue 58 and 59, which appear to be in a loop adjacent to
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the helical residues at 130–139.
Of course, we should recognise that this analysis is predicated on the B. subtilis
structure being a reliable model for S. aureus EzrA. It is possible that subtle
differences between the two protein structures may be revealed in future work.
5.5.3 The interaction between EzrA and FtsZ
This work successfully showed evidence for the interaction of EzrA and FtsZ
using a streptavidin pull-down assay, and used this method to further narrow
down the region of EzrA involved. Due to the methodology of the assay used
— which involves washing unbound EzrA by dilution — only interactions with
off-rates slower than the washing time can be reliably recovered. Performing the
EzrA pull-down experiment using a library of truncated EzrA proteins produced
only one candidate interacting fragment, EzrA24–476; this interaction with FtsZ
was confirmed by performing a pull-down using purified EzrA24–476. The pull
down experiments used here also showed that EzrA24–214, EzrA24–238, EzrA277–564
and EzrA280–564 do not interact strongly with FtsZ, suggesting that a necessary
component for a long lived EzrA–FtsZ interaction is present between residues
238 and 277 (Figure 5.20). According to examination of the protein’s structural
homologue and protein foldedness by NMR, the four non-FtsZ-interacting
EzrA fragments do not contain a folded domain 3, so the specific site of the
interaction may lie beyond residues 238 and 277, but very likely involves domain 3.










Figure 5.20: FtsZ pull-down of purified truncated EzrA proteins. Full length EzrA (without
the N-terminal membrane anchor) and EzrA24–238 interact with FtsZ-coated resin, but EzrA24–214,
EzrA24–238, EzrA277–564 and EzrA280–564 do not, suggesting that the region between residues 238
and 276 in EzrA is important for the interaction with FtsZ.
The interaction of EzrA24–476 and FtsZ is interesting as previous work by Haeusser
et al. (2007) showed that deletion of the near-C-terminal EzrA QNR patch
(B. subtilis residues 506–510) — not present in EzrA24–476 — stops mid-cell
localisation of EzrA in B. subtilis. However, no direct interaction has been
observed between EzrA and FtsZ at this site in any published study; maybe the
QNR patch mediates another interaction at the divisome.
Further, Son and Lee (2013) attempted to narrow down the S. aureus FtsZ–EzrA
interaction. These authors used FtsZ–EzrA pull-down assays with immobilised
N-terminal GST tagged FtsZ351–390 and FtsZ370–390 to show that EzrA67–564 does
interact with FtsZ but that EzrA164–564 does not. Moving on from these results
Son and colleagues attempted to co-purify His6-EzrA25–163 and GST-FtsZ but
were unsuccessful in doing so using GST affinity chromatography. They did
observe its association with GST-FtsZ using IMAC. These authors also performed
analytical gel filtration using EzrA25–163 and FtsZ and failed to observe co-elution
of these proteins. These results purportedly show a weak interaction between
the C-terminus of FtsZ and domain 1 of EzrA, but further work is necessary to
understand this interaction fully.
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Possibly relevant to the apparently contradictory reports of the EzrA–FtsZ
interaction are the interactions of other divisome proteins, that show evidence
of multiple, weak and redundant interactions. For example, E. coli FtsN
appears to have multiple, synergistic, interactions with PBP1b. FtsN58–232 and
FtsN58–319∆129–242 have both been shown by pull-down assay to interact with
PBP1b (Müller et al., 2007). These individual FtsN–PBP1b interactions are of
course much weaker than the interaction of full length FtsN. The divisome — a
very large protein complex populated by many protein–protein interactions —
may be regulated by multivalent interactions like those of FtsZ and PBP1b, as
these would provide a more dynamic multi-protein machine than is possible using
the alternative individual, very strong interactions.
Perhaps then, the various reports of EzrA interactions with FtsZ suggest that
this interaction too is mediated not by a single strong interaction, but by several
weaker interactions that cooperatively bind the proteins together.
5.5.4 General discussion
Generating protein truncations by out methodology appears, in the case of EzrA,
to be superior to limited proteolysis in identifying protein truncation variants
and soluble protein fragments. This work gives access to truncated EzrA proteins
that have previously been unobtainable, some of which are now predicted to be
truncated directly at or near domain boundaries. In addition to identifying soluble
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fragments of EzrA, we now have a very useful EzrA protein library pull-down tool
for narrowing down the folding units of EzrA involved in numerous interactions
within the divisome.
If a single, long lived EzrA–FtsZ interaction exists, the work presented here
suggests that the third domain in EzrA is responsible. Confirmation of this
interaction will require synthesis of domain 3 alone, using mutations identified
here.
An intriguing target for identification of EzrA interactions using the protein
fragments generated here is the important S. aureus PBP2 interaction. Depletion
of EzrA in S. aureus strains leads to distribution of PBP2 — normally localised to
the division septum — throughout the cell wall and appears to halt peptidoglycan
synthesis (Steele et al., 2011). These data suggest that EzrA helps localise and
activate peptidoglycan synthesis by PBP2, with both of these properties being
enticing targets for antibiotic effects. Delocalisation of peptidoglycan production
in S. aureus should severely inhibit daughter cell production and may even lead
to cell death. Interfering with the action of PBP2 by mimicking EzrA might also
allow inhibition of, or even activation of peptidoglycan synthesis, which would
have deleterious effects for cell reproduction and viability.
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Chapter 6
Concluding remarks
This Thesis presents a new technique for protein domain identification that works
by uni-directionally truncating genes using ExoIII and then expressing truncated
mutants with a solubility reporting fusion protein. These experiments result in
soluble, truncated proteins whose deletions did not hinder protein expression,
folding or solubility and therefore are unlikely to contain substantial poorly folded
regions. Chapter 3 presents the rationale behind gene deletion and solubility
selection, as well as the various plasmids that were constructed to produce the
truncation libraries. This new technique was then used to identify new soluble
fragments of both DnaG primase (Chapter 4) and the divisome regulator EzrA
(Chapter 5).
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6.0.5 Caveats
Some proteins are not directly amenable to application of the technique presented
in this Thesis. The solubility selection methods applied in this Thesis are biased
to select well expressed proteins that fold efficiently. Potentially useful proteins
that express poorly, or that suffer significant aggregation after correct folding
will be under-represented. This technique is also poorly suited for proteins that
contain multiple domains that fold in tandem such as Bacillus amyloliquefaciens
RNase (Neira and Fersht, 1999) and barley chymotrypsin inhibitor 2 (Neira et al.,
1997) that fold only when the near C-terminal residues are present; or proteins
which require a complementary protein for correct domain folding (San Martin
et al., 1995; Kamada et al., 2003; Zhang et al., 2003; Klammt et al., 2006; Katzen
et al., 2008; Wuu and Swartz, 2008). It is also unlikely to be useful for proteins
that have a discontinuous domain structure, i.e., where all or part of domain(s)
are inserted within other folded domains.
The technique developed here is capable of providing an abundance of truncated
proteins that are soluble and do not aggregate. However, identification of mutants
that do not contain flexible, unfolded ends is not certain. Structural modelling
of the ZBD and RNAP domain of DnaG (Chapter 4) suggests that soluble
truncations occur at the start and end of protein folds, yet at these domain
boundaries, inclusion of flexible extensions and deletion of short secondary
structural elements is tolerated. As the basis of selection in this technique is a
high level of over-expression and high solubility of protein fragments, flexible ends
and deletion of short secondary structural elements do not necessarily negatively
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affect these properties. In fact, it is plausible that in some cases, protein sequences
that are not present in the mature protein domain will play a role in the folding
pathway of domains, which may result in positive selection. Depending on the
intended experimental use of a truncated protein, the fact that some proteins
contain flexible ends and can be produced in soluble form may be more important
than identifying proteins without flexible regions. NMR techniques can be used
subsequently to identify these regions, providing soluble samples can be produced
in the first place.
6.0.6 Usefulness of this method
This new technique has advantages over previously reported physical domain
identification methods and does not require prior knowledge of the protein.
Gene deletion from a single terminus provides gene libraries of manageable
size that can be fully sampled easily, in contrast to other genetic truncation
methodologies used for this purpose (Miyazaki, 2002; Dyson et al., 2008).
Although uni-directional gene deletion does not sample all of the available
truncated sequences, the straightforward methodology can potentially identify all
protein domain boundaries in a protein. To then isolate internal domains of a
protein, this information can be used to design new domain mutants.
Soluble mutants of A. baylyi DnaG RPD–HBD and numerous domain mutants of
EzrA are truncated directly at or near domain boundaries, which highlights the
success of this new domain identification methodology. In addition, as this new
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technique allows straightforward production of soluble truncated protein pools
— as performed in Chapter 5 — these can be used for initial studies to identify
interesting regions of proteins, such as sites of interaction with other proteins.
Unlike limited proteolysis, this new technique does not require soluble expression
of the target protein, which greatly increases the applicability of the method.
Further, limited proteolysis necessitates that flexible, inter-domain segments are
accessible to proteolytic enzyme active sites, which is not always the case. In
limited proteolysis experiments performed for S. aureus EzrA (Son and Lee, 2013),
the core of the protein is resistant to proteolysis, and these authors were unable
to produce soluble C-terminally deleted mutants. Yet using our new technique,
we have identified numerous domain truncations and soluble C-terminally deleted
EzrA mutants with greater variability. Also, protein breakpoints identified by
limited proteolysis do not account for regions required for nascent protein folding,
which this technique most certainly does, since it identifies protein solubility
following over-expression.
Work described in this Thesis has shown the utility of this new method of
soluble protein domain identification and provided, in a straightforward manner,
expressible soluble protein domains that were previously unavailable. This
technique should be applicable to many proteins which currently are recalcitrant
to soluble expression.
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Appendix A
Apparatus for generating exonuclease III
libraries
A library truncation method was constructed by setting up an apparatus to
constantly produce samples from an ExoIII reaction into a chilled EDTA reaction
stop solution (Figure A.1). The apparatus was constructed from a 10 mL syringe
and a 25 gauge needle supported above a 10 mL centrifuge tube containing a
magnetic stir bar. The 10 mL centrifuge tube and stir bar were placed in a chilled
container on a magnetic stirrer where the ExoIII droplet apparatus produced 10
droplets per 7 s, with a combined volume of 70 µL.
The ExoIII reactions were initiated by mixing pre-warmed DNA and enzyme
solutions. DNA solutions were prepared with an appropriate amount of DNA in
ExoIII reaction buffer (60 mM Tris-HCl pH 7.6, 5 mM MgCl2, 1 mM DTT and
100 µg.mL-1 BSA). A separate ExoIII solution was prepared by mixing 100 units
of ExoIII per µg DNA in 1 mL of ExoIII buffer.
ExoIII reactions were initiated by mixing DNA and ExoIII solutions together and
Jeffrey R. Barrett 254
placing the resulting solution in the drip apparatus. The ExoIII treated droplets
were collected in a 10 mL centrifuge tube containing 1/20 ExoIII reaction volume
of 500 mM EDTA and a magnetic stir bar so that the final EDTA concentration
would be 25 mM at completion of the ExoIII experiment.
Following generation of an ExoIII truncated DNA library, the DNA solution was
concentrated to a volume of 250 µL in a pre-washed Centricon 10 k MWCO
centrifugal filter unit. The concentrated DNA was then precipitated by addition of
750 µL 100 % ethanol for 30 min. Precipitated DNA was collected by centrifugation
at 21,000× g for 15 min. The DNA pellet was washed with chilled 70 % ethanol and




Figure A.1: Apparatus for generating exonuclease III libraries.
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Figure B.1: Distribution of truncation lengths for an ideal uni-directional exonuclease III
truncation library. Truncation was modelled using Equation 3.1 (Hoheisel, 1993; Ostermeier, 2003)
where L = time points samples for C-terminal deletion of A. baylyi dnaG (blue; sampled every 15 s
between 6 min 30 s and 8 min 45 s of the ExoIII reaction) and c = 0.075. The theoretical population
from pooling each time point sample is represented in red.
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Figure B.2: Distribution of truncation lengths for an ideal uni-directional exonuclease III
truncation library. Truncation was modelled using Equation 3.1 (Hoheisel, 1993; Ostermeier, 2003)
where L = time points samples for N-terminal deletion of A. baylyi dnaG (blue; sampled every 15 s
between 1 min 25 s and 2 min 40 s of the ExoIII reaction) and c = 0.075. The theoretical population
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Appendix D
Enzyme buffers
Table D.1: Enzyme buffers.
Buffer working concentration
NEB 1 10 mM Bis-Tris-Propane-HCl, 10 mM MgCl2, 1
mM DTT: pH 7.0
NEB 2 10 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2, 1
mM DTT: pH 7.9
NEB 3 50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl2, 1
mM DTT: pH 7.9
NEB 4 20 mM Tris-acetate, 50 mM potassium acetate, 10
mM magnesium acetate, 1 mM DTT: pH 7.9
Fermentas T4 DNA Ligase 40 mM Tris-HCl, 10 mM MgCl2, 10 mM DTT, 0.5
mM ATP: pH 7.8 at 25◦C).
NEB T4 DNA Ligase 50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10
mM DTT: pH 7.5 at 25◦C
Promega T4 DNA Ligase 30 mM Tris-HCl, 10 mM MgCl2, 10 mM DTT and
1 mM ATP: pH 7.8 at 25◦C
BIOTAQ Red 67 mM Tris-HCl, 16 mM (NH4)2SO4, 10 mM KCl,
0.1% stabiliser: pH 8.8 at 25◦C
ACUSURE 60 mM Tris-HCl, 6 mM (NH4)2SO4, 10 mM KCl,
2 mM MgSO4: pH 8.3 at 25◦C.
ACCUZYME 60 mM Tris-HCl, 6 mM (NH4)2SO4, 10 mM KCl,
2 mM MgSO4: pH 8.3 at 25◦C.
VELOCITY Proprietary Hi-Fi Reaction Buffer
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Appendix E
Mass spectra and NMR analysis of
truncated EzrA proteins
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Table E.1: Mass spectrometry of His6-tagged EzrA truncated proteins.
EzrA Predicted mass Observed N-met Fragment Remainder Notes
(− methionine; Da) mass (Da) mass (Da) mass (Da)
EzrA24–564 65353.9 (65222.7) 65435.0 √
EzrA277–564 35752.8 (35621.6) 35760.2 √
EzrA280–564 35381.4 (35250.2) 35260.1 X
EzrA302–564 32809.6 (32678.4) 32687.6 X
EzrA381–564 23476.2 (23345.0) 23482.0 √
EzrA425–564 18236.5 (18105.3) 18109.9 X 16434.5 1675.41 −15 aa
EzrA443–564 16161.1 (16029.9) 16033.8 X
EzrA453–564 14902.6 (14771.4) 14905.5 √
EzrA476–564 12103.5 (11972.3) 12105.0 √
EzrA484–564 11220.4 (11089.2) 11222.4 √
EzrA24–97 10406.7 (10275.5) 10407.5 √
EzrA24–126 13806.2 (13675.0) 13807.6 √ 9655.42 4152.13 −35 aa
EzrA24–128 14020.4 (13889.2) 14022.0 √ 9870.42 4151.83 −35 aa
EzrA24–129 14134.5 (14003.3) 14137.5 √ 9984.82 4152.83 −35 aa
EzrA24–139 15309.8 (15178.6) 15311.7 √
EzrA24–214 24238.9 (24107.7) 24242.9 √
EzrA24–238 27082.1 (26950.9) 27088.6 √ 25703.62 1385.2
EzrA24–238 21440.12 5648.74 −48 aa
EzrA24–238 21311.62 5777.25 −49 aa
EzrA24–476 55205.4 (55074.2) 55223.5 √
1 mass is consistent with proteolysis liberating the 15 N-terminal amino acids: SKKEEVYRRLLASN
(predicated mass 1692.9 Da).
2 fragments from secondary chromatography peak.
3 mass is consistent with proteolysis liberating the 35 N-terminal amino acids:
(M)RSNKRQIIEKAIERKNEIETLPFDQNLAQLSKLN (predicated mass 4169.8 Da).
4 mass is consistent with proteolysis liberating the 48 N-terminal amino acids:
(M)RSNKRQIIEKAIERKNEIETLPFDQNLAQLSKLNLKGETKTKYDAMK (predicated mass 5664.5 Da).
5 mass is consistent with proteolysis liberating the 49 N-terminal amino acids:
(M)RSNKRQIIEKAIERKNEIETLPFDQNLAQLSKLNLKGETKTKYDAMKK (predicated mass 5792.7 Da).






































EzrA 277−564: 35760  Da
B: Mass spectrum of EzrA277–564: late anion-exchange
chromatography peak
C: One-dimensiosnal NMR spectrum of EzrA277–564 D: TOCSY NMR spectrum of EzrA277–564
Figure E.1: Mass and NMR spectral analysis of EzrA277–564. A,B, Positive ion electrospray mass spectrum of denatured EzrA277–564. To























A: Mass spectrum of EzrA280–564: early anion-exchange
chromatography peak
B: One-dimensiosnal NMR spectrum of EzrA280–564 C: TOCSY NMR spectrum of EzrA280–564
Figure E.2: Mass and NMR spectral analysis of EzrA280–564. A, Positive ion electrospray mass spectrum of denatured EzrA280–564. To see






















EzrA 302−564: 32687.64 Da



















EzrA 302−564: 32687.64 Da




B: Mass spectrum of EzrA302–564: late anion-exchange
chromatography peak
C: One-dimensiosnal NMR spectrum of EzrA302–564 D: TOCSY NMR spectrum of EzrA302–564
Figure E.3: Mass and NMR spectral analysis of EzrA302–564. A,B, Positive ion electrospray mass spectrum of denatured EzrA302–564. To






















EzrA 381−564: 23482 Da
A: Mass spectrum of EzrA381–564
B: One-dimensiosnal NMR spectrum of EzrA381–564 C: TOCSY NMR spectrum of EzrA381–564
Figure E.4: Mass and NMR spectral analysis of EzrA381–564. A, Positive ion electrospray mass spectrum of denatured EzrA381–564. To see






















EzrA 425−564: 18109.85 Da




A: Mass spectrum of EzrA425–564
B: One-dimensiosnal NMR spectrum of EzrA425–564 C: TOCSY NMR spectrum of EzrA425–564
Figure E.5: Mass and NMR spectral analysis of EzrA24–139. A, Positive ion electrospray mass spectrum of denatured EzrA24–139. To see if




















EzrA 443−564: 16033.83 Da






A: Mass spectrum of EzrA443–564
B: One-dimensiosnal NMR spectrum of EzrA443–564 C: TOCSY NMR spectrum of EzrA443–564
Figure E.6: Mass and NMR spectral analysis of EzrA443–564. A, Positive ion electrospray mass spectrum of denatured EzrA443–564. To see





















EzrA 453−564: 14775.11 Da






















EzrA 476−564: 12105.03 Da




















EzrA 484−564: 11222.40 Da
A: Mass spectrum of EzrA484–564
B: One-dimensiosnal NMR spectrum of EzrA484–564 C: TOCSY NMR spectrum of EzrA484–564
Figure E.9: Mass and NMR spectral analysis of EzrA484–564. A, Positive ion electrospray mass spectrum of denatured EzrA484–564. To see






















EzrA 24−97: 10407.46 Da
A: Mass spectrum of EzrA24–97
B: One-dimensiosnal NMR spectrum of EzrA24–97 C: TOCSY NMR spectrum of EzrA24–97
Figure E.10: Mass and NMR spectral analysis of EzrA24–97. A, Positive ion electrospray mass spectrum of denatured EzrA24–97. To see if






















EzrA 24−126: 13807.11 Da
















EzrA 24−126: 13807.55 Da




B: Mass spectrum of EzrA24–126: late anion-exchange
chromatography peak
C: One-dimensiosnal NMR spectrum of EzrA24–126 D: TOCSY NMR spectrum of EzrA24–126
Figure E.11: Mass and NMR spectral analysis of EzrA24–126. A,B, Positive ion electrospray mass spectrum of denatured EzrA24–126. To





















EzrA 24−128: 14022.02 Da



















EzrA 24−128: 14022.02 Da




B: Mass spectrum of EzrA24–128: late anion-exchange
chromatography peak
C: One-dimensiosnal NMR spectrum of EzrA24–128 D: TOCSY NMR spectrum of EzrA24–128
Figure E.12: Mass and NMR spectral analysis of EzrA24–128. A,B, Positive ion electrospray mass spectrum of denatured EzrA24–128. To






















EzrA 24−129: 14137.32 Da
















EzrA 24−129: 14137.32 Da







B: Mass spectrum of EzrA24–129: late anion-exchange
chromatography peak
C: One-dimensiosnal NMR spectrum of EzrA24–129 D: TOCSY NMR spectrum of EzrA24–129
Figure E.13: Mass and NMR spectral analysis of EzrA24–129. A,B, Positive ion electrospray mass spectrum of denatured EzrA24–129. To







EzrA 24−139: 15311.71 Da+8100
50
0















EzrA 24−139: 15311.71 Da


















B: Mass spectrum of EzrA24–139: late anion-exchange
chromatography peak
C: One-dimensiosnal NMR spectrum of EzrA24–139 D: TOCSY NMR spectrum of EzrA24–139
Figure E.14: Mass and NMR spectral analysis of EzrA24–139. A,B, Positive ion electrospray mass spectrum of denatured EzrA24–139. To






















A: Mass spectrum of EzrA24–214: early anion-exchange
chromatography peak

















B: Mass spectrum of EzrA24–214: late anion-exchange
chromatography peak
C: One-dimensiosnal NMR spectrum of EzrA24–214 D: TOCSY NMR spectrum of EzrA24–214
Figure E.15: Mass and NMR spectral analysis of EzrA24–214. A,B, Positive ion electrospray mass spectrum of denatured EzrA24–214. To























A: Mass spectrum of EzrA24–238: early anion-exchange
chromatography peak
EzrA 24-238: 27088.71 Da+23
+10















) EzrA 24-238: 21440.13 Da






B: Mass spectrum of EzrA24–238: late anion-exchange
chromatography peak
C: One-dimensiosnal NMR spectrum of EzrA24–238 D: TOCSY NMR spectrum of EzrA24–238
Figure E.16: Mass and NMR spectral analysis of EzrA24–238. A,B, Positive ion electrospray mass spectrum of denatured EzrA24–238. To























A: Mass spectrum of EzrA24–476
B: One-dimensiosnal NMR spectrum of EzrA24–476 C: TOCSY NMR spectrum of EzrA24–476
Figure E.17: Mass and NMR spectral analysis of EzrA24–476. A, Positive ion electrospray mass spectrum of denatured EzrA24–476. To see






















EzrA 24-564: 65435.29 Da
EzrA 24-564: 65191.48 Da














EzrA 24-564: 65430.65.58 Da





+23 +22 +21 +20
B: Mass spectrum of folded EzrA24–564
C: One-dimensiosnal NMR spectrum of EzrA24–564 D: TOCSY NMR spectrum of EzrA24–564
Figure E.18: Mass and NMR spectral analysis of EzrA24–564. Positive ion electrospray mass spectrum of A, denatured and B, folded
EzrA24–564. To see if purified EzrA24–564 was folded: C, 1D NMR and D, TOCSY NMR spectra were recorded in 20 mM Tris-HCl pH 7.0, 50
mM NaCl and 1 mM DTT.
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